var title_f2_53_2896="Subumbilical incision in obese";
var content_f2_53_2896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subumbilical incision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subumbilical incision is made after retraction of panniculus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2896=[""].join("\n");
var outline_f2_53_2896=null;
var title_f2_53_2897="Rx MS mild symptoms I";
var content_f2_53_2897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55549%7ECARD%2F68528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55549%7ECARD%2F68528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: Management strategy for patients with mild mitral stenosis (MS) and mild symptoms (NYHA functional class II) - Part I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 540px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The committee recognizes that there may be variability in the measurement of MVA and that the mean transmitral gradient, PAWA, and PASP should also be taken into consideration.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guidelines: Management strategy for patients with moderate to severe mitral stenosis (MS) and mild symptoms (NYHA functional class II) - Part II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 390px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The committee recognizes that there may be variability in the measurement of MVA and that the mean transmitral gradient, PAWA, and PASP should also be taken into consideration.",
"     <br>",
"      &bull; There is controversy as to whether patients with severe pulmonary hypertension (pulmonary artery systolic pressure &gt;60-80 mmHg) should undergo mitral valve replacement to prevent right ventricular failure.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2897=[""].join("\n");
var outline_f2_53_2897=null;
var title_f2_53_2898="Hepatoma in cirrhosis CT";
var content_f2_53_2898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatoma invading the portal vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast- enhanced CT scan of a cirrhotic liver demonstrates a multifocal hepatoma (arrows) which is invading the portal vein (arrowhead). The spleen is enlarged due to portal hypertension secondary to cirrhosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2898=[""].join("\n");
var outline_f2_53_2898=null;
var title_f2_53_2899="Vaginal yeast infection";
var content_f2_53_2899=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Vaginal yeast infection (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/53/2899/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2899/contributors\" id=\"au4223\">",
"       Jack D Sobel, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/53/2899/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2899/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/53/2899/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2899/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/53/2899?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Vaginal yeast infections (also called yeast vaginitis or vaginal candidiasis) are a common problem in women. The most common symptoms are itching and irritation of the vulva and around the opening of the vagina. Vaginal yeast infections usually occur as infrequent episodes, but can recur frequently and may cause chronic persistent symptoms.",
"    </p>",
"    <p>",
"     Yeast infections occur mainly in women who are menstruating (having monthly periods). They are less common in postmenopausal women who do not take estrogen and they are rare in girls who have not yet started menstruating.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      VAGINAL YEAST INFECTION SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptoms of a yeast infection include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Itching or irritation of the vulva and around the vaginal opening (",
"       <a class=\"graphic graphic_figure graphicRef53704 \" href=\"UTD.htm?0/10/160\">",
"        figure 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Pain with urination, vulvar soreness or irritation,",
"      </li>",
"      <li>",
"       Pain with intercourse",
"      </li>",
"      <li>",
"       Reddened and swollen vulvar and vaginal tissues.",
"      </li>",
"      <li>",
"       Some women have no abnormal vaginal discharge. Others have white clumpy (curd-like) or watery vaginal discharge.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Symptoms of a yeast infection are similar to a number of other conditions, including bacterial vaginosis (a bacterial infection of the vagina), trichomoniasis (a sexually transmitted infection), and dermatitis (irritated skin). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=see_link\">",
"      \"Patient information: Vaginal discharge in adult women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     It is often not possible to know if itching is caused by yeast or other causes. (See",
"     <a class=\"local\" href=\"#H6\">",
"      'Self-diagnosis'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      VAGINAL YEAST INFECTION CAUSE",
"     </span>",
"    </p>",
"    <p>",
"     The fungus that causes yeast infections (named Candida) normally lives in the gastrointestinal tract and sometimes the vagina. Normally, Candida causes no symptoms. However, when there are changes in the normal flora of the gastrointestinal tract and vagina (caused by medicines, injury, or stress to the immune system), Candida can overgrow and cause the symptoms described above.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      VAGINAL YEAST INFECTION RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     In most women, there is no underlying health problem that leads to a yeast infection. There are several risk factors that may increase the chances of developing an infection, including:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Antibiotics &mdash; Most antibiotics kill a wide variety of bacteria, including those that normally live in the vagina. These bacteria protect the vagina from the overgrowth of yeast. Some women are prone to yeast infections while taking antibiotics.",
"      </li>",
"      <li>",
"       Hormonal contraceptives (eg, birth control pills, patch, and vaginal ring) &mdash; The risk of yeast infections may be higher in women who use birth control methods containing estrogen. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"        \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Contraceptive devices &mdash; Vaginal sponges, diaphragms, and intrauterine devices (IUDs) may increase the risk of yeast infections. Spermicides do not usually cause yeast infections, although they can cause you to have vaginal or vulvar irritation. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"        \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Weakened immune system &mdash; Yeast infections are more common in people who have a weakened immune system due to HIV or use of certain medications (steroids, chemotherapy, post-organ transplant medications).",
"      </li>",
"      <li>",
"       Pregnancy &mdash; Vaginal discharge becomes more noticeable during pregnancy, although yeast infection is not always the cause. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=see_link\">",
"        \"Patient information: Vaginal discharge in adult women (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Diabetes &mdash; Women with diabetes are at higher risk for yeast infections, especially if blood sugar levels are often higher than normal.",
"      </li>",
"      <li>",
"       Sexual activity &mdash; Vaginal yeast infections are not a sexually transmitted infection. They can occur in women who have never been sexually active, but are more common in women who are sexually active.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      VAGINAL YEAST INFECTION DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Yeast infections can be diagnosed with an exam. During the exam, your doctor or nurse will examine your vulva and vagina and swab the vagina to get a sample of discharge. Do not begin treatment at home before being examined.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Self-diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with vulvar itching or vaginal discharge often assume that their symptoms are caused by a yeast infection and then use a non-prescription treatment. However, in one study, only 11 percent of women accurately diagnosed their infection; women with a previous yeast infection were only slightly more accurate (35 percent correct) [",
"     <a class=\"abstract\" href=\"UTD.htm?2/53/2899/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Diagnosing and treating yourself:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Wastes money (on non-prescription treatment)",
"      </li>",
"      <li>",
"       Wastes time; you will not feel better until you use the right treatment",
"      </li>",
"      <li>",
"       Can make you more itchy and irritated",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      VAGINAL YEAST INFECTION TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of a vaginal yeast infection may include a pill that you take by mouth or a vaginal treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Vaginal treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment for a vaginal yeast infection often includes a vaginal cream or tablet. You apply the cream or tablet inside the vagina at bedtime with an applicator. There are prescription and non-prescription treatments, so ask your doctor or nurse which to use. One, three, and seven-day treatments are equally effective. The duration of treatment should depend upon severity of infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Oral treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;A prescription pill called fluconazole (Diflucan&reg;) is another option for treating yeast infections. Most women only need one dose, although women with more complicated infections (such as those with underlying medical problems, recurrent yeast infections, or severe signs and symptoms) may require a second dose 72 hours (3 days) after the first dose.",
"    </p>",
"    <p>",
"     Side effects of fluconazole are mild and infrequent, but may include stomach upset, headache, and rash. Fluconazole interacts with a number of medications; ask your doctor, nurse, or pharmacist if you have concerns. Fluconazole is not usually recommended during the first trimester of pregnancy due to the potential risk of harm to the fetus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      When will I feel better?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most yeast infections go away within a few days after starting treatment. However, you may continue to feel itchy and irritated, even after the infection is gone. If you do not get better within a few days after finishing treatment, call your doctor or nurse for advice.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      RECURRENT VAGINAL YEAST INFECTIONS",
"     </span>",
"    </p>",
"    <p>",
"     Between 5 and 8 percent of women have recurrent yeast infections, defined as more than four infections per year.",
"    </p>",
"    <p>",
"     There is no evidence that eating yogurt or other products containing live Lactobacillus acidophilus, or applying these products to the vagina is of any benefit in women with recurrent vaginal yeast infections.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;As with initial yeast infections, it is important to correctly diagnose recurrent yeast infections. A woman who has frequent signs and symptoms of vulvar or vaginal irritation or itching should be seen by a healthcare provider to ensure that her symptoms are caused by yeast rather than other common problems (eg, other vaginal infections, allergic reaction or sensitivity, eczema). As with initial infections, self-diagnosis is not accurate enough to recommend treatment.",
"    </p>",
"    <p>",
"     Most vaginal yeast infections are caused by Candida albicans. Persistent or recurrent infections may be due to infection with one of the less common species of Candida, such as Candida glabrata or Candida krusei. In women with recurrent or persistent symptoms, vaginal cultures should always be obtained to confirm the diagnosis and identify these less common species, if present, since different medications are used to treat these infections.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with recurrent infections are usually given a longer course of treatment for infections, between 7 and 14 days for a topical (cream or suppository) medication or fluconazole 150 mg by mouth with a second and third dose 3 and 6 days later.",
"    </p>",
"    <p>",
"     Preventive treatment may be recommended after the infection has resolved; this may include fluconazole (150 mg orally once per week) or clotrimazole (500 mg vaginal suppositories administered once per week).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Treatment of a sexual partner",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vaginal yeast infections are not a sexually transmitted infection, although the infection may rarely be passed from one partner to another. Experts do not recommend treatment of a sexual partner.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2489383\">",
"     <span class=\"h1\">",
"      PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Sporadic attacks of vulvovaginal candidiasis usually occur without an identifiable precipitating factor. Nevertheless, a number of factors predispose to symptomatic infection:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Diabetes mellitus &mdash; Women with diabetes mellitus who have poor glycemic control are more prone to vulvovaginal candidiasis than euglycemic women. Maintaining good glycemic control can help to prevent vaginal infection.",
"      </li>",
"      <li>",
"       Antibiotics &mdash; One-quarter to one-third of women are prone to vulvovaginal candidiasis during or after taking broad spectrum antibiotics. These drugs inhibit normal bacterial flora, which favors growth of potential pathogens such as candida. In women susceptible to symptomatic yeast infections with antibiotic therapy, a dose of fluconazole (150 mg orally) at the start and end of antibiotic therapy may prevent postantibiotic vulvovaginitis.",
"      </li>",
"      <li>",
"       Increased estrogen levels &mdash; Vulvovaginal candidiasis appears to occur more often in the setting of increased estrogen levels, such as oral contraceptive use (especially when estrogen dose is high), pregnancy, and estrogen therapy, including topical or intravaginal estrogen therapy.",
"      </li>",
"      <li>",
"       Immunosuppression &mdash; Candidal infections are more common in immunosuppressed patients, such as those taking corticosteroids or with HIV infection.",
"      </li>",
"      <li>",
"       Contraceptive devices &mdash; Vaginal sponges, diaphragms, and intrauterine devices have been associated with vulvovaginal candidiasis, but not consistently. Spermicides are not associated with candida infection.",
"      </li>",
"      <li>",
"       Behavioral factors &mdash; Vulvovaginal candidiasis is not traditionally considered a sexually transmitted disease since it occurs in celibate women and since candida is considered part of the normal vaginal flora. This does not mean that sexual transmission of candida does not occur or that vulvovaginal candidiasis is not associated with sexual activity. As an example, there is an increase in the frequency of vulvovaginal candidiasis at the time most women begin regular sexual activity. Partners of infected women are four times more likely to be colonized than partners of uninfected women, and colonization is often the same strain in both partners. Individual episodes of vulvovaginal candidiasis do not appear to be related to lifetime numbers of sexual partners or the frequency of coitus, but may be linked to orogenital and, less commonly, anogenital sex.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There is no good evidence showing a link between vulvovaginal candidiasis and hygienic habits or wearing tight or synthetic clothing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Vaginal yeast infections are a common problem in women.",
"      </li>",
"      <li>",
"       Itching is the most common symptom of a vaginal yeast infection. Women may also note pain with urination, soreness or irritation, pain with intercourse, or reddened and swollen vulvar and vaginal tissues. There is often little or no vaginal discharge; if present, discharge is typically white and clumpy (curd-like) or thin and watery.",
"      </li>",
"      <li>",
"       Symptoms of a yeast infection are similar to a number of other conditions. A physical examination and laboratory testing are needed to determine the cause of symptoms.",
"      </li>",
"      <li>",
"       There are several risk factors that may increase the chances of developing a yeast infection, including use of antibiotics, birth control, diabetes, pregnancy, and a weakened immune system (due to chemotherapy, HIV, or certain medications).",
"      </li>",
"      <li>",
"       To diagnose a vaginal yeast infection, a healthcare provider will do an examination. It is important to be seen and tested when symptoms are bothersome and before any treatment is used.",
"      </li>",
"      <li>",
"       Do not begin treatment for a yeast infection before being examined and tested.",
"      </li>",
"      <li>",
"       Treatment of vaginal yeast infection may include a vaginal cream or tablet or a pill taken by mouth.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804467503\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11567681\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/1/14354?source=see_link\">",
"      Patient information: Vaginal yeast infection (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=see_link\">",
"      Patient information: Vaginal discharge in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/62/27618?source=see_link\">",
"      Patient information: Probiotics (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/52/20292?source=see_link\">",
"      Patient information: Diabetes and infections (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/54/33634?source=see_link\">",
"      Patient information: Vulvar itching (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=see_link\">",
"      Patient information: Vulvar pain (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11567715\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=see_link\">",
"      Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link\">",
"      Candida vulvovaginitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37876?source=see_link\">",
"      Desquamative inflammatory vaginitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"      HIV and women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/46/37609?source=see_link\">",
"      Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=see_link\">",
"      Differential diagnosis of vulvar lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"      Overview of Candida infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/yeastinfections.html\">",
"      www.nlm.nih.gov/medlineplus/yeastinfections.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://womenshealth.gov/publications/our-publications/fact-sheet/vaginal-yeast-infections.cfm\">",
"      womenshealth.gov/publications/our-publications/fact-sheet/vaginal-yeast-infections.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Nemours Foundations",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidshealth.org/teen/infections/fungal/yeast_infections.html\">",
"      www.kidshealth.org/teen/infections/fungal/yeast_infections.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/53/2899/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/53/2899?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2899/abstract/1\">",
"      Ferris DG, Nyirjesy P, Sobel JD, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002; 99:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2899/abstract/2\">",
"      National guideline for the management of vulvovaginal candidiasis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2899/abstract/3\">",
"      Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:662.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_53_2899=[""].join("\n");
var outline_f2_53_2899=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           VAGINAL YEAST INFECTION SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           VAGINAL YEAST INFECTION CAUSE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           VAGINAL YEAST INFECTION RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           VAGINAL YEAST INFECTION DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           VAGINAL YEAST INFECTION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           RECURRENT VAGINAL YEAST INFECTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2489383\">",
"           PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/160\" title=\"figure 1\">",
"           Female external genitalia  PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_53_2900="Cold panniculitis on thighs";
var content_f2_53_2900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cold panniculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5qRGb7o/GpCVjPyjLeuabJKSMDhah3dAOvtX0kpX1m/kcqiS7hnLcn36U1Fed8IN39KntLXex84E8ZwP61pxCKMSLs2jbwoGMnPeuuhhZVUnL3Y/iZzqKG25VtdNzuaX5inX0H+NaFsFgJwMk8buw9KZGJZZhFGhZpOUVRn8K63RvCM+Q2sSC1iYBlhUb5X9tv8P1NejCNLDRvskc83Kem5zovZWCoz9RgMF5p2n6bdazfR22nxvJITtLHlUHdmPYCvUdK0W2tWVrPTreJwMGW5HmyN+HQV0NraEwmN3Vo+pVECAn3AHNedic+w6TjD3jelgKrd7WMTStFii00adbk/YF5l2/Kbp/7zHrj0FbljZW9tEscESRKv8ACo4q5HGv3Y/vccY6VMsOFOG6nPI/WvkMTip4ibnNntUMPGlGyK/yhiM7R2GKYyhfuH3NWiiKR78bsdKaqHJ7461zHTYhOQcjGD68802S3SSNo3VXVh35qyo+b5QSRwc0oBDDAAA6e1K9hOFzjr/wxC1s1oEZrF2MqKnLWznqy+qnuK4e+8DXjTyhUguUHKssgUsP908g17aiBCec554qGaC3ckSQqx7llBr28HnNShD2c1zR8zz6+XKcnKDszwTUPCeo6c0cXkXkJIyxTLDP4VAlnq1nC0ksLmJTndKhABxxXvT6XbsSEEq/7jkVn3mkytFJHDfTNHIMPBN+8Rh9D/SvThnmFTvyOPozjnl9e1rp+p4jHffOPOiaIdSzDr+VW/OR9xAVlfGGBxnmu6uPCVoBIzRTW0hPytB+8j+rA8iuWvPClwGkkgiE0aHcZLduce47flXvYXGwrRvSqKX5nnVaLg/ei0ZrQlotwj+Qscc96gNtkLwynOOOaJILlI/3MzEKCSr8H86gh1CMSCOctG3QBhyfoa6pYiMP4it/XchQk1eGpOBsfBblRnbjrTgCwQHOT7c1LazRMUO5CS3JPJNStDGzFlPIOBg1tGUZK8WZSdtyjIjkNuOWUYFO8pSMFfnIGGHep540Q4Zs5z1/lUQIUITgqTgA9qUkUmV5IXhLBsYzng5oWTDFCvXB9K0Y445YSrrhex9PxqhNBIsuGBOP1qVroylLm3JIsIrqAHAIbcxwBVCCN3fbASJ8kDaeGHp9farjSkxMr5ZMcgdj2rPEzWjyJ5auCemenoR71jNpPXY0p3NWF5Y9LFu+UyxkRsYHPUe3SmxyySovmbSwycg063bzLCJWUtgEnJzzmowpEzphlAYkbe1awXupoyerdywoxCMyA4ORg80sQy/yAbGIxuHQ+mfWmRqAvGDjufTvU+xfLkG8gBs4POPeuixm3YinUuACjKU5bmkkAZEkXKkjkH171IcYAY8Y68nNIw+SVA+Gxu+fqPXFNghsi/MGPA4yM5qSV9oV3w36D/OKp3N/FEMeYNy8Ek9vasi71ISnZCJJD37c1x1sdRoaN69t3+BtChOfQ1LiVNwC4HPQVVnuEUNkiPJBwap+Rfyy/vR5BwCM8cHoatw6SQylUa6Yjq4yM/0rilja1VXpwsn1en/BOn2MIaSepUFxJKwW1jeQjnODitex8Pyzwrd6jG5iZvv9FQDqSM5NSGMW6GKaXfdxthIYyNigddxHB+gqBxMXL5Ys55LHOKyWGqYhXnK/32+X/BNPaQp9AaAoQqsFXkA44+n0p6oBjbKRg4U9wakt1KFjJz/CSe3vVmxSPzpEePJ28ZGckenvXqKmrWZwym1sEUUs9oLc5MKOX24wC3TrSJpz8E4GRjbnB/DNaC3IZEKo2GyEAHQjsfT8Kc0avy/BIwB3z6gDnP1qlTitIowlWm9zDuo3jCuozEfut39x9at6ZGHkjVgFdjhD03Z4wf8AGrzpHmRJAqRunzM5wdw/iC1lFT5mxcuFPB6c9jS5EtS0+ZWLduI47jZKu1o2Kk4z3wc01nCh1DEgHCt34NQCKTzWb5gdxVuf696l3MFJyccAZHX8apNCaHyXDK8blVJX+I/xD0P8qFvJQg8ltijgDHQemaZsG0KQQwPBJ6jvSGIFBwoTOTmk2FkI1xJJkSSNIrdtx4PrVVhJyeBtOc55/CrkKx/vDIT0+TaABu7ZqGdGcIQ3GfxHtipci1poQnzHck5G9eTjrj3pjTYiO1gNx9OePftVk2zBAZGJTnBaojDCzHy3AB654zUN9C00M+ZiFOAuMjn19aAcp8ox3JPT6VItuQyoW2rn73apJLePJj83MhORgcUcwrorLuKnkD6+lRn7q7QQ3QntirpESodxYDocEZqMiJlwN+0dGx1+tQ2NMpuuGx8p7ntVDU4t0bED50OfwrWbYUIBYk/KP4hVJ1GdrY9CCK4sZBVqUoM3pSs7owKKdIpR2UjocUV8O4627HqN9iZInkIxwD3NX0iWNBsTaMfebqfenHBkYtkjJCitnQdAuNXR7iV1trCJsPcScgHsFH8R9hX2NDDwotyer7s4pzbMiJyisI+CRndiuo8P+E7q78u51Bvsdo2CpkHzyj/YXr+JrqdD020sgg0+0QuBzc3ahpD/ALq9Fro4IwreZKfMkxjc5ycensK5cVnNKkuWl7z/AANKeEnU30RX0fRLOzQDT7RbYAH9/Md8zfj0X8K2La1gh3FNqsepxnP1NJCVLHOSMdxVqMYXGwYzXzOJxtXEyvUZ6tDCwpfCh6RL3Iz6ntVmIIOnJ7H/AAqqAxzt7cfWrcKlv7xCjpXJc7OUlGAuASM9fc06LcxHB2g8+tIilRlgAOvvU0anzMjnAznHFKxLSQSxgrlgFIPfvTMKxGABj8jUrE7gCCw7kD9KHXOSVIzx7UFJFfau7G3A/PNP2bsM2eOPSpliUNyuB0yDUgOG4PQdAO1JDsQmLBIxgkccdTUTwkR4B59+KthgS2TnnPJpjEBcDBb3FPoUkUlXYOS2fSmEsGJzwO9W/L+8Byf89KheIAkOCOePep22L5U9xqRgjBKYOMZqpeWEFxu3xKH7svyt+YrQ8sqePu1EMM2AMtnv3q41HF3WjMZ0VI5nUNBS4SQSxx3W8ceZw6j2Yf1rgta8BytI5tJAwLf6qYYIH16V7CUOMkAZ4qpeQ9yNrYyRXr0M6xFKPLN8y8zzqmXU2+aOj8jw+68D31vG8saSKFOPMgO9QfwrIuhqelsouFM0JHykDBr3KSDa+VYoeSNny5rLvoUvRtvI4p0XpuXDfgRXdRzTDyaaTpvutvuOKphKse0keSWep20kab5tkgJGCDnFaCPFIpKsMg5BbnJ9q2fEHhC0u4rq7tg8TxfOyg53L3/KuKFpd2BDQkvEe7Cvfw+Lr8qk0pw7rf5o4JUoNtXs+zN3Eicylig655A/KlmAmidPusvK89V7is231NySsyKD05q7hRIksb7wOeld6qRqq8TBwcX7xUd3iiKleHbPTpimSNGoDMAQ4xk/w89R7VoXSJLCJFXk8txis+4ty0TjBPGQBzSldp2LhJOxetgfIfbuCE4/A8/0p/KkMGY5GOBnOKqadKjQrk5ZlwewBzU8jqQ6KdrBty5OPyram/cVjOUWpWHADK+WOAf4vSrDnCeZIfmHBzyceoqBVWOHEZcSbdx6Y+lQ+d5kfK7n29Sc596vntuTy3ZYErCJ9qnru3Fh+NZl5LK0gECsWBxux8o47mmtIS0e8nLMFBAyAO5I7/SrywwxW10i3CS7pFYODtJwf7v0rirVnN+zjprq/wCup1U6Sj7zMtdJXzA0rySI/KtjAb1x9Olal3pp03auVWQp8yoOhI6Z71Z+0fuVgZEktk58s5Iz3IPYmoHa1ZwyRTxsPnKlwy5zx2zxxWcMP7Frlj+G/q9zR1IzTdx+q3cdzqMjpGAqhU2j0AA61XBLjaAEXaQDjkjtmp4bN5f30rBFOWaQ9D64HenSRNDMm1gyEBlfpkV006XJFQXQ56lXnk5ENlB5s0cIwJSflLetXrSBvtLxzBlkCkAKOc/5zUtzBFLcsYwEus71A6OOox706aeNLmMuWWFsSxyKDujPce4zkYrZRsc8pORFaxNB5v8AEjoWXIyDjnFV3YGdWjDRjOVDNnB9varf2n7HqM3kFJInY4UjK4I64PeqJyVkcY8rOMkdD7U9ECTZoNfRGNjtcyvguittTPr6mmNdu8K7SI4+pVAB+A7mqkL/ACqj7DkkkNwfzFKcu5ZFyAdxCjhfrUudgVNCkqJMgNnacs3IJ9KFKE/KPLIGBkdfeoYi8rFUX94vzZPTHvV3ymUGa5YeaQDsXgVF9dCnZDUXCM23Jzy3arAjyVGGBPbIAHvVfzRKzGXzH2Y2KGximP8AOjPhYwCARv5NPcizJZIiScbu2Qxzn3zUTtCpVmjVTkDduPX6VCVAwGcgjopzkir1naq8rI0Vz5eM7ootxzWVWrCnHmmzaNGUnypFZ/JGWCI+BwuD0pVlRNrKWZcYwBjI966JfDck6KYBfbcZIlRR25/WmDwfftgRPGqgD/Xctnv0rzlm2Ee87fI6JYCrHS1/mc20iMQfLYjPO9un0qJJJVbfEuGxtDKB0rrY/BV22d13D8xyQVNS/wDCGSAgNc44xkLSeb4Nfaf3DWCqrocaWZTuYq7E5+cZA+lNkd3BMgHlq235QAM/hXWT+EXVQEmG5eAxB6emKpXHh+9itpkCxyBgAMHGPU+5rNZvhp6Qf3lPBzjrIwPtJVeGjdB2aPtU1zbXVqUSS2dCy7tu4Mrg9MGormzmtWzLE8fqMcfnV6xW31OOONrqaG8RW2lxujZR0+nFb1cSopTi7x621Clh+e8evQzDbr5xSNiCBuwex9D61WYs2PmH0A5HvmtS0j+2W8kxCr5bqm3HLg56H8Kr3wEaqqs474AGAKHOMrrqiHGUGrrc5rUlKXjZGNwBoqTVUIkQnB4or5DFp068ku56NOTcEzoPDukDVtQk852SzgXzJpFHIHp9T6V6FAiu8AEYiggG2CEdEX1+p7mqlsYlgFvZwi2sw25Uz8zH+857n27VpWiZbuK68zzD2j9nSenUrDYf7czRjRdu5eD7Dmrca8AsASf0qO3iHqDVuNfu+nNeDI9OMbEkeFJxw3TnpVyGNuCucZ/KoUXKLjntmr0CEEY2+uPU1Nrmy0JIolVASfb8atRIgxwPz5qADLAEZwfSrcSjaW/QcY+lVETI5EDAhVIL9Md8U+Ndp2txjjPalb5SFQ5X6c08oN+HPAGePWhlJdBVBDAdBnpjigDBb5gQDjn1puHLBDgE91Pb3pwyAiYAGfSp1K5bDgiuSSpGOCPeiRCo746YFOywZsYPGOBQpOMKeQOeaY7kSjAICg4681G3QKikAc/jVoRNtU7hkn5s81GQBgYB4xSsUmipubG3gY9e1WFUTDkqT0+lRSAgHjp0PpUiYRR0yeSRSLdmJJGB36VCY2TgkBieoqyrYxxx6mhgHPYMaZCdtyt/EWMQYD36/SormFHcspyQOlWyvlgZx9SKayEsx+6T0460yZK+xizx9A3UdPpWZdWpycevUCt65RtwL/yqpOAzY79uKIsylCxzhBt5BIoDcEEHnIPBFcHrtudP1CaErugceZCx5+U8cfTkV6ZcQHOcCsPxBYC90yWIRk3EAMtuwGSf7y+4xzivqOHscqdT2E9pfmeJmWGuvaR3R5cYEhukEy7kPOD0NSOnkyPNbgi1yFOBnZnqBVy82TW42gu5Hc9B2+lQAIlupbOOc89foPWvrHTtseSp33LVpdxNCQS/lnA2kZAX1/lUEgdGZVPAPAPOBWbHIbaYLJny3yy8fmK043aZSC2XUZA6Aj3qKdTm9VowlDlemxlxkR71JwQTnjtmrJ2na6biRwQecVDeoTmSPnBH3R1p1myOuCXO77oHY/8A1qIy5XyGkldcxYVtuSWUMOetRStuJKgsv+yOc+gFNdHXIfoO47/jVFpTK+cHy1PrjPuanEVnBWjuwpwT1Jrfc0/mbiXJGAB09qvmJQ7MwwnY4pllE20sD8vBBBrQW0kn+dEBWFcuCeo9RXRQpcsLGdWfvCQKkgCO4GemOx7VqizitbsWsVs11fLwSRmNO+QO/wBTxTdMMD6fcR3AjBMiHzQvMZ5GPp606K7n8wW3K3cBxC5PJHdD6qe1b69Tlbu9CURLHNIZWjuLlvl81+Yo27bQPvH9BVW4hEy+WigCVjtxyFlHUfQ/1qxKsccLFUEcWcH5s89xn09h+NVVvicRxb40zguODj2HRfpSehMbvYzHzvEi5yuAxJyV/wAKt3d4byGPzI4wYgQWUf6w5zk+9QNKkjL5YG85A46jPf1omZUZkyAFXrjPNRdWN7XepCdrAnIG3qfQH2owELZABzjryKUEMPn+SHqXK9fbJqaCze5bFjDNI2MDjKj3JrJXLbQwwmV2I2gkYAHH+TUzQq2PMZyxGBjjP4DmrFvp1tbTCTULv5ycGO3AZs+x6fzrdsNP1DUCqaRYC0hYAGV/vH6t1NRUq06MeatKwoxnUdqauYkdoLdQ91kFVwsf8R9CfSoQZLqbbBGXxg+WoyD9fWvQ9P8AAUSHfqdy88jHJReFrp7DSbexG23hjjxwCAMmvDxPEVKC5aEb+b2PSoZTOWtRnmFj4S1S8KsYlt4jjJfrn2FdNo/gyC0l864uGkuDwDtHy/7vp9a7VonEgVQenp1oONpJ4wa8DFZxicQrSlZdkerQy+nRfNFamDD4e06B9yWsZkP3mcbifzq8luqLiNFX2A4FX3GCSR1A59KjKfJ8vB75rzpVJS3Z1Roxjsir5Z+U8cc8d/rRInBde3XNW3i3AHGCOSKryxZJI/Ks+Yfs0VQp38Hp1JFKI9qk4GfQd6MBXPGcjt60rKcYY5U8/SmpMmdNEEsWXAGORwTWXcwsG2sMN0x61rHlQV6g46/rVa5yxBGCR3AqlIzcDCuohICMA9uR1rltU0SNt8luWgcjBKnAI9DXaXCDHOMegrLuIvvKQAK3p1pRejOadI4uz1afT5ktpI7eC3XLOuzcZT9eu7t7VUiRnslY/JvbZGM8sc1ta9pq3EXQKwycgdK5i3uAt3FBfzSRwwH5MchT2OPSvWwuIi7zt73Xzt+v6GM71LU57LbyuU9XiZI9rJgowPJzgUVJdukmny5bfIrABh/Fz1orkzDWrcmj7qtc9Mi+Zsbc4HOK1rZSERQBgCsuzBJyeBnnPWti0YdeOnSvLbPQgi/AmSADz3OKsqn74biSPSq9t0yxAzV6N+NoHv0rNmyLluFGzuSfumriIWbPTnkCqluBgOCR7VoRYwBnOPwzTRQ+NSpGBnd+lWD1+flicfhSKwHEYX0I9KVep77ec00ylqOKbRgEEZ6ClZnK/LtHFP2ZAboQeB609hyBsGBxxTLRVjDbSDkuDknoTVj+H5N2R60saoDk5Kn1pGTkbVAGOx6VJW4zYxyQMEdADzTgu7DluT1GKDgYBB4POKcCoHz55PQelADCGOcblHsaQIwyGPynuRnFTzHeQSSCRwAKaFDKOpJ4Ap2EiuyBW3Z3g9B6U1HRSckZPGM1MUw5ZV/DPSoXRBkBcDuQc1JoNADEhR05xSco53/MMjpUwRQ/y42+hNJjaeApB4z2osDfQSRhjawyo5AptywMJ469hQ6/Jg4DgYHNRkK2Np464oYrEBywbnHsapzoyPwoAHNaBUfeI4NV2XIOCTj8aSHJXMyVA2RxyMis26jPLrwycjtW3IvG04yOnFUrpMbtyjnrW9Ko4SUkcVekpJpnlXiCw+wXrtFEy2sp8yJicAHuB64NZ7DzVlkVQD0bI5z7DtXomr2C6haPAQPMXc8Jxzvx90fWvNZpJEumE3Eh+Ug9a/ScDjFiqKqLfr6nylalKnUcStdW4uLJ1T/Ww/Mv9abZXBaIOjbdhGBVzSyh1Fo2wFcMv0yO9ZcyC3uiFJIJ6ngEUrKM+fvo/wDMa1XIzWkiRC0hQyRfeDA4wfes6/t1t5oih5kTzHX+6x9K0LAh4wrgbQ247j1WqGoziR1dmB+Y4J6Adq1qW5eZ9CabfNYW8kaeMMxJYALnGARRHb7BGzIQhOdvtRalZnTeu0JyWY8Ee1aMm54pAVYbfnAI54PP6Gs6UVUftOgTk4e6i9pKtZC7dVEieXtYEDDKSMCp7aHZdMAWMc0TtER14GcH3GKhtZUbTw7MDJ/qCO7c5B+mKuaLfQW4Md9Hvt2BZQv3kYjGQPQ9CK9BaK6OOV22R2aR3YuFKqsphYumRjPUEf4VlTXDuVaRyVC4x6AcCpWijjjjaTb87bSFzlfrVeXIdkEgSNMnJ43emB61Mpo0hC4+aWWdkaWQMFHGegX2A6U9LZ5E2qTtXq3CqPfNRBX2RM0eJXGAAcF+epzU73UruGuDEYIhhAB8n4DuazT0vIp3XwkZQLH8nzkfxudq/Qd2qLDyxlJGCg87FGPyA/rTy8lw5KMUGMFm+8f8PoK3NC8L3t+gkjKxgkFeN2R6se30rnxOKpYaPPWlZG9HD1KztBXaOfghZZI3eXc6EYVhu59MV1mlaBq2qqpnL29uegcYB/4CK7fQPCdlparIUE05/wCWr8/lXTRxKifNzjgL6V8zjeIpO8MMrLu9z18PlKbUquvkcrpHhPT7D5xH50+c7n5x9B2rpY7dtmQu1QOQKsiNeoPzUiswf7xAPavm6tedWXNNts9qnQjBWirDRH0+Yrz90UkiEOMgHHTA709upLZycnpT4wD25xwT3rFs1UCFMh8Pz6UskAfBJwxOfYVMwyV3KN2abKACw798mhhbsV2AyWKMc4HB60SEBuMA9+KmHHAPAHNRnBJc9CenXNFwcSArkHAz2I9PeoXQKQScCrjcDKgEnnApjgjBbGe/pQIoeVkFjyDwDTDFkg7zxxx0zVxo8+2eaikUITs6nH0oREii8RVm4welVmUNj5QCeOK0JTk4KHPfHOKrMMn5hjvzQjOSMyeI4bqFzms6dN/bFbc4bBUjORWbcxNuHIKkj86tNmUkc/dxNtb+XrXGeJLDIM0a/OvX3Feh3keQSOvTPSuc1OHcrKckHtXRSqOElJdDlnDmVjz6Rs2kp78UVJrEP2aZkxhXbNFdWKrc8+ZHNCLSser2g+VSvOT+latuApCj69KoWS5XjgAda1LSMhwM/N948dK8xqx6EWX4CBwAD6nsBV2JCT1xjqR2qKGMBDkjd61cjk2rhQACM49TUvzN4snhUZAxz2q6kZBBHTqcHmoLYY5bt396tqA2c8EjqO31pWsabj40JYgMQQOMVKkW0HuueSTTIE+fAz65xVnbk7W2gqOpqrB5ABk4BJPQc8CpY1aP72ATxmkXGAANoHAp+7eu0YwDx6013GmEgYvtTBHQ5qEjYxKcHoRmpRhk2jjsS3aneUhDEjjgKQM8Ui46EcSMyZ3Auckc9qEVldSSpVjyAamjiGwfLz70NFsI2jcvfFFhNjSv7zG0hRyDSRjBbuPp1p5OExnjp/kU1CFILsMHlQKAsRMoUcZB70rRDaFBwf51M+1hnALEcDOM00qC21sA45otYaZDgAYbp69aXA2sAORznpRGh3bUYY7k09U2MQeffrTG2VJUU53cnvg4FV2Cq+VGR3q7Mu5AExjqTVUquT8vvioY4MqlWwwycHke3tUZYhMnOSMc8c1Yf5WOOhHBqGRP3YwQQTn1qbM00Kc2Tz/kVBINyEsMgjFWpVJJ2kk9x7VXkPyEkgitInPVWhjXKku2Gw3UH0I6VwXjjTNs8V/Fgxzn95gYCSDr+dehXaj7xIOaxb2CC6P2a94tLkiJznHltn5X/PrXvZNjfq9Tkk/dl+Z4mOoc651ujzrT02zrIcnB7/xDvVrVrAMS9vBK0eA5bGQB14xTdRilstQngbKvCWjH1zjik1V5NO1K2mtpHjIbaxDcHI6H2r7KTSTPEV5STF0WB3vFHyNFsYu3aNe/PSslhbhi94iSxjKqhJDE9sYrX1XUbq7Y5YJECNyooQH6461lTwmTc4PAIYD1z6Vliaftabp9zWjPknztFmzVch8EFs4X720j+fFaULYCvIGCnt3wOPxJ71nNKkY3MhYgKVA4AOOc0PMZCGcg44AB4X2rohaKUUYzi5u5YRQ5wD32+vHtVlgGtuXbaBiMAdT7moIQ0KCTeME4B2/lirMUTq4RtweTJUk4Cn8a2vzIzdkxjy7EUn90rY3DPOc9fWq9ubeUs7RlpFYhd/CKP7zdyfapLlIIi2+T7RIemPuqfr1NRzCXKwCIQoAGx3Y9cnNQ1qVF6WRFInnTiRg8u4YVW4LH1PoKsw2sk9xCpjeW4/hRR0+g6AVf0TQ7rWbrMGRCeXmPRT6V6toHhu00aABIw0p4aRup+hryMwzelhE4x96f5HfhsFOs03ojmPDXg8ho7nUm/eLjbGOgP9a72C2EarHEqogHQCpIIgrZPQHIHXFSvncSenavicVi6mKqOpVd2fR4fDwpR5YLQI024G4HFT+SqKW2/nUSIACSpLA9AetWo/uZbG0nHXmuVanWlbYZFCJGXC5B96Qrhn+XO3jJFWVDY5yAOmO9K7LjKZOB1x3pgr3K6ovPUnHOaayKD8ufSnAEluSdxxUixLG+JByR68CkU3YhKkt93BzwfamMMZZwDuPB9Knl3FcLxj071EqhUJbceMcmgI9ypgjeSehxTjhQMgkn0FPCuX3tjZwFHrSAYJKhgueoHSkORXclsqeB04pzDy4+ME9Tk1KVwORknnP+NQOu4Y3HpnijoS0RMcHqAM8Y/lUW3Jwewzk96lKgrg7cjrzz9RUSkbCfToxoTIlHsQ7Q7sUyvHORwaYUIUBs+gyKf5m4g+h5pmdzc5yBxincylEgkiZkw3LA9D6VnTxYfkZ9cdDWmxYKSxGf1FU5i2Dkgr0qrozcTDvVycHqO1ZF7FujOT9BXRXSg5OP/rVj3ScZJ7Zq4u5lKJwXiO03xMUHI5zRW5qkG5XbCknrRWyZzOOp0tkAAcnmtm0O7ABwSefcVlWgCJ0JB7+9a9oVLZbgDtXK9ToRpoCI9oPzE9atIgUgZ6dfc1XgwynrknoKtwQ5cbjkY7dqRtFlqIjy9u0jdwR3q4N5VFK4xVWN1HIPTrnrU8Mn3j1ai5qkWI2ZDnGSe7elW4kOCcA/1qqjHcOCR/tHp7VNvDuAikn1NUhtE0WTuBK59MZxSnAILqCfbrUaMVIUAAeoPWpiXUnnjjp1NHQFuNdP4gcDOOnWpYlYfwsR1A7U0AsQ7KTg4AqVjtKqmCSeKEU9NADfvNuOT703JVvvcZwM96ncKh3AAMeDmopQd3yqFIGCc0yU7sjH3ycHcemPSl2px1z3z2p8QLHK8kepqOVMurbcSE+vFIq4mzneDnjp1pG+dypGMc4NShGG7++OMCkWNtxbHzDqewotcVyJlIOF2888UnzMgKnt07k1L5ZZht4PuOKZcIVDZxlT1FNuwXTK7nady9B1B6Cq8qjOQcelWGRs4IIBI75xVcpIJGP8IqGUtiB87sAfNjHSo2O1eejHAB61PKp3l1HFRluoI4PU0upbehUKYIyeRwTVW5XavBzn0rQeMAHgZAzn0qrccJgLz0H0qkYSkYt4MK3JGRWHqMYltJEY9sfSuiuFBTcT+VYd2OSBn61tTepy1dTmvElp5+swXcgIVrZbiUf3iBjA+prC1RhcaakjqN/mHc2cjiuns9cGn6nNaX9v9rgbDRb5MCI+oHfn1rl9QEkVrIlwoYtOxGT2+nbrX6Dh63tqMZd0fLzi4VLdjJDI0YU88d85BqSFmVGVedxyPrVY5A+TI46GrcaCNR/sYJ9RW6bckuxbSsOiC/uyw+vOTz7VKyhW+Qsyjr8vAGOuKQDyd2GCkEEADlvcmpILhFtgjJI0Rb5+xPsPatUu5k77o07LEUKuoC56TyruOfRBUV3C1xOHmllX/anbk/8AARUAnnW+DzMyEYUAAZUH+72HFWBNJeH7NZWrFpB16s31Jq51IQjeTskYxhJytHUbJcw2gBtULTD/AJavj5f91e3410XhfwrPqZW41JWSBjuH95v8BWn4Y8IJalLi/Cyy9RH/AAoa75AAgwMDjAzXyWZZ85p08Nou/wDke3hctUfeqEVlZwWcSxW6IigYAAx+NaDBmAXbuAHX1oQqzc4IH51KWUAHnIONtfLym27vU9uEUlZDEDLwPvNzT2+ZSCPmHYU6Ab8Er7VNLEQpwRn69ak3Q2MBowVTO3vmrMCqMFhziqkf7sDGcH0qdXbaQxODzj0pXsaWuh8rLg7iS2c9abgAbckg9vSiSNckMFBOBx3NIUKuc88ZBxRe5VluSRrhiVQ8Dr/jUbAP82eVOBzjFI7MGPGMCmxuH4IYsR6cUri5eojPjcMZxycHpTSnmK25Tx61KiMpJI/yaUK0bfNxk5Az2/woHoQxxkgMeF/ummyRlZDuPGeBU5YYbH8R6CmyKFOCQc8896ZN3uU5EKrjHzepP8qrMNueTtxmtCTcT0y2OmeKhl+VQQQP7wx1pMrmM4/K3zDa3UYPWmSAF2znGelX54EYAjaBjPFQSxiMY6t296Gg0bKTpkdQB6d6JAipjjdnoKn2jaOORyKjKBh82QvfNNGUkU5CCpXnHoRzVOVXOR8pGO9X5U2/3jz9aqtnGG69RntRcyasZ9wvUjAHp1rJuI8MemwH8a25AGU4PJ7Y61nTR4x8o/z2qkzKSuc5fQhlLEkgjkYoq/coMkYz6iitUzBl2zQsAD36Vq2nzsAAdo6EVl2G4BfQnqa2bIbMnnJPAFZFpF+A7GLYJx1q7bAg/N1bkAdKqxL8+0E/NzxV2MBI+QOOgFI1iiywVAdxH0HenxjePlOSOo9ahGXZSygnouOKu24aPHHzjkk9qS1N07ImiJAKNjbjpjkGpEUgFlGB271JEAVJJKk9CRnNSFFAIUdOpq7Ec1xuN3yuFyTninElydoIHXBHSnQ7WQkkbT/niiOIxr8p+Un1pFRY+NzgDC7j6nGBQxAY7QMnv704BFQhhuPcnvTAI3O1h83QKD+lBaZKuXhHy8Hq1PAGRk7s01dyltw6+nGPahtwIxGwxzxTJcR7RjfnoD6d6hJD5wCcHHBqUMpwzrjPbNShcrkKAMd+9AytncrfKc9Mk0qsOQFUHuR1NOWMqcNgBunrTJFYI3U+vHNF2Ll1Gljt2pxn73tSTFlAKY5pqIcZZywPBwKcI8Jwcr2HrSvcXLZkLKrY+U7qrsjBiOmOtXVBAbcVxiq8qtyTjB9O1NgnZlVo9znLdcgYqq6nPOeuMVaZQjdiajePcBjlucegqS2yDcudpJzVaVR1ToT61adNuS+Bx+NVLgZT5Tj8OtNGMkY92pAOzJx2NY96OWx0xW5cr+7BOTjisW+PJGAMdq0g9TCexwviAH+17TygTJJkKAerDtVTxhIBqTqDgFVZ1xjacc1s3MPneJdGKnb5dyJWY9lAya5jxNdG51y7mByrysw79+K+yymo3h7Po/0R4OJivbaFe1jYW8zjOSVXaBn5TzmrSx/KCy5b68Y96r6feLCHjf7kow2eOe1WoI2S2ZpT8ykrn19DXr0tVdHLUbW5JEiuuC++QnoPuovrTJnaCWI7GAXmNW7/AO19asIUii8xwBEckJn5pW9/YUzTLOTWZd7M4hBy0vQyewqcXjKWFhzTfyFQoyqy02HaZZTatMY4CXGcO7cYH+NekaBpFvpUYEYLOOC56n/61RaPbRWcCLGgVF4wO/vWxBIABn6jIr4fMcyq42XvaLse9hsNGjtuaduMleatxNsckgFc/lWdbPhlbOeeauh1bJUjd/I15Z2otgKSMk4I5PrUjPv57DjFQK2VUN90cECrETERkOOvb0pqxtFliDHy4baQcDPQVIjFyd5ByeBUca5B2g+vPpUgUbiwUig0VrjsBF+ZiOOvpUbjGWBBBOOetOCO25jjA4AxQm0nDDcynOe9Jm0Uh0fLHcDv7YqSQNInyjOOhJpyKoG5jz1464pjN8oAGPXjrSsJ7kErMAq7sn0p8KhSpxnnBx2pYUEgO7C7Tge9SRREngAf7PWhK+pbdkPK5Jx1XoPWkQiRssTtUYz/AEqY7QeWw3cVEy7g+0gADPPeqsYXIZBuxuyeeewpkqnPzr27dqkyzEF8AA5A9aR42zw5wefpSL23K5wGOQFX1zzijapiORz6gVOIdwGe/PFRyghDuJG44BHP4UWG7PYqyqWBChlwMEZ4NV3J3cr+FWnY7cHkdcelRyYcHbnK45Pek9RrQrSQ5OVwDnuOopsybVJ/QVZbCKN3OT+FQS7SRt3AnjAo2IbKMh2/Mo2gep61VnDM33QPTjNXZlO/29MVXlBUnbnIpamUkZsqkZK9e+P6VSuBn+8CTWnKvyktjJ6mqEqruCqvUetNGbRj3CnnHPfpRU1wME4OfSirMWh1ooC4PPfNbEJI2jGDntWRbAsVJwa24SQ/I47cVLEi4GCkA5znkjvV5VLMo+8Rxg1TtkBQHAHzcVpwplTtPzHn60kaonjXCqCvHrnoPQVoIEKKFGAD096oW7HGME+gNXUJO0AgDGDmqKepbVwVPIA7kUxXO/YPmOORUZyp4YhAMbVHWpEwxCgspBz/APrplRSRK4dj91dowOO1ORCwJyoXnANCoFLEhueDk96ng/1YUD5iPu46fWkF7DCdsS7Tx7DvSINp3ADJ70+7dYUUEFlJxhR71KsWUBYBUyQc0ilOwxkcMWyQp46075mVVJ68Z7mplQLww+XoKUsCQR0+nNND5rkJVVyByfc1GgfzDg5GOQasooZ2Cn24pVOTjZg+jHrTsPmIyCqD1Hqe9Vw4+dTkE9c1YlGABjPbg5pkifc243D16GgL23KqoUkXb0xzk0KxzkLkZ6YobzMZYZPTimkYAZMlhjrxxQSx7sSzAAEDFQT7SOCQ3UjtRIw3hgcY79z6VFK24OSy7xxyKAsU5SpHX24PWoy2CCrcdasSx/KCcYzyKqyAIC3GcY+ntUJ2ZW6CQhmDKp5/Sq07fMA5Hp9ae8jYHAHHOKrzI5OTjAH5U73IcSpeL8rEfUmsK8A5B5Nbtw26PCnlutYepHapKDp61cWjnnocx5q295fXEhBWK0kAz6nivPWk8zayHJYZ610PjG9Fta3UCkia5AVcdNoOTXE2c5gI3DMZ568ivpcvxcaUIU3s73PIrU25ykaDAbeRnHUZ6VuwXcVz5Rj8sTogVklO1ZD65rAO1iX/AIeuPWq7tJcMyQnty3oK9qeKVFe7q3su5yul7Tc3CH1DVZIp5FaGMgOyHIY9gMdhXc2O1I0SIKFUfdHauAfbaTWdxAuyC5iDAdg68MP6/jXWabeBlQkgZAwK+SzGpUnWl7Q9HDKKguVHW2rjIB5OMir0UoJ2qufXnpWDaTqzfe/Lsa1LfGCSQSQc15rR2RZqQzHLA4yByDWjaPtGcc/yrHTBUZxgYNaNrJuIBI5NRsarY2ICNnK5Ht3q4mflOT6YPpVK3k3AE9ehOKtxsRweM8imjRMtxqwbAYkY5wakJyVUA4znHrTIMhGZR1qeN1dSMZOefY0epomNjBDEoucDpUsSAjO3LDpSiJQpY/MR1GelPjmSNMkEmnY0v2IAMxsMHzMk+tRYGVQfKxOOtXmACcEKTzkVX2o7H5uQeualotSVhqwtle+DzxVjlcrgb85yOn1puxsbQSDjkkdalUJGNhI4xgU4ik7oaFBOMhRgZ96GAI3KMjOMgZpwQljxjjpn+VSKm0YjyAOMY607EN2KxQAA8gqeAaY5CjIBPb0qw0WHJ7n1pjADIPLdc5oEnfchZGK5O0hvzqH7ow2Np6exqyMmM4Uk5xx60kkIEe4fMw9fWk0F1fUz2jQknnOevrTHjDjPTaDkHpVsRDGVGM8njIprJ3z15wKVi3IzZIyjdfoCc02X5wVLYPUY9avNERL+8G7IPQ1TaMjJXDHoOKQr3KciEjaSQeozVWZWBySCe2ea0yA4G3gng59aqzxgNk9vSkyWzLkHBJHJ4/GqFwoxzwv61qyqN24EHtn2qhKMDJ6ds0jNmZcR7icZPHT1oqWUKp2ng54oq1Iya10K9ku0Ddjpmte1kCxjBI7nNY0JO3OMDOCK1bT5yCSNoOPpTsZRZp2jFmXsDnqOlaNswDHrtHQ1nW5BbcvT37+taUTFSM8jpgDGaRrcuRnj5Me5NW1RgmBtC5qshyDsGcDpmrULsVUfw55PvVFRHQqzsMjbzjrjP41ajCgnnGTyc/p71DsZn5ycnFT/ACxLliNmCFGOM+tFi7khUqpfOVU+tSR5A8xV+Yn1qLLFSVBPA5x1FSIow5bnAyfagroSs3Kkdf4qkEisirgEH7wqNPujACk9B1JqSB1jcryc9B1xQS11JlXzIyCuAvRelRv5YIwmCB3PU1OqkkjBAbgknBprxnYQy7SRlSeRQJPuQwcuCFK5PHNOlXO0quRkjdnr7ZoRcYXGcD1zinqGwVI+VecU7jehE6/KWHH9KgkYGT5hx2NTSDBDsDzUMrAkgg7T0OKBpsjkQBC3IzznvUM678cgAjr2FS7m5Xkqc5x2qKQb7cAfeWkh2KsvMewAl+vA4qI5EYLEbs8mnsQCVyAfY0jMMODnaPWlYqVyrO7Y29Mng1Wl4bnJFTSEMw7A8/WoZ8LkDGT0HeoKSIpACMgAY9+TUBkLMBj39jTmbgYHQVGWBHGR60IJRsV7hAXIPpnisLVF/dkNyfXPSt+ckod2AR3rn9WUoCRjkdCas5Zo8o8cAS6hCh7A859656QoFVQRtXjmt3xkQ1+F9B1HbmucWNd/zKcehr0cPiFRi1bc82rG8tCSKZ3/AHcSknpu9KsxLNZhg0fmp13Ien1FRRPJEQ0f6VaF4Mhmj6dQO/1r2MJXw8kpTqNT/A5pxktEtCZZYbvw9NB56RXNtN9ojWQ7SykfMB79OKfpGpHKZOfr2qu9xbyZLxncR6Vks32e5JjPyg8VyZpCErVIzUntoXQbW6seq6TcB1B3DPpXQQyYC85I64rznw9qakoGOa7O2uFJB6cdB2rxmdqbZ0ML7/vng9hV+FwWUfXFYVtPle4JrVtXBAK4wOMVlI6Is37bJ27jk4zWlGfkAP8AFzWNasSg6Z7VpwSEJt29TjmpNEatvIR8sn3TgVcWJPKYpkE96qRAYIY5+lXFYfZzxg9h6VasPm10GwyNG5idQA/44p7NlwMYzweKXaMKSuW6ZHrUJYo5yxPYZ70GqaepIyoScH5TwPrTABGgA4x19aCwL5IJPoO1OyCPlGd3rRuaIQTNsIXIYcnjrSouDuIJz6c0ojJALHafXH6CnopQfIobJ4FIp2toPgLBeF4H61ZBbb83DHjFQwkhxgYYfex3qQbtzbiAOw65pmEtWJJxuBQjI9ag429AX/kferBOSdwyAcCoEUh9ykbWPJ6CqtoLYjkViyqeW5OBwKjmfhUjAGcjmrZUAtuy6ketUwNpT0HOAMkUio73IirE8sCV7CkIw5IJKkc4FWVK58wRnJ/hNRyiMYByGHOBU26jcr6FWViuNgwDzy3NU5DkE8kg9h3qzKAAzL8w7e9RowIDBTyORUMfQrPkrjGAO596ryDHI9MHtV+XkhTwBxzVSX5s44GevqaZL1M2cY5KgY4IrMudiMx2kk8fWtq4jLEAg88DHr6VHqemwWV9Ha3V0xUY890TPlHHQDvik0Rtoc3dq6tiRGV8ZwwwfaitLXrSa21BxPN9oPlqVmJzuXHy/pRRYjQwbA5POOBkVqQDD8H5ewx1rHsgMHI6itu0KsVzx9elWzBGjaAHAI56nnoKvId2cnlehJqhCw3Z4Y9Dj+VaMCll2kZOeB0xUrU1RdgJ4Crl24FXI/kHJ2nue1VYGVVDqN3uPWpsned4Bx19jVJ9C1qaMbh1UKCSPXvT9oO5tpLdwelVYwQyMRtX16kVc+U55PI596sLW2HKuFCyOAPY8fSpkQBSc5HtxSIucAoNzc5xyKkWLMjhjkLyc8c0th3IkYCQMCNxPOeoFTAYJ2kH3xyfwpjxFnGwYbGeOgHrUsa52kZLA5+pqTS6sJAjA/M7FuozVhgWiBzxntSfd+VVDuTkn0qXCKhZfl/lTM7ojDsjqWHB6YpyqNxLkHPXJxxT1aMqPMUrxnI6GkkGFYpt9MHk49aNwvcgkUbQEGaZsVm2t1HehwVBMZ61HklW5HXHSqGyB1WJiAM546YxVaQMMAkbe+PSrM+dynPI6D1qnKwycN9c1LKRTnIZhtIB7/0qJWXac4BJ+uamlCIcH7x5J7VSbCt175qNjTcWQ7XxgDjt61BJlmbH3gOoPSpJHaQ8HvURJ2tyM9MdzUjuVHQjOMjPX0+tNUrkg88VLK5BA2n2prYGTimhTkVpzlDyDjI+tc9qbYjyTnAxW7dsN7MOlc5qp2Iydx0qkcszyrxR8+qNnqBWM4AbI61ua2qy6nLuyMVmyQlfug7T3xWyehwyWpWUHOF+7n1p+SpYnDU/ydhwo/MUbCTz8pHrTuTYjkw3IyG7iqzw7tw7irzRkglRgD1psileMZJ70rhYqWF01pOM8DODXfaVfCWNTuzxzXBXcW6PeCNw64rT8N3myTazE0PUqLPTLSU/JnHFbFs5AUDt1rk9Pn3uSCcGuhs3BxknGOtYnRF2OosmXAYH7vate3YHnr7GuesZFweeQOvY1t2RViOc/wCNSbI3ISwABJwferxBTnIGB0rNhcIu4Nk56Hmre5iwfdg9wPSqQbk7SkkY/L0pmwsAM/M3b0p8bo6ZK5b2pWdFcjb82OKuxcW0RsCBlgVbpwas2xyhAUAgciq6qzk9Djkkip4yiRZBYMetCRs5EmAmF3BlPepIlQtuc/8A1hVdj8hz19B1py8LhuCeuD2ptk7j2jLTttYKD05zUiqY1w2S54zSKd7AjAAH6VIm1s7WAK8c8c0rXJbsRqmYiwO7J6+/0pIlL9HBOP0pWBIIJ+boR0pYo1yDyAc1WwXuNbcFJzuA544qtkr93r1HoKssp2ApnPTnioipYZkYnA/zmpZaIid7ZOQevXpTZlXcTyz57DtU0YC/KWXI5HvTGGw5Y5J5wPWkTbUqIB6bu2OgppOBnAC9xnOKkuGYqQOnqDjPvUT5yQsfQYPNQy+W+5XkYSO3ydO3rUDEhuRhakn2oDtU564FRSfMcqpx/FkUXvuNR7FebhAwYgDoR1rWntJL9kubnQp5ZXUEukwjWT3IPNZTp8m5uFXGPrWlqlrb3t89wNXtl34Oxmb5OOQPahbGU1Y5zXRcS6jL9uh8iXAxEuMIoHyge2KKZqcAt5miWdbleMSRnI5+vpRQTY5O0ODyOOlakGCox17ViWTEqOeTW5asW+UYz0B9qDmRo2wIXGcgH9a04CzOwGc+vtWXbLscAHhcZLetaUEmT8uAvYgdaSNUaMDbtvIAUcDPU+9WYzvKJuwpGScYqpbgMc+vr6VdjcBvlzx0JFUi2+xahcgDOF68DuafBuaccA88j2qOEKWBxyeh9Kmzypb5RmquKPYtb2YkE44zwakkYOAc8DgAVXUxjoCWP8NSqwAi8xRuycgClcpIlCblDZ5HXn9DUqKVbKKRtHXNRkuGyEAHoO9TxMxIGcMRyByaZVmiWJmccjLdS1KSrAAjnPanrsUDaMHGKMKNuSDuPGKCNyKPaSyZAz0ppDYwGwOh5608jLsq/I55z6e9IUDSZyTzgetBfqNJZQUPykjOKqOWXgDPc5q5Mp++FPuxPIqpLuK4GMDnrzTBK5UbGwbvmPOCKrXCr5ZJxuHNWTlRubjPaoplAC7ujdD6Uhp2M6Uh9oJ3EdM8VXmBwOgx1I7VbuUUHEXRvxqk25twbjPWpdyrrcic43FQAe9RO5IPGPpTmYBmJAA/nVfeFbOSc9sdKgoACGBLdqZMdqkHrTW5Ock8+tRStkgEk46cU0ZTd2U5pThgQAD0rm9Xf5HOeRzW7c5wxJrl9alxFKSQAAeapGM2jzzUD5l5MynOG71CpYLleVPqaklQS7nydxJ6UxI3favUjovpWhyPcjfYzKoLZx82fWkPyOSwPI6CnFdgIccEkA+9SCItErOQR2xyaLi3KzbAgPPPPrQr7/kOMeoFXZLUAqxwV6ZHVTUKxElsggKc8DmldC5WVTCBu3AqOoxzmqIzaXasM7TW3NG3mDIKoeDgVVubPzYiFOMckHsacZg12Oj0S73RjLcY4zXV2E2ApB56V5hod20beWxwwNd3ptxnB9R61ElY2i7o7aylOSSA3rW7p8mVyRx1xXJ2cuVGDnFdDYSYGRz7VFmapnS2sg2g7VGABg96vQsAR90juax4JdoDZznjntVsSc9eD1xTTsWjTQkBWVhknpTt7FOOdn61VjuPk2g9ByfUUrSSZxnA4x71dy0XkYhSCSMjn0pGJB4XPHGKjQhQCSpI7mmvIXTKMc5J4ouVEVZWyVyCCeD61IZSJAuMcdR2qOCP5i24jocGrDLtY7c5I5zRZmjaHRk+X8rLz3p0RwzDkr1LHuaijDrGFXuep7VagRdg+fgH8zTSsZsWNS8p3HbkeuaCjLKFIyc9qeFYAYGTmnliX2kg+5Hb/Gq0FF3GumcAnJ7Y/hqtI7KhCrhj3B7+9W2VmfcTtGfu+3rVW7UYxt4Bwc96TLj2GxqxXPyk+vvSGMFGLkbDyW7YqcKNp7KvY/0okVWGGHygcUrDbM1wHcDAAAwPemuRtLBeR0xxirbRqCwUEonOcf1ppQuuTjsfqai1irmXMS3IGeOcjvUUiPt5yGPatOXJlJ4HGOBVN4mwTnBzgY70mhqRFa3ZtVfzbeCYtgkSjOB7UHVV2nOm6e2D/wA86imRScKMgDt61XlRi5LYbt6Urmcop6lHU3E900xhjhHA8uMYUY9veirF/BAD+5uWlcYyChUcjse+OlFJ3M7I85tmwVC4wDW3asABg4J/zmufs23OD90Dt61vWi/UjvzTOZGtbhgwJwTjGPWtKBsgqp4FZtptO3BJbJ79KuHCJzjnqDQaI0bduCN2QPyq9AH2AuD7e/8A9as22JRAAckjkYrQRc4fJCcAnNP0NFpuXrZ15BIBPXA6VOvzAsRuOO1U0VVJ2A7TgnJ6VoxAHO4bQePl6VQn5AqbY1bHQYOTzmpUBVw7bcY49s0KuI1OcL6HAp4jIyysuG5z1JpGsXoOSRhLs5B9cdasgkTAcbuu/wBKjhQhmydzNxn0qyuSqgYwD82e4pjbERGIymd3TkcVIyZKglQMY2+tNeSRWVVUlCeCD1qQxt/eIz2qiNmOgCrG2CSq8D3poVlIYoRngcVKiB2GAOOxOM0jMY2Ksvy5yM0IVytdTEfKWGCQAMdTVGTBJ7sM+1XriM8dgecVTn2kYPftSZcSnI2Aeeeg9hUAyUKsOWqZl427flPUHrUFwCDuGAV45/xppCZUlynzsvJ7CqUoBODkqfT1q9cZyCT8vaqcy4U4OST371LApzbeeD75qu+MnIxjp71YIV3weHxz7VE2SrA9eh9KgrmtoQSHK5wCOhA4qtMcEHJqzIMR5zlR/OqcxwpyOvpTRjKVzNu5CTuAwc9643xLNtgkHHPGa6i+c/MTxn3rhvEc8jOFh++Dn8KpGMmYIt5Q+NjMrdcqeKsLaswUor5B+Yk8n2qLEsj5mmlYkc/NgCovsfPLucDGSeDSuZEzwMsw3bdoGSCe9KiLvy8iAdWVW+8ajS3Hl5YZI9D1/GnNaLMzHaOMYA6E0m0CTJ4DAiBfOgUZBwDnikkeBMATKWJ6YzmpJLGMAbfllA3Yxx+FKbQytu2DcRjbnGD61F0NJkBaEgFJNyE4JAzz9KoyFI2JEnGeMjjrWq1t5eUwQFAK4H86Y0ERGPL+cDGMcU1JILM5zUhHFMtzAwwx+dRztrotDvgVGT7VnvaLIzRmNgH4APas6yaWwvTBJwQe/et1qrEL3Weq6bODjBPPc10djPgkN3rgNJvAwQjJ5rrLK5zg5xWZumdfaynpjK445rVgYMoDHPsK5q0mwQMjHStqKXAXBAx1PrSNFI1QV3DB4Iwac7A7QxJ9qqIwO0knBqZGB6k8dDTuWmW45VTYi54/vd6sDKgDb15yO1VEQl956r0zViBmKHcSMdQe9NDehaRFA553enFPkXkfMHZTimIFCZRuc5x1Ip0TKE9HJzVXFccqkNtYheTg1chCrGSoySOc1WC/MMjdzx7VYhbfu+vBzwKE+4MtMv7vAPz4zkjp7VHIhYg54A+hFCv85BJIHXHrUobcxG0E45Apkp2Gx5VdvRB1I70wRZG9kP8AvdeKmRiQAAG29uxqSQ/MOwHOB2pj59dCBIOmfvMePcUskSlDwGH8qckgZw20K3IFLIn8QyB054pMakykYyFOCCD+lBhATJXLemOKtzQgRrgZAPXOM1VkLZG05XuKhjbuUrlVOccHPCiqLKShbBwOeO1auCzklQV6jHGKgnjwgIXgnBHpRuPmS0Md8E4BCg9TjofWtqS1SzN1LFaoNgSK2Vl3CRjzux3rPkiOwKAAGbAPfJ4q7e28NvayBnuHltJEVm34Az12jt9aSFOVzC8SRLDqTLFGqYVWZB0ViMkD8aKdq9kLe/Yxu0kbASKX6kMM8+9FSwTVjyWzIJzn0xWxbSbcZXGOp9KwbN/lXPI71tQnkDseo9aZzRNa2JBHQjGSRV+LrzgqTjisyAgM23PrnHWrqnJCnqfQ9KnY0Rq2xPmjHpzzWjGzYGHyB+lZUGFAIPQcVowfIBtGdx6VSL6l+BmG4kguBnjtVuM5yrAhe+TnFZ6qQx2uEA/M1oQHH3gCSMg/1porlJURW6nB5I9h6VYhLZ6FumD0xUWRJuUg5GCCB0q7BEVXnLMefYUFvYeuOdoJx1JNSwRHHmHgHkilEKqvmblyxx7Yq4iZXJZcjj2pkOSsNjARcH5gTkHGcVJCN24Zz6jHNKnB7Y7kcingAOpAUf7QouRqRPC3lkHaTnOcYAH9arTK2FUk+oArRnJYhMgZ6YqnIi7TvB3/AFqkVF9ytKGaTaOMe/SoJdpXPylu9WPug7gT26c1VmAXK8knrxSZRTlRcNknAPWq8xG/Y4HXGPX3q1L8uCMnPG2qc3IPJPcA0IZXn2rGcHBHaqMzeZE3OCDxVu5fPT5cdzVGZipOwAcd6lsWxTIIkcjjJ5qOX5TuBBz19qeDhhyct6moLgEZAHXrmpJkyJnDR4XFZ92+1iMnHU1bkO5DgY5HHSsrUWwwZcZ5700ZsxtSnIUk5rjLmaJruRpElcqcLsIGPc10Wrz4idieK5i0geR90pC7huHPWnJ21MmyukkCscxSuQcFS3U4pyTjaUNssiD5huJ59qsC0idywZgQMsaspaCWAyZwMj34rO6ZNysZHRQyRxjB4BHBpYby4aTaVSOQLhvlzj6Vf+yME3HDAdQRyfpUMtsZGV0VgSAuKlO/QHpqR/aHuFYlgCOFwMcD1pqTSvN5nmOIzyCe1XIbVVkCBSpzljjj8KuW9mkjtHGVViuU3A4Y0rPZA5Ix5ftG/IYnuMchx3/GoLhJA4dJH55LdMVutYNDLskIDck47fhStp/ngfKck4ywz+VUotBzI5x1lI3LJwRk5rM1uxeSNJ4iWaMY967OTSWWHy0BZeOcdPpiqDWh2tgEYGelNSlF3E+WWhzuh6gdgycYOMV22l3m/GTXnurWzWN2LiIFYnPzD0NbOiagCwHcc1u/eV0EX0Z6lYXO9hjtzmt+KUGNMng/mK4TTbrcQWPXtXU2cyCNQTkj1rNmyOhgmPKjOPU1dXbKuVOP5isiFiEB3AHrirsJOAVIAoNEzXtkKqMnIYdfSpEDCUlpCyZ71FaMSATgIe/vUsudmAOemaY76lpWKjIG0dc0+HMj5XkdaiTEqxly2ehAH61aQbHXGBxjFML2LDAoABgnPJFCMBgfdA5/+vUUoG0BT84INHmDpyGHBzTJW1y0u1SwDEd/rTl3joBx0PrVeWQHHy/d4BqxH86cHBzRcb2J7dSrHed3HrUwIcjGFX09arR4QquQQue33qmhYlkyQFHfpQRfsSJD+8JPCnoBTzHGCVkXgHmkI2gnkZ/i7U1mZXfHXg9eKGCbY5mAJC7QSOntVWRWLEooAPO0datJt8sFuQBzxUb7NmVBz7DkUbjTKrKu4Z+Y+3aqlww6tnB55q1Ip8wv0zxkVXkB2sCM0vILFB3E4OEA9jxitd47ho2jubCGUyBSSZQN5HQkZ5rKkGHYsNxPHPGasXkMN5cG4S+ijBwSsmdyY7AUDkZur294kklxeREb+PlxgHoBx0oq5fTQvHfyLIWE4SNEI5bbjMh9KKTKi+54DZdAfSty2I4PYetYOnnIUAc1twuMgYpHOjUt8cDO0k9T1NaEUeGz8o9Md/esy0bc244xWrGFdCcc46HtQaIuxuC4GV254Y9TWrbnKd1xznGaxowQVXPUge9bMOMhByPc8UXLsaEa5xgAMe+KtQxg9B8vf2qpbtjJLDc3p2NaNq25cvgDoRnqaaHdotQRLuyxYJjrVhdq/JuwDjA96rhyXURhi2cYA/lVkLyd2APY0MNepLGh2kRkHBzVqNAVZWYjI4UjHNV1ZMfKuOfm5x+VTszFz5bdeAdvaqGywn+qOOB09efapBtRSc9BzVdHCxqRzg8n0NSysJANgAZT1Io6CaEdgADn6jHJqvMhwDnJ6EdOankbEQ+TnvzUbMAgIG7A60FaorO43NuOCOx61SmyXLHJ9DU8oyqsQcsM/X2qI/LDyhVj6np7ZoGVpY2djuHQcEVnzhlJDYGBWjKxTCMQOM9OlULr95gEEkHNIaM2di5IYbuOvpVOcFQX5J+tXbpiBnOGNZ0hO4AkkHmlITkQuwJ6cioLjBQNz7ipZjgnOOvHNVJGLRfMpz6UjNlVmwSOfasjUGOGPpWhKwXODgDpmsnUmG3IIoIZyWtNuVYgSDIwX9aksYUdFhUZ3Z2lTyvsfaqGqXLJqEQUbtrZxSC4Nud3HX5eentTehhLVmgkcSyOsoGN+BgcEVbtXWC3udyksSMJjt6+1Y09467GZM4OQOxNDXEk8b/vP3jfwg4PShSsRy3NO7nibY8TKhCjOMn5qZbzBotgwHU5RmHrWLDMYo1RmGeu4cgj0o84xllBBGCdyvk/Q+gpX1ugsbD3apOrM25l4fHTHpVsXSs8bo2ApyFHHA7flXMXDll80EAHJIJwc46ip4yYoCQWyRuLH3pXHy3Oo1K9gkkeWLbiQbmIHTP8P4UmnXYOGkw0KHC46iuXjuUj2KjbicgbuSoPerUdy2AFI4HAx096t1eouTQ603SkFWCFlOVJ9Pr7VHaRwS3MceCS5+bOPmrljeY+XLFOSSMHn0oj1J0Qqrk7fmKs3X601U7k8nY3tT8P28lzNExWS2lBAJAPPQH29a8snhn0XVJLS5HMbcHsR2Nd4dale32lnJY7iT/EayvGSQ6lYLOo/wBLh+bjunfNPmj0C0luTaJfhlGCOevNdrpdzgY6145o98YpFXJr0LRL7eq7TjpUyjY2jK6PRLGbPfgciti3l54HPXFcnp11yCOOetdFbPkEgj1JqGaxZtRPsVWXqR0q9FsKgsSO4zWTbuDjuPQ1eDgyBVwAOcCnc0ReGSwYfc71Z3DAKjJxjd2qss3QAjilEvOWOB2FULVlpWBY4PB6j1oV1LEHhuuDzzUEWDGXDYxzk1KjAEsMFjzihFbFhVBQZHPAPvUhlwygcE54pi56EcY4pr/JIQOBnoe1DIvfcsRS4YM/Jxx3wKntt7A7h747fiaqQqWw3AB4OKtRMPLPl42jrk00yZWLe4jPzZPQjFODB4skYOeT61WDAxqgBBbkcYzUqNtUEEsSD7YpskUZPyqd/PQiorjehIdgO59BU5CqoKoqt9ck/jVaXLoWcAANzSLi0RFDIQSSP6VGy7HbO456HtipQ3zDdkLnOD1/OoLjPmD5jg+nSlYorzRqSpJHXGM8AVpXU7RPeRw20P7gI6KYwdydznvWfcAEgFQR90+n1qa4EFlOMzXheMbC0ZHHsPamibGbre8XrA4G5UYKONoIB24oqvciJr1nRp2DjIaTls+9FQ7miVkeDae33R94VtQMFIBOMDsOtc/pp+QE55GK3LdsjBxzxxQznRr2jZyOmOv0rWt3Mhz/AAgVk2ij7x6YwRWpAPnVUOUHXFSzaJo2ylpBmtmFCcDA4GTk9qy7YYXfgYAwOK0bN0JCjJB6nHAoRTNG3UZBVevY1bTzHcYABHQZqvB8wU4GOgJq2JUGcN16eoqhouWquQWJ5J6g1ahUu+1iSD74xVW1IjXk/f561dy0SqxY8cgdM00DHbVRn3HPPB61YVgclScgcAVXhxnqD059KugqWLDkYwCOM07jskQICRuP45qdmbJDkLx8pB61MIC0eQxLH1HFBiES7GUk/wAJx3oQXuRttYsAn50zAUZ3EJjAB4p4yqsGJ3H3/SmkYX/d7HnrTQ2Vbg/JhjnngrVUuAT3+lXJV2w54IHYHpVKTHAwfwFAuhFIgKgrgnqPas2fhTkce/U1oNuGSf0qldsSrB+3Q+lAkZV2cAkA81nMxC89Tk9a0rlVcbc4bHSs6RQvOOBmpYMqOfmXOMdSMVSmfBGeh61amZQmMA/zqnKRu5HHp60jO5n3HQknIz26CsnVJBsORWpedW2msLWG2xkZ6D9apImTOF1KX/T3XOQBjOaikkwoGR5hGQM1XupyJnYKCS5wcdKr5BJLFs55GOnvTaMGzRNwzRLJghs4O09aRZIz0J3HILDrVaOYKrK23cG4Y9c/SoGfIyG2v69KSQNl1rlj0Gce/SmyviFimMd+OxqokgDD92j8ckn+tLJcb12KApJ7dh70+UVy4JFlUOE3EAZPTFTrM6DyxtJHGD1/+vVCKQqGUscEdU704NsjzlRvPDf/AF6hxGmWZJws/wAgClcAgAcmkgul80biR1yo561RLj5sbivr70iuqY4z6mjl0C5eZ9rbmJDA4wMYANRO+2fdIMg9g3X3qvNMQRtyU7Ad6IsDBbG4e+c+1NRFcvG53MQTgjqSP0p7vG+4FuAOMH27+1Z4fdIEYMAT1z0qK6fMZQFgQevrRyg2ZWowi3uiYv8AVscqcY59K6Dw3qJDBWOMd6zLn9/aujY+XlSOxrOtZmgmDDj1ra11YhOzueyaXdB15PBGcmutsLhNo+mK8s8P3wfaQ3JHQ9K7nS7ngbwMdMVkzoizsraQjaVJPsOmKvW5Q/vC20msC2nYqNvJ6CtG0lDAAZyO/rU9TaOxtxEbuDgnj1q02CwAALHis+GURyDcPlPU1ZfdKB8xAzVDLIxGQg6j1qxE+AVbgf3hUAClQV45wfrTkyyOM5yevcUMHsW3b5QNuD0A9aXmRAuen51Ucl1XHDHjrVuNggGHGQM49aCJLlLCYTAwSMc+9Spjd8gwBxwKqxTFpMZ+XPSpS+zjOTnkelMgtRltjAbQDxz1FOY4AC/xDAOehpmdvOAORwO1Dk/cKjB5oGlcsblAbIPI/wA4qGbC9gAOTx/nmlDYA+UkkcAdqczA7ShBzySe9NlJFQCTaSRxnI9cU4qe44DYJzU2whhvUlW5zjv6U12cRkAbRn681INlWSEGRVJGM8kHrWlffaEbbDZK8YACFo9xx71WgijziVxHzlflzmpJfKbj+0WHbgHj9aaE9TDvlkeYtNEsLnjaBt2/hRUt+0bTOBKZVwPnbqaKDWO2p82abL8q5Pbit2zKkn1P5VzOmsDhe3b2ro7Q5Ucjjp70mcy1NuzYHABx1Fatou0ZHH9ay7AZ+9gDqK1rduQQPaszaJqowwuRkHrg1qWqAx54XPTisq1VlIHcda2YEDABcZC0jRFhBtBVD27irtt8qguo59uQPWqMY/eLuIx2NaaqRCf4V75qkXsTpIrwqw+YNkLVyMkKx68AAHsaq2kYtURFULnJA9BVyKLcucAjdyzVSEyWJS5OUUNjPBqzFGx2jA49B0qNFEcYUt97kEHNWwo6s2Bjoe5p2JbJAdoXZgsOxpASNwLEDOdwPHvUmwxquWGD2AxmmM28bSmFHTnHNISIZVAwVOWPtz9adkS5wMjt9aCzNu35545qMAtkpwBTGMliDNwN2OMHg1nXAaOZVbGPY8VflYsSTnHPSqMxAzggjsDQJMpyckbTiqdyr4xjg8YFW5OAW4KjgGoJXTHTIPX2pibszIvVbIJGOfvVlz7iTn61q3IJ3o2SgyRz2rJmwjY6ripKvdFKYkRsRtzVJ33MQQSBVq4OBIFzyO9Z7Nj146YosZla5fKcjv0rmvEEgED7T90ZroLg8DPGK5HxPNss5WJ7H8apGcmcIZOSfUk0RsGlBYcEYH1qt1BGc98mgPvIBH3OfSrsczLUhK8dGU5Pt9KYxUkfNjvUU84ZR1wO4FQhwT8x5PQeooUQuWVYL0PBGMYpQVDhcdueM5qqCS3HTv7U8HGMgcHNMCwjlZCqj8DTpbgkICEJAxnriqskmBuYnPt60jglVJ4b696XLqFyffuJVWyD6jnPtQ7FXA3jkYyO1Vlbn5ufanPP2IG3v3zTsBIrMQFQn0Oe5pYmKfeIzk5FVPNIGQMHPXsaQv8AxEnnn8aLCNHzSASpyecc9KjklUrlyuP1qiJSUBOd3ekkYkYPTrxQohzEssgAypwCc8VTnwJSV6HnNPLeYvPQcUxyWNVYTZp6FeGGQIxOOxr0jR7wOqg8HrmvIVJVgRnIrsPDepZKqTk9Oe1RKPU0hLoetWNx3HOOua3LR84bqvfFcbpV0GTqDnqa6OxlAbG7ms2joizo0cSKuOw5zVq3k+YqDknse1ZkEhKnI5A/Sr0J3nsO4xSNL3NB3IX5Rjnkep9amglKqM4x3IqjACGO8Hafx4qVm5DJ0HaqY12LrgOQeMdTz1NLnd8wB4GOvb1qohZgC3APYUvnEZ6KB2J6UkwcS+pxgA/LgZI6iplba4JPQcH1rOilzx6+p6CrKMC4zgE+tMjlNaN8Y2Hcev1pfM67uVPBxVWGRQQdu5e+B39KlBjGPlw2eo7UBEtjPOACD05zT4crk4GD0LDmooCGQkNjtjpVgAEhthIA5BNPoJuxFI20tnoO1GcoCxxz0HU09gN+TnJGAPWlPyKc5643eg9qQEQt5JsiL7y9QxqC50y6lfb5KqhGCSw5qxMp+Xyo8kjG7qBU8kVsBMrpITDjcS/XPcU0i1dGDLZta7lk3eYBnb1/Wir98iRzNHGpCEAjnJ2kZoos0O99z5O0pvukHniuotVORgCuR0eQsinAAxzXW2hOzCnHpUS3OeOxtaYdowQMngZ7Vs2h3Iu0cjIrFskLIrcAg8VuWyjCnqR09hUGyNK2JKqH5c9PpWzZk4YjOfUjNZFtEyueSxz1rW3iI7UPXoQOtM1WuiLkIU8Zzk9fWrsbnYoQDA6j+tUI0K8NlsVejOSSA23+92zTVy2aEaq5DF+w61eDhOSDg9MYxVOxQLEWfH7vjgg7s1bZgcqFyeCqgdarlaJ3HQkyMCeFzkHHUVdR9+xTn2OMEn61UgXcM5Yue3Aq4skYG4AEDjaR0NKwpIerx+YEZvmxx82cVH/DwdxX3qSQI4TCgFWyG96Fi3ZwpVyMk+gpi0I3fc3J28duuKYxIyoYEDrxSuCP9oj19KjkLDaAcjuCKVxND3AZRzx2BqhcQ4DHAJHtVsyhI/mXJ7VBNuOM5xjP40ybMy7lGI56j261QfKg565wQa1bn51c8BgMYrJu2CjOSeMEUwKNwoH3uAM5Gayblgc8fTFad2SsX97HQHvWPKcncAe/FSx3KdweTis+TkfKD+dW7j5c8E+1Zs0jKx3ZGeKaIZRvm2IwXPTmuF8YTn7GVBA3HFdnqTDY2SfSvN/Gs3zxoDyTVRV2ZTehzjMBleeeBSbmVRk81G7/AC9enSo2JIB6YraxzXJnfBJJPNOglGTklmI/KqxOe/WhW2nIosFyy7jd0P4GmtJlcHGOn4VX3c0hIBp2QibzWZcN09KEkwpBOc8VCG9zSEijQCRm5Pf60m/3NR7hzzRnPTJougHs+aCcjBzx0pFR26Ix/Cl8mXrsOPei6DUTJ7jigse1OEEhYDABPqacbZlPLDpmpuOxDu4xRn2qcQJtBMhOfQUGKEA4LbuwouFiv2qzYTmCdSCcHiq1FAk7HpugajvVSD9a7awudwBzn0zXj3hu+2Oqk47V6XpF3uQcg8YrKSOmEro7Szn3hMn5hxjtWtD91cEDHpXL2Mv7wEnJIretGO04PAqTa5qO5xlCfXaO9Sx8wlSTuqrGVXBb6YzU8UrbTgZHQ96dx3JVVxsA6Hse1SOoVg2egx7VCeTjdkjkiiZmJJJ3AdscCkO9y1Fgk4IA7Zq5CCuSeVz9azYiFYlj82BircEg3AliAvf1pktl/fggt/OpdwCqWGOOg6iqAmYhfMyXbkDGBV2J1YFMDIAzimrCWhdjkbgpjkdSO9SRSlWIzkZ61HEQQQD+JpyxqjLgHaPmJ607Be+5aYeYyhAd+M8t0qd3EaoFxjHzqfX6/wBKpxK4PXOecgc+1OmlJBR35zuyOgpWsNRuWFjdsjZleg5xTpy8cv74xEMu2Rn6EehqqJCULhiwX2zmpnEc582aO4RmHzqq5BNUNprcoX7v9rkFwq5AGCnTbjjHtRTrqRpbgnZ5YVdqqf7uO9FBokrHyBoPKAfjXXWQJXk/WuP8PMDt4OK7OwGcZwPQVE1qckdjodPUeV8uMD5m9q1LYliBuAx14rNtRiMhcZNaNq2AQfvdPwqGbxNq3kOVGRtx2qxEwEmSSWIwB6CqMXyoBnHOKuwxhVLDO4kE+9SzeBrwDbGMcn0J/StCJkSIkrkgZ5PFZBcQ2ommVtuMjC5P5VpaehaVJXZvLdfukdKpMtR0uzS85pU+6oyBuIGPwp6tJvG5hllyBjBpyxAFi45J429qk8gndzlzx05Aq3qSrLYt2RV4SW+bHccY+pq2A5i+UFsdMiqmnWbR/cHyNy3GcmtDy/LUPGTgA/KRwR7UbkyauMkibCnG1mHJA6Gn7mAxldwHGT1pFaQRnJGWI5znHt9aekkaxHzsHJ7L0pMm5UkUtyRnHOc/1pjsCmFwQD3qzII5M7GCgnHTrVS5Pl4WQbtxwG4qdhkD/PySeOgzVfzDzhuvGDVohSjblIJPUdqqz56AZ/z1pk3KUsiiRl39f85qtdIGXsRjnI5p85C4KZyecVUhlJ3A555GKaYpLS5RnGcdd39KxLrKu2MA1v3vyPycgjnjpXP3bYJHUjmiW5CZnXEhJ5xn3rIuW+fk85NaNz94Mc9enpWPeHkHv3oQMo6m42deSeteXeMJGfUlRQSFXoK9F1GU7W+uOe9ed6kWlvpTn5M9R1q46O5hPaxheTO2MRP9cU4W1wf4CPrWmsY4BLH8aFiyuclV9SelVzmXKZgtZSMnaOccmmm3cEA9T7VrOAcE7fpUeBuwemKakHKUlsmHLnFH2RR3bjtWjsIGQdwxxxTUjLKTtJOeaXMPlKUdoC53KcHpzzUohiDY8sbgOasvESRhSAO4pdrg+WcgHvS5g5SCOJWIG1c+4xUqxg5AGD7CpUhXJBySBw3UVJHEWRgWKr2JHWpchqJWwyqfl5ppB6MDz1qzPHjpzjgio/LMbfd5POCelNMOUi8ocFufSkSIByeMduKueUxjJZM54yT/ACqHbk4yABwBQpBYrPHn5gM471FIi52ngHkGryQlY3baTt6jNCxZlG4DJ6DrxRzBymXNCcBgOOmTVY9a3poY8cH8KyLuAwv7HkVSdyHGwWc3kzo3boa9E8P3W9Bz8vTIrzSuo8L3nAQnkcUSV0VTdnY9Xs5gyAgkgf5xW7aTYC5IGfxrjtOud6oVPtXSWcrFQRg46joRWR0xZ0McgPQ5J55q1EzBCBxxxWVDN8i+4+YmrlsXI3Eg8cH1ovdll+FyxOeec4NWWYNhQMEjOfSqcZzhs8cVIWLcnBPf3ouR1JSzKM9BjkUtpNiQbjnkjBpjsDCTzuNEJGdxOGUZwOppNlxemppjIO7JwOfXmrUBEbK56dh0rNWQuBnd0yDjrV6KQsD+7Len9DVrcl3NNGw+zIwRzj+VWJBwo5GecVUgKqXdmOMADtj3qcMuM8f4VVyFuTQOTKxidgSMEtTpFToQWyc4x1+tRQOMq5c4Pt29Ke0m6RyxJPQAelK+hrG5GC8Z4cqrnA/2se1XpWEU4SS/lLnBICZ2/rVCQpy5Yk4wMdT9KvsrXKq89q+5udokChvw60ym+5VvLNN0jiZ5pEIMm8EHB6Eeooomm4m3JslcBHPZFHRQKKV0XFaanxvoLAKuMcciu1045AI5zzmuF8PkeWv0rudJKtCDjjHPNEtzihsdBbPx2x3PpWratyD/ADHasa227gp55B4raiIAwOnFZSOiJoWx8xzgZB6AdK1rUELtBzk8EVl22YjgnazHCgd/8K04nACljljzUo1TNYn+DGR/WrqsV5BJXjtzms2zc8EscZ/OtBDyPm+TuQeapMpXRsWpYnLMSB17CrIcbi0ZbLfkaoWjs6jaG25645q7EChGCck9z/nFWhWZbiygJRiVI6ZwferA2NgYIToCTnNQQhSHaN3zwudw/HFTyPHHt4kQA4yRkChi6lhzhVK/uzjB2t1/A1DcypKu0sFC8HIxUTvliAxPqd1RMd4yocgjgEBv1pCUSQooIRADkZPtVKZXiY4wxPGW/wAamWVfLZWKbzwd46fjVOeSPJJIAJ6daQJiyZcE7yGz0qrcsQRyMsO1LkkAg7cg8dMe9V7joOpPc4pAyncfdyDj1FZ23Yw67e3NaM/AIOelZciqqcux7H0pokSZkcEFjzwcVi3hVQeO5xWhK7JwduO2Kyb1gwHqBVXIaMm8fAbryeorGvDtLZNat7IdrbR/9asS9J5JOe1UQ3oYuqyeXESW561wso3ysXbaGOc11muyYgcAj61zRt9v3hySOoxk0SaRElchXaW2RksB60skLFQEXPH+eKt26JGxVx856kUroy8gZLdCO496zuHLoZpidCQF/KmrySpAyOQRWmtuzthgBvOQRzn609dLdHZnB9VIHFVzaEtWIIogVXI68805YwJBtByfusK0DbvlsLyOeR0+lAtCpO/If3OMVndsvQz5ImGSmSehz0oS0jK9xjoc9a2o7ATRb1GAwwQBUK2qqwhZuRzg0LmsK8WzJWIIcoV2YPA71G43MpUPszwTxzW4mnod6bzvUFkBPX1Aq7Lp9m09s8UmLa7BDM3/ACxkH8J+n65rRRbRLkkYEcRB2sikHkH3qu0IPRfmJxuJ4rUBgEhikYrg4DEdfpTRLb7pI8YDcZP8P0qUncq6KTwt5IKBiyfeC/w020iJ3NsL7ecEZIHrV5p4IlRYOJAm1mH8VQG4jUh4yEkXgsp60ttAK3lq8pKA4PUt0/CnGCVSCCBv/WnvcoG83YEbGDjvVeaYyop3ED0NNJhcYVPnLngdM+tRava+YpbJ3jnGKebtI2CgBecZ64qO4n8zO4kAdCO9Wrp3JbVjAIwcGrWnTtb3KsDgHg1BMAJWxxTK1MNj1HRbgOqMD8p7eldfp8pJOGAAHWvKvDd791Wb8M969B0y4JVS3pWUo2OmDudbbuRGO2R3FaFu3ygH5T29qwobjKgBucdK0YJNu3n/AOuajqbp3NhJmaPHAJ5/Cp1bChMYHpnrWesgYgEYUcZ6VYLjg5yKCC4kyo+ApP60/wAwBsLwSQckfpVVG3AZGD3Pal8zzAMbsH9aBovW8nnO24kD7oAGMVfWTawx1Ax+NYsU2zAKjHr3zV61+U7gCMnLZPHNUmVY1onZVQcHJy3ercbHeRg/P+ntVDzVRcHGeOf6VYgdmKgkAEdScmqIsWQrAllJz/CvXB/pTRIobC5PO5vb61DJNiQL8wC8sPalUqVJw5aQY44x7UJlrQuLIpAOAceh4qe+QTzGdbmLZuH+sfBT2xVG33yxs6xF9gxiNT+AFOjtJZEaaeFxg5Ee08/h3obKXcNSlW7uTk4hGAW6FyB1op2qFEvCroxby1GxRgIcd6KXLctPQ+N9FYjaAeDxXe6ZhI1B7DIGK4HQ8lwe4ANd5pkn7sFTnsPpVyWpwQ2N61xtBA5PUVrQOPl4Gc9+1YtsQoBVs896uwy85znuaxZ0ROgt5E8wEjIHetKGRM4IJJ5FYUEodQM5XIx2q+hz8pJCH0qHodFNXN62YEEMcZ7e1aUJVURhhj3zWHYPIxAl2qmflI9K2lVQqgIzZ6YPWqWxry2ZqWkny8b+T0HU1fjjWYk7nyCMcfe9qzLdGH3CPpnFa1uzF/uxgN1TfjFWiZLsTxuI0UEBUJJ3Fec1cVjtBj+bIxkd/wA6rKjnZtK8ZAIarY2RjHnEkDJ3YwPxpozk+xXmXKEGJnJ6kkc1BGUiXDRugQ54PUVJfywNCN4wzcBhkDFZ/IPEjMee2c0mNarUlkcAklzsB+XevFVJAXQmRRnrhDxTJC+zKyfKByAO3vVd2yCwOx8Yx/WoCxKZWCHcxUYwP/11BI4RcktgHl88EVDOzRqzoxx0x2NRmbeCCfLOM7WGaBNWGXT7thV+D046VQmIHIGR34p5m3gjHHQc9qiJIbA2lVJ+WkmJqxQu2AjOSQV56VkzMc54JxjIFad429nxgkDtWPctt4xhs1XUzkZt6434X8awruT5SCcVr3uSpIGSM1g3rn+I/StEZMw5IP7S1e0szL5KzSBWfbuCAc5I9K2l0ewnFyktzCLgN8gT7jgfxg9h7VzD6lNYamk9uxSVQwDDqM8VVm1AkM4O05J470+aK0auZNSb0NizsliE1w7oCHMSbgGVx/nvWvpGm2U/hu5u7lBH5c2RL5g+YEEKoXrnPOa4qbVnMPUg9x2/AVTTUpUtzErsoyTtB4pwkl00Jknbc7WY2EVp5bFBgbgzHBJ9BUNvrgjsjakxPCDlFZc7e/WuJF3ldrY25z71HJcjAG/Ppg0XfQEl1O0fVbdJAYtrY5Kg9fxqtNq8bRuBH+8zx0workhdKpOTtJpv2sB+ow1TZlaHRzarLG58psdxVRbyVpxI5y/fJ6ViG95Y5XBpkl8W6D8aOVi5kb4vXB/1jcZNVLq8Z4wnmYQnJye9Y/25xwDn3FQvcM5y3NNQaBzNxLvkhWG7jOeuKiluAdwxgelYxlf5sE80jSMwAJ4p8hPOayXYRDtADMcH6U0T/KNw+Uds1lFz24oLsRyaORC5maD3aq3zHcB0FRSXZfG3Cj3qln1pDT5UHMy4bobOFycfnUZuWOBzgVXop2QrsdI+5skAZptIeaKBFzTLgwXKn9fQ16Pot3viX3ry1SQcjtXX+G74lQvy7h2NTJXRdN6np1lLxkDFalvJyuTke9ctp04ZVG7kep6VuW83A/hNZM6os2zKQMk5I7Zq0kmY8jgdcGsmNjsyehHPtVuGXaACDn0PQ0IcjQEpMXUn2702OQRoxkzkdMdRUSSDGBnPTHpShsuFPLHjnijcUWads4lRcDgdc9c+tXBIOWjwVH5ZrKs2bbiUEMORj09KuwyBBmM9Rjb60FmlHN91nIAB/OnrciSdv7gGcr/Ks+KQNlgozngAdKcmVcg4AJz9aGykjS88ITkkB/mGe9Wo3bl3fA7gcVnLulAV8Bc5wT39verCOJF77EPXHfsKalYC9Dcy27IVyqkcIvG4erVIdRvAS/mFmkztO7BUe/p7VDZFPKuZJ4gyxAMqAkkkngN7U9o1u7SeWGDyp05kjY5/4EPUe1NCIrmaXiR3KZG3LNu3+vPpRTtRiSGdhCkSoI0wWGSTjsKKT8jRNWPj3Q2UDPAOMZrtNKc4G7nA7dq4TRzniuy0o7UGScdOK0m7M4IbHUwy5UYIOOM1Yil+cL2FZcMikhcH0HvUhnGSB1PT6VizZHR2z7gDHkMOp9a2bU985VRggd65bT7jkKjY4PJORXR6cxaEGT5W/n71D1OmnI37FFaNSfzrdhXIC7GyfwrBsCDxuIxyBWiZhmNcnzF+YtVdDbd6HRRA+WFCSDPGc8VbhVUzn5XTuTnP0rKtpFZAQr4K/wB7pWlaXcao/wAzxgDOCNwb/Cq3JsaKtJJF8ruqkbicDg1WnmQw/vHbDHqy8VPuWLarTROjDJIO0/Sq1xOhuisefu/LuO4UWsKIizGVEzNwoIAAzj8KoGcs7RllO0YBHBFWFeRGOCmM8DHP50x1VQWCgue+7IJ9aXUbaRQlm2u/zsu4cjGcioElOzBVWHQAnB/KnzZMzKM7VHbjmq0i5BkQsRnBzUsHZ6A8g8zEJ25H3T0qmzuhxKdoyTn69qWWcq7gnAPqOtQPNufLMCp6A+lTcXQaZNrOxTk8fLVecnZvAOOuB60SFwfvAg9h2qKZiDjDCQcntinfuSylcPmPbn52Pp6VmXJHOBjvmr10wVQVbIYde9Y88qmMjBGOpqkYS3Kt458ok88cVzF++E54HQ1u3sgKNjqeAK5nU3GxiOR1P1raOpizitdvTHfMEbnHX/Csv7c3U5J7UmqTeZfyswyc4zVLPPQZrWyZzuRYa6YtkZyKYZmJyxyaiJPtSZPc8UWQrkhkY+vvmm5Pbik596CDQAuT35PrRn1NNwaXA7kU7MA4oJpBtzwRTsA8AE/QUgGj6UufapY7eaT/AFdvK30Q1Zj0q+kztt2GOu4gVahJ7ITkupQowa0hpF1/F5SY9WpV0lz964jHrtGcU/YzfQnnj3MzBoxjqa2F0mMN+8mcjsQAM09rCzViEWVhj+J+atUJdhOrExKMj1rdSwR8eRZMR05ViSa0LfSdQKbY9NbnncYgP51SwzYvao5NQWPyqx+gzUsdrPIcJDIc9OK6v+xr8D5/KiLdN0qj86f/AGWI9pmv7NM9drF8flVLCvqS6yOUaxulB3REY65Iqswwea7Cay09AS+ou/8A1ziwD+dc9q0VpHLi0aZh6yAVFXD8iuioVebQz6v6Rc+RcAHpmqFKpKsCOorlNj0/Sbobl6EHvXSxzZUEfezmvO9BvRJGik8+h712ljPvVR36c1nKNmdEZXR0ttMCdp6Y/h71dEvzYJz7ViwSnIAOO9XkmLHtkcgVFizUDbUBJOCfXkD1p24Mc9e4rPS4JX/aqxA3YcHtmnewWNKCcJMoyNzDgetXBKCcAfNn8R71lRgbt6jkYAJqYNtlJLEEnj1pNFI0kcn7mCe9P87bNjAX0LdPpVWGaPaQScsQCDUiOpXawY4OeP51LLi7mn5paNVRQrHndmnW8o2Y3KvzcdqorIyqQ0Z6Dvzj1pYXDZ84PhR8v/1qm5orG9pst2sjtbBmUDEiBdxfPrUiWl9BIssdpN5pPynbyvsKyNO1GW0uUkjJZyMBVz849D68VPLPfKshS2vkjY5GSxAH1qlITi76FnU7u6aYzXUapNgLgrgDiisd5vNl3OxY7RzIeeO2KKiUnfRmqgrHyxpHIwe9dhYfKN2RgYBNcdpJ+VDnvXXWIBGecDrXVUPMpm1E5KcHmh5Si/MOT3qBSwIzjj0okJbbnkjmsGbLQ2NKcnAwMEZ+ldXpzDywScgjOOlcbpsuCMAEgevNdLYygKMRlj71OxrA6KCTEymNXPHUVoQSmKZ2lBOVxk1j2+ZtrfOoHpWwroyBSFJxg4NJHWpWNvTp0cjEag44+ataDbsDoY2fkbd2K5W3l+zgyBCAowRjOa1dF1RpiNltmMHDFlwa0jLYuUG1dHVrIkkK+WxBUkYwGx/jTTMWDGQqGJxtI2kGqCTKyAoDCF5yR/WlMyuhkZjk9d561ozmWhI00bKiwkFwfvJ82R6VRkn2j5ScHjnGfpTiqsQiFUHOW+7VMlRlRtwuRn1qGVoQO7ebIchcnH0qFzvD5LeVj73qfakRYnydy/Mc45FVpZNwXaSNpOcdKjUb12I5WwygH5cdahkZgD5Q6diKSVumXwhHp1qKaYsw2HIYck9qmxLGic9AoGOuBmqskjbMICSc5JPNHmEEgnPzdV6Gq1y5MmMkDue1ESZMrXT7QFVSF/nWHMzDOSQO4B61pzsDuIPXjp0rLvmAAYYyRjNaRMJMzL2Uhic9RXLavMRC5P3Tzmty/kABOTkdK5e4iuL++gtLO3kuLmR/liQZLevFbU/ekkjCbsrnEsVeRmG9sntUsdpPL/qrWdx7Ia9YtvC+uNGHj05LcHqrbIgPzp6aDeAsLvVdLs0HP7y5BJ/KvVWDfVnmvE9keWR6RqEgLJZSBf8AawB+tTr4f1EoHdIY0PdnH9K9Cm0zTEI87xBbGPHLRI7mqX/FPrKES41K5K9oogg/U1f1SK3ZP1iTOQi8PSmQCW8gVe+wEmrI8PWsZcTXE7/L8pVQMH3rpZZ9Ft8bNOunkJ4Ml0Bge+BTU1ayLEwaVaKPWQs+f1qlh6aF7aZzCaTp/BDTyL7sBmp49KtHkxBYySegySTXQyeIboDbbW9mnGAYrdOPzqE+JtQYZF1Op7BFCj9BVKjTQnUmynbeHbw58nR3KnkEx9Pzq2PD2qWrDfDBbkr8peRV/Gs261C7mwWup35yd0hP4VTlmlfGSzEZAUtTShHYFzPqbr6Yx2ifVLKN84bExY/pUL2NhHJtm1sPu6+TAx5+prFDZCu8ZIU85PBpWkd1IYhQuMAdaXMuwcrNZRokLHdNqNxjghEVcj8ae91oqoBBp07nofPmP9KxUx5Z2uQRyxPP4UwyAqFO5h0IxikpWHym4NUto0zHplko7M+X/nSNrtxki3W2QtyBFCoxWVGkjoTgER9Fx2pqonnAFQPX2o5pByo031u8wxa5nDn+6MAVVk1GeQASXEnPU7yc1ApiBP3yoGQPU1GkqjLMGG7jgUczDlRO7lgWUhdxHJNR52tuUA89j3pqOBI2BkDkE80lzOWxhl4AIwMUmxpWHckoV6dTis7UohjcpBGduO9Wml3qByTjpUUwDxnbGRjvWckpItaMxSMGkp8owxphry5KzsdSZf0m68idRkYzXf6bdeYo5615ipwQR1rqtD1HKqDyRzgUPVFwdtD0O1m4XJ5HOa0IZN5JwTiuds7jOCuMHqM1rxy84BwDxmsmje5rKwzycc1bBAxjJ9/SsmOTON3XNXg4CAk4yaRaNO2YGPBI9frUmQxA3duM1RiPyDafc4qcANh9xyBipBE/zYwB27GrNu+AxBwuOR7+9U4xuYNu2ccA1PE4A+QgbjkgjvSLTLxmy2CTt2/nRGxHzZJQ/wAXaqXmEk7SMdgOxqaOViA6kb+hAGfxqWWmb+gzMpu1hmjS8kQLE7MAevIBPQkVMLPWluARcTRYP+secbfx5rL0+G3eK6vL1Wkjt1U+Sjbd5JwMntikuIILqwludNaRDD801rIxcoP7ynuP5UitGyxrs0Mmqu0ZV8Bd0kY+Utj5iPxoqtrIhh1EQ24WNFijZV6g5UEnP1opPctbHy7pbHaAeldfppyBkZ4rjdKGMcc9a7GwYGJW5z9K7Kh5tNmsCpyP4scUxjyvPH86aj47ZHrTWYdCRyeKwkupsi7byZmX0JxW/ZPtwMnj3xXNwKHC4wD61vwZcLjqPvGoaNIs6SxnAIA4boea1I513DIUAmudtn2gcEmtOOVgnQFanY6Is6ETLIQD8y9MLV62MUbDY+1SMfWuctp1zhj+Oa0Yp8p8xDHpnpmri+pTZ0EU+6M45Gc7TVhJw0ahhyF4z2rAgn27wQNv15qzHcHO4K3PQVd7k8prSOgQKoZm6tk4BqjM4HZs44weBTHfdGSS3qeagmnAtSMHJ9OSKdhJiGUHIbnjoB1qrPcEHZ5YGAaYjMzBug9+9Vp5FUggjPTHrWbK6kbSvkLwcjIHpVeaZsEnGCe3amSTBs7AU9/aqTTnccMNo9e/4VFmTJliSXI4O0Dn61UmkWSJtg3EfkaZLLmMDcMY5x1qq8vQnjHTHerRmxLqXEZXPXsO1Zd7KGjUkdO1TzyEDcSBj1rIvZm2FC3qRWi1MJGVqcuM84x3rmYrqVNYEsM5ikjUlXDYwT71r6tN+5POT6Vg2LDE0zbSrNtGRnHvXVg4XmmcmJlaDNS4v5Q26eZpM9sk7vxqjJKQRuzz2HOKS4nYYwyn02gZ/wDrU0M7A7GbzO/HIr2HK7seckkSBn2MUTzScc4/zzUciyK2QAo6ZJpypKrrucuF6jf/ADqK9IDZZSAx6qeKHsNPUW3hLNtEqCPHzMTgUO0SswXaQOu3miGFmtmGBjPDDBA+tRiRmjYorHI6nv69KnoMXaAcxCXcf9nAIok3qPlBx/CpP9KB5hVRKWRDwMkjimeWGyoaMdgxOC1A0OV3XbgbXGQaGO0kkDdjruwKiJtIi3m3S/KOAMk1E15ZIqnzGZu4CcVDqJbsaV9kPeYlgNw5/iA5NL5iurbgzsBy2OT7VUbUoMMBEzZ6En7tINYKY8uBVIHPPWs3Wgt5FckuxbA/dj5NqDofejByrFWIHbPSsyTU5mBCoig9gOlRNfXDJtL4X0AqHiIFKnI6GAM0m5MIp6DHJFRj5mO9xjvk8VzpnlJyZGz9aYWJOSSfqal4tdEP2T7nRNLCq/69eOcE/qKge/tw2Q3B5OKw8CjvUPFt7IpUl1NdtSjyVHmFM5xULagu7iHI96zqKyeJmyvZxL39pSjG1UHbOKiN7NjAbGeuKrUVHtpvqPkihzMW5J5ptGaKzbuUFWrCfyZh6GqtAyDxQB32lXZwvUj6100E4Kqw578GvNtGuzuC5+Ye9dlYXQIXlcdNtTJG8HdHSxT5GOgPfFXInyAByPWseGQHHXHoa0InHALEKew6UrXRadjSgkG7Y2cY/Or0chVm7jqMdKyVJVsjp65qykoIwD93H1/ClYpamnCwbaXUkdwB1NWAxK8rjHX/ABrPjf5v3ZPuDUisGK53BunSoaKLYZmJ2oMdMKOKdvbeFUbsdGHB+lV4WZckk49c9aV2yoDHGOnrU2LuaGnX81jMzwBXUgo0bjKuPRhUMd89reC4t28uVe64PXsR6VNpEKytJLJEJhGVjSMtjzZGOFBPp1J+lWI7pri7uLVxYTxxhisSxBBNgchGHIOM4J64pW2GmVb6/bULp7lwgkKqrBBgYAxwO1FU7+BLa5KwBpISFljYnkowyM+/OPwooLTPnnSxzweK6iwbAGcgdK5rTfvJ+FdLb9RXRU3OCmjQjJGMfdx1oOdu73pi9H+lO7Gs2bE9rIS5Gcg8AVuWspG3ke9c9D3+tbOn8gZ9agpbm9BLk7V+YehFaMM2wAHIGPXpWVb/AOu/Crr/AOpT60mbI07aYDnI29ckVfgkB5A5POOlYq/fUdt1XR/x8H60GhreeAQASGzxnnNW4Zwp/wBo8ZzWbbD94v41chA3niqQ3sXVkwW3EDJ65zUUsgDKo3ZPUjoaguCQ74OORUN4SBwT1FaPYjqTFzvJU8hSORwBWXdOuMjGR6U5ydx5PWqc3V6z6CTKrzDeVySMc1SeUAnH3icfSp5v9UPpVQ/6wf71IbHGXJ65OajlkJGSATn8qdKOv0NRfwN9KexjJlG6c9MjHesq5Y7TyM4xV+6++KztQ4D4q4mMmctrk5RWxjFVdsFvaxrJLBvxu+Z+Bn2pfEP3W/GuQUZHNdlCr7O+hyV487tc6k3VhEo33iOw5G1Ontmo31iyj2vGZHbkMu3AI9c+tc0Oh/Cl9fpWv1yXRGXsIpXNj+1oVZysUhUggAkdarDU2U/LDH/wLJqh2FNrN4mo+pSpxNGbVbmWIRny1QHoigZ+vrUT6lduMGZgOmF4FVKQVDqze7KUIrZErXEz/flkb6tUZPPOTSGg1m5N7saSQuaM0lFAwpc0lFJALmikopgLmkzRRQAZooooAKKKKQBmiiiiwBRR60UAFFFFAE1rKYplYetdfpN1lBkgA8AiuLFdDof3Y6C4OzO3spwwPzZx+dacM2QB0xXP2nUVswdKhuxtY1omzgj061IOHznNVrb7p+lWV6CkxoupIQgBG4noQanEhKZ3Zx1HXFZ0ZIBwamjJ80jJxmkUWln2oQGAPf6U0XOCeTwcciqP93/eNPH3BUMo3dIv0i8yGaXyYpNrrMBu8mRTlWI7jqD7GtJmijd5wumWrOCGuo7gy4B6mOPqCcnr0rkZeF49BTW4CEcHNJstK5o6pew3V8zxFooQojjQ9lUYH496KzT91v8AeFFIs//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques are present on the proximal thighs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2900=[""].join("\n");
var outline_f2_53_2900=null;
var title_f2_53_2901="Breast MRI of contralateral breast cancer";
var content_f2_53_2901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breast MRI of contralateral breast cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast MRI can be used to diagnose contralateral disease in newly diagnosed breast cancer patients. This series depicts a patient with right breast cancer detected on mammography.",
"    <br>",
"     (A) Architectural distortion was detected in the right breast on screening mammography.",
"     <br>",
"      (B) Ultrasound demonstrated a solid mass on the right and biopsy under ultrasound-guidance confirmed invasive ductal carcinoma.",
"      <br>",
"       (C) Preoperative MRI confirmed the biopsy clip within the proven cancer in the right breast.",
"       <br>",
"        (D) MRI also showed a suspicious lesion in the left breast that was not seen on mammography.",
"        <br>",
"         (E) Second look ultrasound revealed an irregular solid mass on the left and subsequent biopsy showed an invasive ductal cancer, confirming contralateral disease.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2901=[""].join("\n");
var outline_f2_53_2901=null;
var title_f2_53_2902="Caroli disease";
var content_f2_53_2902=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Caroli disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/53/2902/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2902/contributors\">",
"     Frederick J Suchy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/53/2902/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2902/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2902/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/53/2902/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2902/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/53/2902/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caroli disease is a congenital disorder characterized by multifocal, segmental dilatation of large intrahepatic bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The condition is usually associated with renal cystic disease of varying severity. Caroli initially described two variants, which has led to some confusion in terminology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Caroli disease is the less common form and is characterized by bile ductular ectasia without other apparent hepatic abnormalities.",
"     </li>",
"     <li>",
"      The more common variant is Caroli syndrome, in which bile duct dilatation is associated with congenital hepatic fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Caroli disease and syndrome have been described in the same family. Most cases are transmitted in an autosomal recessive fashion and are associated with autosomal recessive polycystic kidney disease (ARPKD). There have been rare cases occurring with autosomal dominant polycystic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular pathogenesis of Caroli disease and syndrome is incompletely understood. The gene underlying ARPKD had been mapped to chromosome 6 (6p21-p12). The affected gene (called PKHD1 for polycystic kidney and hepatic disease 1) encodes for a large protein (4074 amino acids), which has been called fibrocystin to reflect the main structural abnormalities in liver and kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/5\">",
"     5",
"    </a>",
"    ]. The protein shares structural features with the hepatocyte growth factor receptor, localizes to cilia, and appears to belong to a superfamily of proteins that are involved in the regulation of cell proliferation, and of cellular adhesion and repulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. It does not share any homology with the proteins responsible for autosomal dominant polycystic kidney disease. PKHD1 is expressed primarily in the kidneys with lower levels in liver, pancreas, and lungs, a pattern consistent with phenotype of the disease, which primarily affects the liver and kidneys. The genetic basis for the difference in Caroli disease and syndrome has not been defined.",
"   </p>",
"   <p>",
"    Mutations in either of two different genes (PKD1 or PKD2) give rise to ADPKD, which, as mentioned above, has been associated with Caroli disease in rare instances. The protein products of the PKD genes (polycystin-1 and polycystin-2) are thought to interact as part of a multiprotein membrane-spanning complex involved in cell-cell or cell-matrix interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Polycystin-1 is expressed in the fetal kidney and liver including the biliary system and is likely involved in the embryogenesis of these organs.",
"   </p>",
"   <p>",
"    The proteins that are defective in most of the fibrocystic diseases of the liver and kidney, including ARPKD and ADPKD, are expressed on the primary cilia and centrosome complex of renal tubule cells and cholangiocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/10\">",
"     10",
"    </a>",
"    ]. Primary cilia are non-motile, microtubule-based organelles that are found on the luminal surface of many differentiated epithelial cells. They sense mechanical, chemical, and osmotic stimuli associated with luminal fluid flow and transmit these signals to a variety of intracellular signal transduction pathways, involving mediators such as intracellular calcium and cyclic AMP. Urine and bile composition is thought to be modified as a result of cilia-based signaling. Ciliary function is also essential for normal development of the liver and biliary system through effects on cell proliferation and maintenance of planar cell polarity. These properties are severely disrupted in ARPKD and ADPKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both Caroli disease and Caroli syndrome, the biliary abnormality consists of segmental, saccular dilatations of the large intrahepatic bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. While the segmental bile ducts are predominantly involved, the dilated portions are in continuity with the rest of the biliary tract. The disease may be limited to one lobe of the liver, most commonly the left lobe.",
"   </p>",
"   <p>",
"    The dilated ducts are lined by biliary epithelium that may be hyperplastic and ulcerated. In Caroli syndrome, the liver also shows features of congenital hepatic fibrosis (CHF), including fibrosis and enlargement of portal tracts, which often contain variable numbers of abnormally shaped bile ducts and hypoplastic portal vein branches. The pathogenesis of the intrahepatic ductal dilatation and hepatic fibrosis appears to be related to an arrest or derangement in remodeling of the ductal plate of the larger intrahepatic bile ducts during development [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/13\">",
"     13",
"    </a>",
"    ]. One group proposed that the genetic abnormality leading to abnormal remodeling of the ductal plate can exert its influence during an early period of bile duct embryogenesis, leading to Caroli disease, or later on producing abnormalities in the peripheral biliary ramifications (the intralobular bile ducts) leading to Caroli syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of Caroli syndrome are related both to the biliary abnormalities and portal hypertension from congenital hepatic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/12\">",
"     12",
"    </a>",
"    ]. There are several modes of presentation depending on the age of onset and the predominance of hepatic or renal involvement. ARPKD frequently presents in neonates and can even be detected in utero, although age at presentation is highly variable since presenting symptoms have been reported in adults (portal hypertension or cholangitis) or neonates with renal disease or cholestasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=see_link\">",
"     \"Approach to neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In both Caroli disease and Caroli syndrome, the saccular or fusiform dilatation of bile ducts predisposes to stagnation of bile leading to the formation of biliary sludge and intraductal lithiasis. Bacterial cholangitis occurs frequently and may be complicated by septicemia and hepatic abscess formation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .) Secondary biliary cirrhosis can occur due to biliary obstruction.",
"   </p>",
"   <p>",
"    Patients with Caroli syndrome can present with portal hypertension and its sequelae, such as ascites and esophageal variceal hemorrhage. Other patients present only with intermittent abdominal pain. Pruritus and hepatomegaly are common. Children with Caroli syndrome usually have an earlier onset of symptoms and a more rapidly progressive disease, because of the combined effects of cholangitis and portal hypertension.",
"   </p>",
"   <p>",
"    On physical examination, the liver is frequently enlarged and the spleen becomes palpable as portal hypertension develops. Patients with renal involvement may also have enlarged kidneys, which may be palpable. Laboratory studies typically show an elevation of serum alkaline phosphatase, direct bilirubin, and a leukocytosis with a predominance of neutrophils. Hepatic synthetic function is well preserved initially, but may be affected by progressive liver damage due to recurrent cholangitis and biliary obstruction. Coagulopathy from vitamin K malabsorption may occur in cholestatic patients. Children presenting with ARPKD should be followed closely for evidence of liver disease. Juvenile nephronophthisis and medullary cystic disease have been observed, although they are probably rare [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Caroli disease and Caroli syndrome is established by imaging studies that demonstrate bile duct ectasia and irregular, cystic dilation of the large proximal intrahepatic bile ducts with a normal common bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/15\">",
"     15",
"    </a>",
"    ]. These findings can be seen readily with ultrasonography, endoscopic retrograde cholangiopancreatography, and magnetic resonance cholangiography (",
"    <a class=\"graphic graphic_picture graphicRef71092 \" href=\"UTD.htm?36/17/37136\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The so-called \"central dot sign,\" defined as a small foci of strong contrast enhancement within dilated intrahepatic ducts, is often found on CT or MRI imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/18\">",
"     18",
"    </a>",
"    ]. Imaging studies can also demonstrate the renal features of ARPKD.",
"   </p>",
"   <p>",
"    A liver biopsy is rarely required to make a diagnosis. When obtained in Caroli syndrome, it typically shows broad bands of mature fibrosis tissue and distorted bile duct structures characteristic of congenital hepatic fibrosis. There may also be hypoplasia of the portal vein branches. An acute and chronic inflammatory cell infiltrate may be seen around the dilated bile ducts. In Caroli disease, there is only ectasia of the larger intrahepatic ducts. Liver biopsy may show features of cholangitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be some confusion with extrahepatic choledochal cysts, one form of which can extend into the intrahepatic bile ducts (type V choledochal cysts) (",
"    <a class=\"graphic graphic_figure graphicRef80937 \" href=\"UTD.htm?26/27/27056\">",
"     figure 1",
"    </a>",
"    ). However, choledochal cysts are not a form of Caroli disease. Rare cases of Caroli syndrome have been associated with autosomal dominant polycystic kidney disease in which irregularly sized cysts are distributed throughout the kidney with frequent progression of the cysts with age [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is largely supportive and should be individualized [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholangitis and sepsis should be treated with appropriate antibiotics and biliary stone extraction whenever feasible. Because of bile stasis and the presence of intrahepatic lithiasis, infection may be particularly difficult to eradicate and can be associated with progressive deterioration of liver function. Patients may require prolonged courses of antibiotics.",
"     </li>",
"     <li>",
"      Patients with chronic cholestasis should receive supplements of fat soluble vitamins.",
"     </li>",
"     <li>",
"      Patients who have developed esophageal varices should receive prophylaxis with a non-selective beta blocker. A selective shunting procedure can provide relief from portal hypertension since liver function may be well preserved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"       \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Otherwise unexplained clinical deterioration or the appearance of a new biliary stricture should raise concern that cholangiocarcinoma has developed. Whether patients should undergo surveillance for cholangiocarcinoma is unclear. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"       \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endoscopic sphincterotomy and stone extraction can be used to remove common duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, the extraction of intrahepatic stones is far more difficult. In one study, endoscopic sphincterotomy followed by either extracorporeal shock-wave lithotripsy or intraductal electrohydraulic lithotripsy was successful in clearing intrahepatic stones in four of six adults and partially in another two [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/21\">",
"     21",
"    </a>",
"    ]. Per oral cholangioscopy using a mother-daughter endoscope system was successful in 23 of 36 patients (60 percent) in another report of patients with hepatolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/22\">",
"     22",
"    </a>",
"    ]. Long-term follow-up of these patients suggested that stone clearance can be durable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    .) Laser lithotripsy appears to have a more limited role for intrahepatic stones, and is not widely available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dissolution therapy using synthetic bile salts has also been described. In one of the largest series, for example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for a mean of 48 months) was associated with complete dissolution of intrahepatic stones in three patients and partial dissolution in another nine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/23\">",
"     23",
"    </a>",
"    ]. Ursodeoxycholic acid works probably by increasing bile flow and decreasing bile stasis rather than by dissolving the stones, since most stones are pigmented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Removal of intrahepatic stones by surgery is usually not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/24\">",
"     24",
"    </a>",
"    ]. However, partial hepatectomy may be curative in rare patients in whom the disease is confined to a single lobe of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Patients who have recurrent bouts of biliary infection, particularly those who also have complications related to portal hypertension, may require liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/26,29-32\">",
"     26,29-32",
"    </a>",
"    ]. A study of 140 patients with Caroli disease or syndrome based on UNOS data transplanted between 1987 and 2011 showed excellent patient and graft survival that was comparable to or better than that of patients transplanted for other diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis is variable depending upon the severity of disease and the presence of coexisting renal dysfunction. Recurrent infections and other complications related to biliary lithiasis can be associated with significant morbidity. As mentioned above, liver transplantation may be the only option in patients with refractory disease. The risk of cholangiocarcinoma is increased (up to 7 percent), probably due to the significant bile stasis and the presence of high concentrations of unconjugated secondary bile salts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=see_link\">",
"     \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\"",
"    </a>",
"    .) Amyloidosis has also been described due to the inflammation from chronic or recurrent cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2902/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116771014\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Caroli disease is characterized by bile ductular ectasia without other apparent hepatic abnormalities. By contrast, Caroli syndrome is characterized by bile duct dilatation associated with congenital hepatic fibrosis. Caroli syndrome is more common that Caroli disease.",
"     </li>",
"     <li>",
"      The molecular pathogenesis of Caroli disease and syndrome is incompletely understood. Most cases are transmitted in an autosomal recessive fashion and are associated with autosomal recessive polycystic kidney disease (ARPKD). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of Caroli syndrome are related both to the biliary abnormalities and portal hypertension from congenital hepatic fibrosis. There are several modes of presentation depending on the age of onset and the predominance of hepatic or renal involvement. Bacterial cholangitis occurs frequently and may be complicated by septicemia and hepatic abscess formation. Secondary biliary cirrhosis can occur due to biliary obstruction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Caroli disease and Caroli syndrome is established by imaging studies that demonstrate bile duct ectasia and irregular, cystic dilation of the large proximal intrahepatic bile ducts with a normal common bile duct. These findings can be seen readily with ultrasonography, endoscopic retrograde cholangiopancreatography, and magnetic resonance cholangiography (",
"      <a class=\"graphic graphic_picture graphicRef71092 \" href=\"UTD.htm?36/17/37136\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is largely supportive and should be individualized. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis is variable depending upon the severity of disease and the presence of coexisting renal dysfunction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/1\">",
"      Summerfield JA, Nagafuchi Y, Sherlock S, et al. Hepatobiliary fibropolycystic diseases. A clinical and histological review of 51 patients. J Hepatol 1986; 2:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/2\">",
"      Murray-Lyon IM, Shilkin KB, Laws JW, et al. Non-obstructive dilatation of the intrahepatic biliary tree with cholangitis. Q J Med 1972; 41:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/3\">",
"      Desmet VJ. What is congenital hepatic fibrosis? Histopathology 1992; 20:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/4\">",
"      Torra R, Badenas C, Darnell A, et al. Autosomal dominant polycystic kidney disease with anticipation and Caroli's disease associated with a PKD1 mutation. Rapid communication. Kidney Int 1997; 52:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/5\">",
"      Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002; 30:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/6\">",
"      Onuchic LF, Furu L, Nagasawa Y, et al. PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet 2002; 70:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/7\">",
"      Gunay-Aygun M. Liver and kidney disease in ciliopathies. Am J Med Genet C Semin Med Genet 2009; 151C:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/8\">",
"      Calvet JP, Grantham JJ. The genetics and physiology of polycystic kidney disease. Semin Nephrol 2001; 21:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/9\">",
"      Newby LJ, Streets AJ, Zhao Y, et al. Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex. J Biol Chem 2002; 277:20763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/10\">",
"      Hildebrandt F. Genetic kidney diseases. Lancet 2010; 375:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/11\">",
"      Desmet VJ. Congenital diseases of intrahepatic bile ducts: variations on the theme \"ductal plate malformation\". Hepatology 1992; 16:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/12\">",
"      D'Agata ID, Jonas MM, Perez-Atayde AR, Guay-Woodford LM. Combined cystic disease of the liver and kidney. Semin Liver Dis 1994; 14:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/13\">",
"      Desmet VJ. Ludwig symposium on biliary disorders--part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc 1998; 73:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/14\">",
"      Veigel MC, Prescott-Focht J, Rodriguez MG, et al. Fibropolycystic liver disease in children. Pediatr Radiol 2009; 39:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/15\">",
"      Jung G, Benz-Bohm G, Kugel H, et al. MR cholangiography in children with autosomal recessive polycystic kidney disease. Pediatr Radiol 1999; 29:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/16\">",
"      Asselah T, Ernst O, Sergent G, et al. Caroli's disease: a magnetic resonance cholangiopancreatography diagnosis. Am J Gastroenterol 1998; 93:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/17\">",
"      Hussain SZ, Bloom DA, Tolia V. Caroli's disease diagnosed in a child by MRCP. Clin Imaging 2000; 24:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/18\">",
"      Lefere M, Thijs M, De Hertogh G, et al. Caroli disease: review of eight cases with emphasis on magnetic resonance imaging features. Eur J Gastroenterol Hepatol 2011; 23:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/19\">",
"      Taylor AC, Palmer KR. Caroli's disease. Eur J Gastroenterol Hepatol 1998; 10:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/20\">",
"      Da��li U, Atalay F, Sa��maz N, et al. Caroli's disease: 1977-1995 experiences. Eur J Gastroenterol Hepatol 1998; 10:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/21\">",
"      Caroli-Bosc FX, Demarquay JF, Conio M, et al. The role of therapeutic endoscopy associated with extracorporeal shock-wave lithotripsy and bile acid treatment in the management of Caroli's disease. Endoscopy 1998; 30:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/22\">",
"      Okugawa T, Tsuyuguchi T, K C S, et al. Peroral cholangioscopic treatment of hepatolithiasis: Long-term results. Gastrointest Endosc 2002; 56:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/23\">",
"      Ros E, Navarro S, Bru C, et al. Ursodeoxycholic acid treatment of primary hepatolithiasis in Caroli's syndrome. Lancet 1993; 342:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/24\">",
"      Moreno Gonz&aacute;lez E, G&oacute;mez Sanz R, Hidalgo Pascual M, et al. Surgical treatment of congenital dilatation of the biliary system. Hepatogastroenterology 1993; 40:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/25\">",
"      Ammori BJ, Jenkins BL, Lim PC, et al. Surgical strategy for cystic diseases of the liver in a western hepatobiliary center. World J Surg 2002; 26:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/26\">",
"      Kassahun WT, Kahn T, Wittekind C, et al. Caroli's disease: liver resection and liver transplantation. Experience in 33 patients. Surgery 2005; 138:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/27\">",
"      Mabrut JY, Partensky C, Jaeck D, et al. Congenital intrahepatic bile duct dilatation is a potentially curable disease: long-term results of a multi-institutional study. Ann Surg 2007; 246:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/28\">",
"      Ulrich F, Pratschke J, Pascher A, et al. Long-term outcome of liver resection and transplantation for Caroli disease and syndrome. Ann Surg 2008; 247:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/29\">",
"      Harjai MM, Bal RK. Caroli syndrome. Pediatr Surg Int 2000; 16:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/30\">",
"      Waechter FL, Sampaio JA, Pinto RD, et al. The role of liver transplantation in patients with Caroli's disease. Hepatogastroenterology 2001; 48:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/31\">",
"      Habib S, Shakil O, Couto OF, et al. Caroli's disease and orthotopic liver transplantation. Liver Transpl 2006; 12:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/32\">",
"      Harring TR, Nguyen NT, Liu H, et al. Caroli disease patients have excellent survival after liver transplant. J Surg Res 2012; 177:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2902/abstract/33\">",
"      Fevery J, Tanghe W, Kerremans R, et al. Congenital dilatation of the intrahepatic bile ducts associated with the development of amyloidosis. Gut 1972; 13:604.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 650 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2902=[""].join("\n");
var outline_f2_53_2902=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H116771014\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116771014\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/650|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/27/27056\" title=\"figure 1\">",
"      Classification of biliary cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/650|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/17/37136\" title=\"picture 1\">",
"      Carolis disease MRCP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=related_link\">",
"      Approach to neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=related_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=related_link\">",
"      Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=related_link\">",
"      Laser lithotripsy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_53_2903="Alfentanil: Pediatric drug information";
var content_f2_53_2903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alfentanil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3223?source=see_link\">",
"    see \"Alfentanil: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/41/41620?source=see_link\">",
"    see \"Alfentanil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alfenta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alfentanil Injection, USP;",
"     </li>",
"     <li>",
"      Alfenta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       General Anesthetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11431425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Doses should be titrated to appropriate effects; wide range of doses is dependent upon desired degree of analgesia/anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Dose not established; reported range: 9-20 mcg/kg/dose; a high percentage of neonates (GA: 30-40 weeks; PNA &lt;3 days) receiving alfentanil (prior to procedures) at doses of 9-15 mcg/kg (mean dose: 11.7 mcg/kg) developed chest wall rigidity; 9 out of 20 (45%) developed mild or moderate rigidity that did not affect ventilation, while 4 out of 20 (20%) had severe rigidity interfering with respiration for ~5-10 minutes (Pokela, 1992). In a separate study, severe muscle rigidity developed in 5 out of 8 (63%) neonates (GA: 29-36 weeks; PNA 2-6 days) following a dose of 20 mcg/kg (Saarenmaa, 1996); use of a skeletal muscle relaxant to prevent chest wall rigidity is recommended; however, smaller alfentanil doses may be required in newborns.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3223?source=see_link\">",
"      see \"Alfentanil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Doses should be titrated to appropriate effects; wide range of doses is dependent upon desired degree of analgesia/anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pre-induction, emergence agitation prevention, analgesia in tonsillectomy, or dental procedure patients undergoing general anesthesia: 10-20 mcg/kg/dose (Rahman Al-Refai, 2007; Annila, 1999; Bartolek, 2007; Kim, 2009; Kwak, 2010; Ng, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procedural analgesia for LP or bone marrow aspiration (in addition to propofol): Intermittent doses of 2-3 mcg/kg/dose (total dose: mean: 1.4 mcg/kg &plusmn; 2.4; range: 1.8-9.6 mcg/kg) were administered to 20 patients ages 2-16 years old (von Heijne, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Use lean body weight for patients who weigh &gt;20% over ideal body weight; see table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Alfentanil: Adult Dosing",
"     </caption>",
"     <col align=\"left\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"74\">",
"     </col>",
"     <col align=\"center\" width=\"54\">",
"     </col>",
"     <col align=\"center\" width=\"122\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"left\" width=\"105\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Indication",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate Duration of Anesthesia (minute)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Induction Period (Initial Dose) (mcg/kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintenance Period (Increments/ Infusion)",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Total Dose (mcg/kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Effects",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Incremental injection",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-5 mcg/kg or",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         0.5-1 mcg/kg/minute",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-40",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Spontaneously breathing or assisted ventilation when required.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-15 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Up to 75",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Assisted or controlled ventilation required. Attenuation of response to laryngoscopy and intubation.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Continuous infusion",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-3 mcg/kg/minute;",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         average infusion rate: 1-1.5 mcg/kg/minute",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dependent on duration of procedure",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Assisted or controlled ventilation required. Some attenuation of response to intubation and incision, with intraoperative stability.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Anesthetic induction",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130-245",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-1.5 mcg/kg/minute",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         or general anesthetic",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dependent on duration of procedure",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Assisted or controlled ventilation required. Administer slowly (over 3 minutes). Concentration of inhalation agents reduced by 30% to 50% for initial hour.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 500 mcg/mL (2 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alfenta&reg;: 500 mcg/mL (2 mL, 5 mL, 10 mL [DSC], 20 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F131505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V.: Inject slowly over 3-5 minutes or by I.V. continuous infusion; maximum concentration: 80 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F131510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Bivalirudin, cisatracurium, dexmedetomidine, etomidate, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, propofol, remifentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atracurium, midazolam, morphine, ondansetron.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesia; analgesia adjunct; anesthetic agent",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alfentanil may be confused with Anafranil&reg;, fentanyl, remifentanil, sufentanil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alfenta&reg; may be confused with Sufenta&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F131509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrhythmia, orthostatic hypotension, peripheral vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS depression, confusion, drowsiness, intracranial pressure increased, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Antidiuretic hormone release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Convulsions, mental depression, paradoxical CNS excitation or delirium, dizziness, dysesthesia, rash, urticaria, itching, biliary tract spasm, urinary tract spasm, respiratory depression, bronchospasm, laryngospasm, physical and psychological dependence with prolonged use; cold, clammy skin",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alfentanil hydrochloride or any component; increased intracranial pressure; severe respiratory depression",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alfentanil shares the toxic potentials of opiate agonists and precautions of opiate agonist therapy should be observed.Use with caution in patients with bradycardia. Use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics); may cause hypotension. Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function. Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists; tolerance and psychological and physical dependence may occur with prolonged use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rapid I.V. infusion may result in skeletal muscle and chest wall rigidity &rarr; impaired ventilation &rarr; respiratory distress/arrest; inject slowly over 3-5 minutes; nondepolarizing skeletal muscle relaxant may be required. Due to the high incidence of apnea, hypotension, tachycardia, and muscle rigidity, alfentanil should be administered by individuals specifically trained in the use of anesthetic agents and should not be used in diagnostic or therapeutic procedures outside the monitored anesthesia setting; resuscitative and intubation equipment should be readily available.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F131499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Anilidopiperidine Opioids may enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Anilidopiperidine Opioids may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Alfentanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Alfentanil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Alfentanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Alfentanil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fospropofol: Alfentanil may enhance the adverse/toxic effect of Fospropofol. Specifically, the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or grand mal seizures.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Alfentanil.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Anilidopiperidine Opioids may enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.  Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propofol: Alfentanil may enhance the adverse/toxic effect of Propofol. Specifically the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or grand mal seizures.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Alfentanil. Management: Monitor closely for decreased alfentanil effectiveness.  Increased alfentanil doses will likely be needed.  Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10112601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alfentanil is known to cross the placenta, which may result in respiratory or CNS depression in the newborn. Use during  labor and delivery is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, blood pressure, heart rate, neurological status (for degree of analgesia/anesthesia)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds with stereospecific receptors at many sites within the CNS, increases pain threshold, alters pain reception, inhibits ascending pain pathways",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &lt;15-20 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     An early study of continuous infusion suggested nonlinear pharmacokinetics in neonates (Wiest, 1991).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     beta:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns, premature: 1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.163-0.48 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.46 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 67%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 88% to 92%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bound to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns, premature: 320-525 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 40-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 83-97 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Annila P, Viitanen H, Reinikainen P, et al, \"Induction Characteristics of Thiopentone/Suxamethonium, Propofol/Alfentanil or Halothane Alone in Children Aged 1-3 Years,\"",
"      <i>",
"       Eur J Anaesthesiol",
"      </i>",
"      , 1999, 16(6):359-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/10434162/pubmed\" id=\"10434162\" target=\"_blank\">",
"        10434162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartolek D, Lajtman Z, Zdravcevi��-Saki�� K, et al, \"The Optimal Pediatric Induction Dose of Propofol in Combination With Reduced-Dose Rocuronium and Alfentanil for Day-Case Tonsillectomy in Children,\"",
"      <i>",
"       Int J Pediatr Otorhinolaryngol",
"      </i>",
"      , 2007, 71(12):1873-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/17936918/pubmed\" id=\"17936918\" target=\"_blank\">",
"        17936918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis PJ, Killian A, Stiller RL, et al, &ldquo;Pharmacokinetics of Alfentanil in Newborn Premature Infants and Older Children,&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1989, 13(1):21-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/2505988 /pubmed\" id=\"2505988 \" target=\"_blank\">",
"        2505988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim JY, Chang YJ, Lee JY, et al, \"Post-Induction Alfentanil Reduces Sevoflurane-Associated Emergence Agitation in Children Undergoing an Adenotonsillectomy,\"",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 2009, 53(5):678-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/19419364/pubmed\" id=\"19419364\" target=\"_blank\">",
"        19419364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwak HJ, Kim JY, Min SK, et al, \"Optimal Bolus Dose of Alfentanil for Successful Tracheal Intubation During Sevoflurane Induction With and Without Nitrous Oxide in Children,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2010, 104(5):628-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/20335182/pubmed\" id=\"20335182\" target=\"_blank\">",
"        20335182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marlow N, Weindling AM, Van Peer A, et al, &ldquo;Alfentanil Pharmacokinetics in Preterm Infants,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1990, 65(4 Spec No):349-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/2337359/pubmed\" id=\"2337359\" target=\"_blank\">",
"        2337359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meistelman C, Saint-Maurice C, Lepaul M, et al, &ldquo;A Comparison of Alfentanil Pharmacokinetics in Children and Adults,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1987, 66(1):13-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/3099603 /pubmed\" id=\"3099603 \" target=\"_blank\">",
"        3099603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NG KP and Wang CY, \"Alfentanil for Intubation Under Halothane Anaesthesia in Children,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 1999, 9(6):491-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/10597551/pubmed\" id=\"10597551\" target=\"_blank\">",
"        10597551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pokela ML, Ryh&auml;nen PT, Koivisto ME, et al, \"Alfentanil-Induced Rigidity in Newborn Infants,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1992, 75(2):252-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/1632539/pubmed\" id=\"1632539\" target=\"_blank\">",
"        1632539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rahman Al-Refai A, Al-Mujadi H, Petrova Ivanova M, et al, \"Prevention of Pain on Injection of Propofol: A Comparison of Remifentanil With Alfentanil in Children,\"",
"      <i>",
"       Minerva Anestesiol",
"      </i>",
"      , 2007, 73(4):219-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/17159759/pubmed\" id=\"17159759\" target=\"_blank\">",
"        17159759",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saarenmaa E, Huttunen P, Lepp&auml;luoto J, et al, \"Alfentanil as Procedural Pain Relief in Newborn Infants,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 1996, 75(2):F103-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/8949692/pubmed\" id=\"8949692\" target=\"_blank\">",
"        8949692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Von Heijne M, Bredl&ouml;v B, S&ouml;derh&auml;ll S, et al, \"Propofol or Propofol - Alfentanil Anesthesia for Painful Procedures in the Pediatric Oncology Ward,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2004, 14(8):670-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/15283827/pubmed\" id=\"15283827\" target=\"_blank\">",
"        15283827",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiest DB, Ohning BL, and Garner SS, \"The Disposition of Alfentanil in Neonates With Respiratory Distress,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(4):308-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2903/abstract-text/1923912/pubmed\" id=\"1923912\" target=\"_blank\">",
"        1923912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13308 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2903=[""].join("\n");
var outline_f2_53_2903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131467\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131468\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050854\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431425\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050848\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131451\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131436\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131505\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050859\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131510\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050858\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131512\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131509\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050863\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050847\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050846\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131499\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131445\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131447\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10112601\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050853\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050845\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050861\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050862\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13308\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13308|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3223?source=related_link\">",
"      Alfentanil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/41/41620?source=related_link\">",
"      Alfentanil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_53_2904="Lansoprazole: Pediatric drug information";
var content_f2_53_2904=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lansoprazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"    see \"Lansoprazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/57/24469?source=see_link\">",
"    see \"Lansoprazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      First&reg;-Lansoprazole;",
"     </li>",
"     <li>",
"      Prevacid&reg;;",
"     </li>",
"     <li>",
"      Prevacid&reg; 24 HR [OTC];",
"     </li>",
"     <li>",
"      Prevacid&reg; SoluTab&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lansoprazole&reg;;",
"     </li>",
"     <li>",
"      Mylan-Lansoprazole;",
"     </li>",
"     <li>",
"      Prevacid&reg;;",
"     </li>",
"     <li>",
"      Prevacid&reg; FasTab;",
"     </li>",
"     <li>",
"      Teva-Lansoprazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastric Acid Secretion Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Proton Pump Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12860309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: GERD: 0.2-0.3 mg/kg/dose once daily; dosing based on pharmacokinetic data; clearance in patients &lt;10 weeks of age substantially decreased compared to older patients (Zhang, 2008); higher dosages of 0.5-1 mg/kg/dose once daily have been reported (Springer, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"      see \"Lansoprazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &lt;10 weeks: GERD: 0.2--0.3 mg/kg/dose once daily; dosing based on pharmacokinetic data; clearance in patients &lt;10 weeks of age substantially decreased compared to older patients (Orenstein, 2009; Zhang, 2008);  for infants &gt;4 weeks, higher doses of 1-1.5 mg/kg/dose once daily have been reported (Springer, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     Treatment of GERD in children &lt;12 months is controversial as a recent clinical trial did not demonstrate efficacy in this age group (Orenstein, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &ge;10 weeks: GERD: 1-2 mg/kg/dose once daily (Orenstein, 2009; Springer, 2008; Zhang, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     One study of 68 patients (age &ge;3 months) suggests that 7.5 mg twice daily or 15 mg once daily provides better symptom relief compared to dietary management (Khoshoo, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     Treatment of  GERD in children &lt;12 months is controversial as a recent clinical trial did not demonstrate efficacy in this age group (Orenstein, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 1-11 years: GERD and erosive esophagitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;30 kg: 15 mg once daily for up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;30 kg: 30 mg once daily for up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duodenal ulcer: Oral: 15 mg once daily for 4 weeks; maintenance therapy: 15 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary gastric ulcer (and also associated with NSAID use): Oral: 30 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erosive esophagitis: Oral: 30 mg once daily for up to 8 weeks; additional 8 weeks may be tried in those patients who failed to respond or for a recurrence of esophagitis; maintenance: 15 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GERD: Oral: 15 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pathological hypersecretory conditions: Oral: Initial: 60 mg once daily; adjust dosage based upon patient response; doses of 90 mg twice daily have been used; administer doses &gt;120 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reflux esophagitis: Oral: 30-60 mg once daily for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     -associated antral gastritis: Oral: 30 mg twice daily for 2 weeks (in combination with 1 g amoxicillin and 500 mg clarithromycin given twice daily for 14 days). Alternatively, in patients allergic to or intolerant of clarithromycin or in whom resistance to clarithromycin is known or suspected, lansoprazole 30 mg every 8 hours and amoxicillin 1 g every 8 hours may be given for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NSAID-associated gastric ulcer: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Healing: 30 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention: 15 mg once daily for up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Heartburn: OTC labeling: Oral: 15 mg once daily for 14 days; may repeat 14 days of therapy every 4 months. Do not take for &gt;14 days or more often than every 4 months, unless instructed by healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Reduce dosage for severe impairment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, oral: 15 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevacid&reg;: 15 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevacid&reg; 24 HR: 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral [compounding kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&reg;-Lansoprazole: 3 mg/mL (90 mL, 150 mL, 300 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, orally disintegrating, oral: 15 mg [DSC], 30 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevacid&reg; SoluTab&trade;: 15 mg [contains phenylalanine 2.5 mg/tablet; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevacid&reg; SoluTab&trade;: 30 mg [contains phenylalanine 5.1 mg/tablet; strawberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15241705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Prevacid&reg; capsules, orally disintegrating tablets:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322354.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322354.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Administer before eating",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules: Capsules may be opened and mixed with small amount of applesauce prior to administration without affecting the bioavailability; do not chew or crush granules; for nasogastric tube administration, the capsules can be opened, the granules mixed with 40 mL of apple, cranberry, grape, orange, pineapple, prune, tomato, and V-8&reg; vegetable juice, and then administered through the NG tube; granules remain intact when mixed and stored for up to 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally-disintegrating: Place the tablet on the tongue and allow to disintegrate with or without water until the particles can be swallowed; do not chew or crush",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light and moisture",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Short-term treatment of symptomatic gastroesophageal reflux disease (GERD) (FDA approved in ages &ge;1 year and adults); short-term treatment (up to 8 weeks) for healing and symptomatic relief of all grades of erosive esophagitis (FDA approved in ages &ge;1 year and adults); maintenance of healed erosive esophagitis (FDA approved in adults); short-term treatment (&le;4 weeks) for healing and symptomatic relief of active duodenal ulcer (FDA approved in adults); treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome (FDA approved in adults); adjuvant therapy in the treatment of",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     -associated antral gastritis (FDA approved in adults); prevention and treatment of NSAID-associated gastric ulcers (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     OTC labeling: Relief of frequent heartburn (&ge;2 days/week) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lansoprazole may be confused with aripiprazole, dexlansoprazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prevacid&reg; may be confused with Pravachol&reg;, Prevpac&reg;, PriLOSEC&reg;, Prinivil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F186813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdomen enlarged, abnormal dreams, abnormal menses, abnormal stools, abnormal vision, agitation, agranulocytosis, albuminuria, allergic reaction, alkaline phosphatase increased, ALT increased, alopecia, amblyopia, amnesia, anaphylactoid reaction, anemia, angina, anorexia, anxiety, aplastic anemia, appetite increased, arrhythmia, AST increased, arthralgia, arthritis, asthma, avitaminosis, bezoar, bilirubinemia, blepharitis, blurred vision, bradycardia, breast enlargement, breast pain, breast tenderness, bronchitis, candidiasis, carcinoma, cardiospasm, cataract, cerebrovascular accident, cerebral infarction, chest pain, chills, cholelithiasis, cholesterol increased/decreased,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), colitis, confusion, conjunctivitis, cough increased, creatinine increased, deafness, dehydration, dementia, depersonalization, depression, diabetes mellitus, diaphoresis, diplopia, dry eyes, dry skin, dyspepsia, dysphagia, dyspnea, dysmenorrhea, dysuria, edema, electrolyte imbalance, emotional lability, enteritis, eosinophilia, epistaxis, eructation, erythema multiforme, esophageal stenosis, esophageal ulcer, esophagitis, fecal discoloration, fever, fixed eruption, flatulence, flu-like syndrome, fracture, fundic gland polyps, gastric nodules, gastrin levels increased, gastritis, gastroenteritis, gastrointestinal anomaly, gastrointestinal hemorrhage, GGTP increased/decreased, glaucoma, glucocorticoid levels increased, glossitis, glycosuria, goiter, gout, gum hemorrhage, gynecomastia, halitosis, hallucinations, hematemesis, hematuria, hemiplegia, hemolysis, hemolytic anemia, hemoptysis, hepatotoxicity, hostility aggravated, hyper-/hypoglycemia, hyperkinesia, hyperlipemia, hypertonia, hypoesthesia, hyper-/hypotension, hypomagnesemia, hypothyroidism, impotence, infection, insomnia, interstitial nephritis, kidney calculus, laryngeal neoplasia, LDH increased, leg cramps, leukopenia, leukorrhea, libido decreased/increased, liver function test abnormal, lung fibrosis, lymphadenopathy, maculopapular rash, malaise, melena, menorrhagia, migraine, moniliasis (oral), mouth ulceration, musculoskeletal pain, myalgia, myasthenia, myositis, MI, nervousness, neurosis, neutropenia, pain, palpitation, pancreatitis, pancytopenia, paresthesia, parosmia, pelvic pain, peripheral edema, pharyngitis, photophobia, platelet abnormalities, pneumonia, polyuria, pruritus, ptosis, rash, rectal hemorrhage, retinal degeneration, rhinitis, salivation increased, seizure, shock, sinusitis, skin carcinoma, sleep disorder, somnolence, speech disorder, Stevens-Johnson syndrome, stomatitis, stridor, syncope, synovitis, tachycardia, taste loss, taste perversion, tenesmus, thirst, thrombocytopenia, thrombotic thrombocytopenic purpura, tinnitus, tremor, tongue disorder, toxic epidermal necrolysis, ulcerative colitis, ulcerative stomatitis, upper respiratory inflammation, upper respiratory infection, urethral pain, urinary frequency/urgency, urination impaired, urinary retention, urinary tract infection, urticaria, vaginitis, vasodilation, vertigo, visual field defect, vomiting, weakness, WBC abnormal, weight gain/loss, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lansoprazole, pantoprazole, esomeprazole, omeprazole, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic response to therapy does not preclude the presence of gastric malignancy; use with caution in patients with liver disease, reduce dosage with severe impairment; Prevacid&reg; SoluTabs&trade; contain aspartame which is metabolized to phenylalanine and must be used with caution in patients with phenylketonuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term effects are not known; enterochromaffin (ECF)-like hyperplasia and subsequent carcinoids have developed in rats following lifetime exposure to high doses (150 mg/kg/day). Use of gastric acid inhibitors including proton pump inhibitors and H",
"     <sub>",
"      2",
"     </sub>",
"     blockers has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006). An increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy; patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk. Hypomagnesemia has been reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy), and may be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of lansoprazole may be necessary; magnesium concentrations typically return to normal within 1 week of stopping. First&reg;-Lansoprazole powder for oral suspension contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use oral suspension containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F186800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Lansoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Lansoprazole may enhance the dermatologic adverse effect of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Lansoprazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1059671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases lansoprazole's bioavailability by 50%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not shown teratogenic effects to the fetus. However, there are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with Zollinger-Ellison syndrome should be monitored for gastric acid output, which should be maintained at 10 mEq/hour or less during the last hour before the next lansoprazole dose; lab monitoring should include CBC, liver function, renal function, and serum gastrin levels",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1059662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma levels do not correlate with pharmacologic activity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppresses gastric acid secretion by selectively inhibiting the parietal cell membrane enzyme (H+, K+)-ATPase or proton pump; demonstrates antimicrobial activity against",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of antisecretory activity: &ge;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Relief of symptoms:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastric or duodenal ulcers: 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reflux esophagitis: 1-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ulcer healing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duodenal: 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastric: 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Extremely acid labile and will degrade in acid pH of stomach; enteric coated granules improve bioavailability (80%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.61-0.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 15.7 &plusmn; 1.9 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive by the liver to inactive metabolites; in acid media of gastric parietal cell, lansoprazole is transformed to active sulfanilamide metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 80% (reduced by 50% if given 30 minutes after food)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1.2-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.3-1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 14% to 25% in urine as metabolites; &lt;1% as unchanged drug; biliary excretion is major route of elimination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.57-0.71 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 11.1 &plusmn; 3.8 L/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: Hepatic impairment: 3.2-7.2 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/57/24469?source=see_link\">",
"      see \"Lansoprazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F186736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 3 mg/mL oral solution (Simplified Lansoprazole Solution) may be made with capsules and sodium bicarbonate. Empty the contents of ten lansoprazole 30 mg capsules into a beaker. Add 100 mL sodium bicarbonate 8.4% and gently stir until dissolved (about 15 minutes). Transfer solution to an amber-colored syringe or bottle. Stable for 8 hours at room temperature or for 14 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     DiGiancinto JL, Olsen KM, Bergman KL, et al, &ldquo;Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes,&rdquo;",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 2000, 34(5):600-5",
"     <span class=\"pubmed-id\">",
"      10852086",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Sharma V, &ldquo;Comparison of 24-hour Intragastric pH Using Four Liquid Formulations of Lansoprazole and Omeprazole,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1999, 56(Suppl 4):18-21.",
"     <span class=\"pubmed-id\">",
"      10597120",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Sharma VK, Vasudeva R, and Howden CW, &ldquo;Simplified Lansoprazole Suspension - Liquid Formulations of Lansoprazole - Effectively Suppresses Intragastric Acidity When Administered Through a Gastrostomy,&rdquo;",
"     <i>",
"      Am J Gastroenterol",
"     </i>",
"     , 1999, 94(7):1813-7.",
"     <span class=\"pubmed-id\">",
"      10406240",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2904/abstract-text/16651285/pubmed\" id=\"16651285\" target=\"_blank\">",
"        16651285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chun AH, Eason CJ, Shi HH, et al, &ldquo;Lansoprazole: An Alternative Method of Administration of a Capsule Dosage Formulation,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1995, 17(3):441-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2904/abstract-text/7585848/pubmed\" id=\"7585848\" target=\"_blank\">",
"        7585848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons TE and Gold BD, &ldquo;The Use of Proton Pump Inhibitors in Children: A Comprehensive Review,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(1):25-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2904/abstract-text/12513104/pubmed\" id=\"12513104\" target=\"_blank\">",
"        12513104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khoshoo V and Dhume P, \"Clinical Response to 2 Dosing Regimens of Lansoprazole in Infants With Gastroesophageal Reflux,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2008, 46(3):352-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2904/abstract-text/18376260/pubmed\" id=\"18376260\" target=\"_blank\">",
"        18376260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oderda G, Chiorboli E, Haitink AR, et al, &ldquo;Inhibition of Gastric Acidity in Children by Lansoprazole Granules,&rdquo;",
"      <i>",
"       Gastroent",
"      </i>",
"      , 1998, 114(4pt2):A295.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orenstein SR, Hassall E, Furmaga-Jablonska W, et al, \"Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Assessing the Efficacy and Safety of Proton Pump Inhibitor Lansoprazole in Infants With Symptoms of Gastroesophageal Reflux Disease,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2009, 154(4):514-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2904/abstract-text/19054529/pubmed\" id=\"19054529\" target=\"_blank\">",
"        19054529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott LJ, &ldquo;Lansoprazole: In the Management of Gastroesophageal Reflux Disease in Children,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(1):57-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2904/abstract-text/12513106/pubmed\" id=\"12513106\" target=\"_blank\">",
"        12513106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Springer M, Atkinson S, North J, et al, \"Safety and Pharmacodynamics of Lansoprazole in Patients With Gastroesophageal Reflux Disease Aged &lt;1 Year,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2008, 10(4):255-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2904/abstract-text/18590344/pubmed\" id=\"18590344\" target=\"_blank\">",
"        18590344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tran A, et al, &ldquo;Pharmacokinetics/Pharmacodynamics Study of Oral Lansoprazole in Children,&rdquo;",
"      <i>",
"       Fundam Clin Pharmacol",
"      </i>",
"      , 1996, 10:A221.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhang W, Kukulka M, Witt G, et al, \"Age-Dependent Pharmacokinetics of Lansoprazole in Neonates and Infants,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2008, 10(4):265-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/53/2904/abstract-text/18590345/pubmed\" id=\"18590345\" target=\"_blank\">",
"        18590345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12543 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2904=[""].join("\n");
var outline_f2_53_2904=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572473\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186757\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186758\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059660\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12860309\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059653\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186730\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186715\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15241705\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059664\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059656\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059663\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186815\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186813\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059669\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059652\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059651\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186800\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186724\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059671\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186726\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186741\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059659\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059662\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059650\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059667\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059668\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059658\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186736\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=related_link\">",
"      Lansoprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/57/24469?source=related_link\">",
"      Lansoprazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_53_2905="Angiodysplasia colon light";
var content_f2_53_2905=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1108px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angiodysplasia of the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a colonic biopsy in angiodysplasia shows mucosal and submucosal vascular dilatation and congestion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Normal colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 172px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2905=[""].join("\n");
var outline_f2_53_2905=null;
var title_f2_53_2906="Brachial plexus syndromes";
var content_f2_53_2906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Brachial plexus syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/53/2906/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2906/contributors\">",
"     Mark B Bromberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/53/2906/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2906/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/53/2906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/53/2906/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/53/2906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brachial plexus is a network of nerve fusions and divisions that originate from cervical and upper thoracic nerve roots and terminate as named nerves that innervate muscles and skin of the shoulder and arm. Although detailed knowledge of the elements of the network is important for distinguishing between radiculopathy and mononeuropathy, a syndromic approach is more useful for diagnosing lesions involving the plexus itself.",
"   </p>",
"   <p>",
"    This topic will briefly review the underlying anatomy, pathogenesis, and general clinical features of brachial plexopathies, and then discuss a number of specific brachial plexopathies, classified for convenience by clinical setting into traumatic, nontraumatic, iatrogenic, and congenital types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve roots from C5 through T1 contribute to the brachial plexus (",
"    <a class=\"graphic graphic_figure graphicRef50576 \" href=\"UTD.htm?34/25/35222\">",
"     figure 1",
"    </a>",
"    ). The plexus can be divided into regions that include (from proximal to distal) trunks, divisions, cords, branches, and nerves. Trunks and divisions are further subdivided with a nomenclature based on overall relationships with other upper extremity anatomic structures and include upper, lower, and middle trunks, and posterior and anterior cords.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C5 and C6 roots merge to form the upper trunk. The C7 root forms the middle trunk. C8 and T1 roots merge to form the lower trunk.",
"     </li>",
"     <li>",
"      The upper trunk divides and gives branches to the lateral and posterior cords. The middle trunk divides and gives branches to the lateral and posterior cords. The lower trunk divides and gives branches to the posterior and medial cord.",
"     </li>",
"     <li>",
"      The lateral cord branches and gives rise to the musculocutaneous nerve and contributes to the median nerve. The posterior cord branches and gives rise to the axillary nerve and then becomes the radial nerve. The medial cord branches and contributes to the median nerve and then becomes the ulnar nerve.",
"     </li>",
"     <li>",
"      Other nerves arise from various elements of the plexus. The dorsal scapular nerve arises from the C5 root. The long thoracic nerve arises from C5, C6, and C7 roots. The suprascapular nerve arises from the upper trunk.",
"     </li>",
"     <li>",
"      Contributions to motor and sensory function vary within the brachial plexus. The largest percentages of motor fibers are from C5 and C6 roots, and the least from C7 and T1 roots. The greatest number of sensory fibers is from the C7 root, with lesser amounts from C5, C6, C8, and T1 roots [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/1\">",
"       1",
"      </a>",
"      ]. Postganglionic sympathetic nerve fibers from vertebral ganglia course through the brachial plexus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic basis and histologic changes seen with brachial plexus lesions vary with the underlying cause, which include compression, transection, ischemia, inflammation, metabolic abnormalities, neoplasia, and radiation therapy. Because the brachial plexus is relatively inaccessible to direct investigation, most pathologic processes are deduced.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nerve compression is relatively uncommon because the brachial plexus is protected by bony structures. Contact sports are the most frequent cause of nerve compression injury to the brachial plexus; focal forces to the shoulder region result in brief compression of underlying plexus elements.",
"     </li>",
"     <li>",
"      Overt nerve transection occurs with major trauma to the neck and shoulder, causing downward traction on the shoulder and movement of the neck to the contralateral side, or with trauma to the arm, causing upward traction on the arm and shoulder. High-force traction to the plexus may also be associated with avulsion of nerve roots.",
"     </li>",
"     <li>",
"      Ischemia due to occlusion of small intraneural (vasa nervorum) vessels is more common than ischemia due to occlusion of large vessels. Small vessel ischemia may be a common pathologic basis for inflammatory, metabolic, and radiation-induced plexopathies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. Ischemia causes localized axonal damage, resulting in denervation of muscle and skin receptors.",
"     </li>",
"     <li>",
"      Inflammation, perhaps leading to small vessel occlusion, is hypothesized to cause brachial plexopathies of acute onset (excluding those associated with mechanical causes). However, precipitating events for such an inflammatory response and its consequences are poorly understood.",
"     </li>",
"     <li>",
"      Metabolic abnormalities are the most likely initiating factors underlying plexopathies related to diabetes mellitus. That said, the specific factors are not known and the pathophysiology may include inflammation and focal ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neoplastic plexopathies can result from direct pressure by a local cancer mass, but invasion by cancer cells along nerves or tracking along connective tissue is more common [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiation treatment for cancer is a common cause of damage to brachial plexus nerves [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/2\">",
"       2",
"      </a>",
"      ]. The toxic effects of radiation may injure axons directly or injure the vasa nervorum causing ischemic changes to axons with multifocal denervation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachial plexus syndromes are rare, as illustrated by the prevalence of plexopathies associated with cancer (approximately 0.4 percent of patients with cancer) and those associated with radiation treatment (approximately 2 to 5 percent of those treated) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/2\">",
"     2",
"    </a>",
"    ]. Idiopathic brachial plexopathy, or brachial amyotrophy, has an estimated annual incidence of 2 to 3 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In one large series, the male to female ratio was 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of symptoms from brachial plexopathies may vary from acute to insidious. Acute onset is usually characterized by pain in the shoulder or upper arm, while insidious onset can manifest as progressive pain, evolving numbness, weakness of selected muscles, or any combination. Early on, distinguishing between symptoms arising from bones and ligaments about the shoulder and those from nerves in the plexus may be difficult. Acute onset, in the absence of trauma, favors a metabolic or inflammatory process. Chronic progression of symptoms in patients with a history of cancer and radiation treatment suggests either as a cause.",
"   </p>",
"   <p>",
"    Clinical signs of brachial plexopathy include muscle weakness, atrophy, and sensory loss. With a painful plexopathy of acute onset it may be difficult to distinguish true weakness from reduced effort due to pain. Muscle atrophy may not be appreciated for several weeks. Tendon reflexes may be reduced in weak muscles. Sensory loss commonly involves the axillary nerve distribution, but may be diffuse or reflect the distributions of other involved nerves (",
"    <a class=\"graphic graphic_figure graphicRef75388 \" href=\"UTD.htm?24/47/25335\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nerve conduction studies and needle electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary pathologic lesion in most plexopathies is axonal loss, with demyelination and conduction block as secondary processes. Nerve conduction studies primarily assess terminal segments of nerves, and the distribution of abnormalities can be helpful in localizing lesion sites lying more proximally in the plexus. They can also determine if there are alternative diagnoses, such as nerve entrapment syndromes. Sensory nerve conduction studies are more sensitive to axonal loss than motor nerve studies, and application of a battery of sensory nerve tests can be diagnostically helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Needle electromyography is the most sensitive test of axonal damage in motor nerves and can further localize the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, essentially any muscle can be studied with needle electromyography, and thus any element of the plexus can be assessed. However, abnormal spontaneous activity in the form of positive waves and fibrillation potentials may not be apparent for three weeks after the acute onset of plexopathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine chest and spine films may reveal osseous injuries or altered posture due to muscle weakness. Plain CT is useful for detecting bony abnormalities, and CT myelography is useful for detecting root avulsions. MRI is more sensitive for structural abnormalities than CT.",
"   </p>",
"   <p>",
"    Magnetic resonance neurography is a specialized procedure that can visualize individual roots, segments of the plexus, and peripheral nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It has low specificity but is more sensitive than conventional MRI for plexus lesions, and can identify local factors relevant to possible demyelination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    compression, including nerve edema, thickening, and T2 hyperintensities.",
"   </p>",
"   <p>",
"    Ultrasound has been used to image the brachial plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/11\">",
"     11",
"    </a>",
"    ], and may be able to distinguish preganglionic from postganglionic traumatic lesions noninvasively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TRAUMATIC PLEXOPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic injuries are the most common cause of brachial plexus lesions in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/13\">",
"     13",
"    </a>",
"    ]. Motor vehicle accidents (particularly involving motorcycle riders), industrial accidents, falls, objects falling on a shoulder, and sports injuries are among the many causes of closed brachial plexus trauma.",
"   </p>",
"   <p>",
"    Open traumatic brachial plexus injuries result from gunshot wounds, lacerations, and animal bites [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/13\">",
"     13",
"    </a>",
"    ]. Open injuries are frequently associated with trauma to nearby blood vessels, with the result that the plexus suffers secondary injury from expanding hematomas, pseudoaneurysms, and arteriovenous fistulas.",
"   </p>",
"   <p>",
"    Root avulsions, the burner syndrome, and backpack palsy are types of traumatic plexopathies discussed in further detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Root avulsions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Root avulsions are caused by high-energy traction (stretch), and occur in parallel with brachial plexus injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. Thus, traumatic injuries may include a combination of plexopathy and root avulsions. The torn nerve roots and axons are incapable of regeneration and are not amenable to surgical repair. Thus, the resulting motor and sensory deficits are permanent. Multiple root avulsions are frequent with traumatic injury, resulting in extensive deficits. In addition, most patients develop severe avulsion pain, often involving the hand.",
"   </p>",
"   <p>",
"    The lowest two brachial plexus roots (C8 and T1) are the most susceptible to root avulsion, while the upper two (C5 and C6) are more susceptible to extraforaminal rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8\">",
"     8",
"    </a>",
"    ]. Unlike root avulsions, extraforaminal nerve ruptures may be accessible to surgical repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Burner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The burner syndrome (also called the stinger syndrome) is a term that describes the transient burning and stinging sensations experienced during contact sports due to forceful contact by a helmet to the neck or anterior shoulder region. This type of athletic injury causes transient dysfunction of the brachial plexus and occasionally the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The upper trunk is most commonly involved, due to downward traction of the shoulder.",
"   </p>",
"   <p>",
"    Symptoms are usually transient with no nerve damage. However, some cases are associated with denervation, with or without weakness. Some clinicians use the term burner to indicate more severe episodes of numbness in limbs that implicate damage to the spinal cord. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26375?source=see_link\">",
"     \"Burners (stingers): Acute brachial plexus injury in the athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of burner syndrome is straightforward in the context of American football or other contact sports. There may be a degree of weakness that raises the question of a more substantial injury. Needle electromyography is usually normal, but can detect mild degrees of denervation when there is no weakness, and more marked changes when there is weakness. However, electromyography is only indicated if symptoms persist for more than three weeks, since the effects of acute injury are not evident prior to this time. The physical examination should include assessment for a myelopathy if symptoms suggest spinal cord damage, and when there is a concern, an imaging study of the cervical spine is appropriate.",
"   </p>",
"   <p>",
"    Since most burners and stingers are transient, lasting minutes to hours, no work-up or treatment is usually required. Those associated with weakness typically improve without treatment, but refraining from football and other contact sports is appropriate until strength is regained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Backpack palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Backpack palsy (also known as rucksack paralysis and cadet palsy) is an upper plexus disorder. Patients with this condition present with painless arm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shoulder weakness, usually unilateral, after wearing a backpack or similar apparatus (eg, child carrying harness) for a prolonged period of time, resulting most often in an upper trunk lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8\">",
"     8",
"    </a>",
"    ]. Some sensory loss is also present in the same distribution.",
"   </p>",
"   <p>",
"    The pathogenesis of backpack palsy is thought to be direct compression from the weight of the backpack. The lesions are predominantly demyelinating conduction block, and full recovery usually ensues over a few months. In a minority, axon loss predominates, and recovery may be incomplete or slow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60765533\">",
"    <span class=\"h2\">",
"     Prognosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of traumatic brachial plexopathies, whether from forceful trauma or iatrogenic trauma, is difficult to document but is generally poor, with most natural improvements occurring within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/16\">",
"     16",
"    </a>",
"    ]. However, there are few published data regarding the outcome of unoperated traumatic plexopathies.",
"   </p>",
"   <p>",
"    Most surgical interventions are performed after documenting no improvement over three to four months, although there situations when emergent intervention is appropriate. They type of surgical intervention is dependent upon the nature and degree of the lesion, and includes neurolysis, nerve grafts, nerve transfers, and tendon and muscle transfers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. There are data suggesting that delaying surgical treatment for longer than two to six months diminishes the chance for an improved level of function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Injuries that have a degree of axonal continuity may have a more favorable outcome, and nerve grafts are most successful for injuries of C5, C6, and C7 roots, upper and middle trunks and lateral and posterior cords [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcome may be partially dependent upon surgical experience with brachial plexus injuries, and data from experienced centers supports improved function in approximately 60 percent after surgical interventions. However, many patients remain disabled, with one survey finding that one-half of those previously employed did not return to work [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NONTRAUMATIC PLEXOPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontraumatic brachial plexopathies include neuralgic amyotrophy, hereditary brachial plexopathy, neoplastic and radiation induced plexopathy, thoracic outlet syndrome, and brachial plexopathy related to diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuralgic amyotrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuralgic amyotrophy is considered to be an inflammatory disorder of the brachial plexus. It is known by a number of terms, including Parsonage&ndash;Turner syndrome, paralytic brachial neuritis, idiopathic brachial plexopathy, brachial plexus neuropathy, and acute brachial radiculitis. It has been described in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathology for all forms of idiopathic brachial plexopathy is speculative, as most cases are neither biopsied nor come to autopsy. However, careful clinical and electrophysiologic assessment suggests that neuralgic amyotrophy is a multifocal rather than a global process, with motor nerves seeming more vulnerable than sensory [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/27\">",
"     27",
"    </a>",
"    ]. Hypothesized underlying processes focus on autoimmune disorders. In this regard, approximately 50 percent of patients describe some type of antecedent event or possible predisposing condition, such as infection, exercise, surgery, pregnancy and puerperium, or vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Classic form",
"    </span>",
"    &nbsp;&mdash;&nbsp;In its classic form, neuralgic amyotrophy is characterized clinically by the onset of severe pain followed by patchy weakness in the distribution of the upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    middle brachial plexus, usually involving winging of the scapula. There is rapid or subacute onset of unilateral shoulder girdle and lateral arm pain, often awakening the individual in the night. The pain can be excruciating and may last up to four weeks before subsiding [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ]. Bilateral onset of pain has been reported in up to in 29 percent of patients, almost always with asymmetric involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ]. Sensory symptoms occur in a majority of patients, most commonly manifesting as hypesthesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paresthesia, and usually involving the lateral shoulder and arm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the hand.",
"   </p>",
"   <p>",
"    The time to onset of weakness is highly variable, as illustrated by the finding that weakness occurs within the first 24 hours after onset of pain in one-third of patients, and more than two weeks after onset of pain in approximately one-quarter [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ]. The distribution of muscle atrophy and weakness may be limited to muscles supplied by one nerve, or in extreme cases may involve all muscles of the shoulder or arm. There is a predilection for muscles innervated by the suprascapular, long thoracic, musculocutaneous, radial, and axillary nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ]. Variable weakness may also be present in the contralateral limb. Recovery of strength begins within several months, and the maximal degree of recovery may not be achieved for several years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Clinical variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is worth emphasizing that the pattern of nerve involvement observed in neuralgic amyotrophy can be more diverse than the classic syndrome. Any part of the brachial plexus or muscles it innervates may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ]. In very severe cases, there may be bilateral arm paralysis. Other patients may have involvement of single or multiple nerves in the limb, more akin to a mononeuritis or mononeuritis multiplex. Individual limb nerves that may be affected include long thoracic, anterior interosseous, radial, median, and a variety of cutaneous nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/27\">",
"     27",
"    </a>",
"    ]. As an example, isolated anterior interosseous nerve involvement may be the only motor manifestation in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ]. In a minority of patients, attacks may involve nerves outside of the brachial plexus, including the lumbosacral plexus, phrenic nerve, and recurrent laryngeal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar clinical disorder occurs in association with a variety of surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/28\">",
"     28",
"    </a>",
"    ]. Onset is heralded by shoulder girdle pain 1 to 14 days after surgery, so that direct nerve traction and compression are not likely causative factors. Weakness ensues within several days, and has similar distributions to that seen in idiopathic brachial plexopathy. Electrodiagnostic studies support axonal loss. Recovery is good.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuralgic amyotrophy is primarily a clinical diagnosis supported by electrodiagnostic testing. Clinical suspicion is based upon the pattern of initial sudden and severe pain followed by atrophic weakness with slow recovery. Nerve conduction studies are supportive and can exclude more common mononeuropathies, while needle EMG is important to document denervation. The pattern of denervation supports either specific nerve involvement or a more patchy distribution. Laboratory and imaging studies are normal. Multifocal nerve involvement often obviates the need for imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Management and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment for neuralgic amyotrophy. Management is conservative. Physical therapy may be helpful to preserve range of motion but will not hasten recovery. Glucocorticoids have been advocated by some, but no clinical studies have demonstrated efficacy. In the first weeks, analgesic drugs, including narcotics, may be required to manage patients with severe pain.",
"   </p>",
"   <p>",
"    Recovery occurs slowly over one to three years, and some patients have persistent disability, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early series of 99 patients with neuralgic amyotrophy suggested that most had good recovery, essentially to normal strength [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another series included 199 patients with idiopathic neuralgic amyotrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"       7",
"      </a>",
"      ]. Among 39 with three or more years of follow-up, mild, moderate, or severe paralysis was still present in 69, 14, and 3 percent, respectively. Overall, recurrence of idiopathic neuralgic amyotrophy was observed in 26 percent of patients, with a median time to recurrence of just over two years. This recurrence rate is higher than the estimated rate of 5 percent previously reported [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third series surveyed 248 patients with either idiopathic or hereditary neuralgic amyotrophy; approximately 90 percent had the idiopathic form [",
"      <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/29\">",
"       29",
"      </a>",
"      ]. After 6 to 36 months of follow-up, residual pain or severe fatigue was present in approximately 60 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a pathologically distinct, yet clinically similar, hereditary recurrent brachial plexopathy that should be considered when there are multiple episodes within an individual and within the family. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Hereditary brachial plexopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hereditary brachial plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary brachial plexopathy (MIM 162100), also known as hereditary neuralgic amyotrophy, is a rare autosomal dominant disorder characterized by recurrent, painful brachial plexopathies. Genetic studies in families with this condition identified mutations in the septin 9 gene (SEPT9) on chromosome 17q25 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Hereditary brachial plexopathy is distinct from hereditary neuropathy with predisposition to pressure palsies (HNPP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21895?source=see_link\">",
"     \"Overview of hereditary neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Childhood onset of hereditary brachial plexopathy is not unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/33\">",
"     33",
"    </a>",
"    ]. In one series of 47 patients, the age at onset ranged from 3 to 54 years, with a mean of 28 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ]. Many patients exhibit a relapsing-remitting course characterized by attacks that resolve spontaneously, either completely or incompletely, leaving additive residual weakness. Physical exertion and pregnancy are reported triggering events.",
"   </p>",
"   <p>",
"    The disorder can also follow a progressive pattern. In one study that analyzed 101 attacks in 24 patients from nine different families, both a classic relapsing-remitting type and a chronic undulating type with exacerbations were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/34\">",
"     34",
"    </a>",
"    ]. Only one type occurred per family.",
"   </p>",
"   <p>",
"    Attacks are heralded by pain and paresthesias, followed by paresis of the shoulder and arm. While any nerve in the brachial plexus can be involved, injury to the upper part of the brachial plexus is most frequent. Winging of the scapula caused by long thoracic nerve involvement is common, and facial weakness and autonomic nervous system dysfunction may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/33\">",
"     33",
"    </a>",
"    ]. Sympathetic activity with flushing can be observed. Sensory involvement (mainly involving hypesthesia and paresthesias of the shoulder, arm, or hand) is present in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ]. Nerves outside the brachial plexus can also be involved, including the lumbosacral plexus, the phrenic nerve (causing weakness of the diaphragm), and the recurrent laryngeal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristic somatic features of hereditary brachial plexopathy include short stature, hypotelorism, a small face, unusual skin folds, and creases on the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although electrophysiologic studies are limited, sensory nerve conduction velocity is typically normal, while motor conduction latencies are prolonged. These findings suggest an axonal neuropathy, but are also compatible with focal demyelination, conduction block, or a chronic process with remyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histopathology of hereditary brachial plexopathy is non-specific. Muscle demonstrates pathologic changes consistent with neurogenic atrophy. Both motor and sensory nerves show widely dispersed pathologic involvement throughout the brachial plexus; the changes involve very focal damage to individual nerves with lesions restricted to isolated fascicles within the nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/37\">",
"     37",
"    </a>",
"    ]. The changes are predominantly demyelinating, but axonal changes are also present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pattern of recurrent brachial plexopathies and a similar history in family members should raise consideration for the diagnosis of hereditary neuralgic amyotrophy. Finding of dysmorphic features is strongly supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Management and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with hereditary brachial plexopathy have some degree of disability. In a series that followed 10 patients for three or more years, mild, moderate, or severe weakness was present in 4, 3, and 2 patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"     7",
"    </a>",
"    ]. Management is supportive, although glucocorticoids have been given in uncontrolled studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neoplastic and radiation-induced brachial plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;These conditions are briefly reviewed here, and discussed elsewhere in greater detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of cancer pain syndromes\", section on 'Plexopathies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of cancer pain syndromes\", section on 'Plexopathies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Neoplastic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast and lung cancers are the most frequent neoplasms leading to brachial plexopathy. Pain in the shoulder and axilla is the most common presenting symptom of neoplastic brachial plexopathy. Invasion of the lower plexus (inferior trunk and medial cord) occurs more frequently than invasion of the upper trunk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of cancer pain syndromes\", section on 'Plexopathies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Pancoast syndrome is most commonly due to non-small cell lung cancer in the superior sulcus, and is associated with a Horner syndrome in three-quarters of patients. Weakness usually occurs in a lower plexus distribution, but may also be more widespread and patchy in distribution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=see_link\">",
"     \"Pancoast's syndrome and superior (pulmonary) sulcus tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=see_link\">",
"     \"Horner's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of a known neoplasm and radiation therapy, distinguishing between cancer recurrence and radiation-induced plexopathy can be challenging. In general, compared with radiation-induced brachial plexopathies, neoplastic plexopathies are more likely to produce pain at symptom onset, more often involve the lower plexus, and are more frequently associated with a Horner's syndrome.",
"   </p>",
"   <p>",
"    Primary brachial plexus tumors, such as schwannomas or neurofibromas, are uncommon, and most occur as solitary tumors. These rarely cause symptomatic plexopathies. However, multiple tumors occur in patients with neurofibromatosis type 1, and these are more likely than solitary tumors to present with pain or clinical deficits.",
"   </p>",
"   <p>",
"    The diagnosis of neoplastic brachial plexopathy is suggested by the clinical setting, including symptoms, past medical history (eg, smoking), and physical examination, particularly the breast examination. Imaging of the chest by x-ray and CT or MRI is most useful to detect a pulmonary tumor. A Horner syndrome in the setting of shoulder pain and weakness is strongly supportive of a pulmonary tumor. Electrodiagnostic studies are useful to define the location of the tumor in the brachial plexus.",
"   </p>",
"   <p>",
"    There are limited data on the benefit of treating neoplastic brachial plexopathy with radiation therapy to the plexus; the goal is mostly directed at reducing pain. Medical management of pain is appropriate if radiation therapy is not beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Radiation-induced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced brachial plexopathy is a consideration in patients with cancer who develop plexopathy after radiation therapy in the vicinity of the brachial plexus. As mentioned above, either cancer recurrence or radiation therapy can cause a brachial plexopathy in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications of peripheral nerve irradiation\", section on 'Brachial plexopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung and breast cancers are the most common neoplasms that are treated with radiation therapy in the vicinity of the brachial plexus, but any patient with radiation therapy to the region is at risk for subsequent plexopathy.",
"   </p>",
"   <p>",
"    There are few clinical features that distinguish radiation-induced damage from that due to cancer, but radiation-induced plexopathy frequently has less pain than neoplastic brachial plexopathy, and what pain there is typically occurs later in the course of symptoms. In addition, radiation-induced plexopathy typically has more paresthesias and more weakness than neoplastic brachial plexopathy. Survival in the setting of radiation-induced plexopathy is related to the underlying cancer and is good with respect to the side effects of radiation.",
"   </p>",
"   <p>",
"    The diagnosis of a radiation-induced rather than neoplastic plexopathy is supported by the presence of fasciculations on electrodiagnostic testing. Myokymic discharges add further support to the diagnosis, since these are rarely found in other conditions. However, myokymic discharges are not a universal feature of radiation-induced plexopathy, and their absence does not exclude the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Thoracic outlet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic outlet syndrome (TOS) is a term used to denote a variety of upper extremity syndromes, with only a small number having a neurologic basis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/38\">",
"     38",
"    </a>",
"    ]. TOS is generally divided into true neurogenic TOS, true vascular TOS (with arterial vascular and venous vascular subtypes), and disputed TOS. The vascular forms of TOS are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link\">",
"     \"Overview of thoracic outlet syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    True neurogenic TOS is rare, with an estimated incidence of 1:1,000,000, and occurs most commonly in women, with a female to male ratio of 9:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/39\">",
"     39",
"    </a>",
"    ]. Symptoms of true TOS include slowly progressive unilateral atrophic weakness of intrinsic hand muscles and numbness in the distribution of the ulnar nerve, with occasional numbness of the ulnar aspect of the forearm. The motor involvement is much greater than the sensory involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/38\">",
"     38",
"    </a>",
"    ]. Weakness and atrophy involve the thenar eminence (median-innervated hand intrinsic muscles) more than the ulnar-innervated hand intrinsic muscles, while medial forearm muscles are less involved. The syndrome may be caused by a taut congenital fibrous band from the first rib to the tip of an elongated C7 transverse process or to a rudimentary cervical rib. The lower portion of the plexus is stretched over this band, and chronic traction injury results. This explains why true TOS has the clinical features of a lower trunk plexopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of the nonneurogenic forms of TOS is less clear. Arterial and venous forms of TOS are caused by compression of the subclavian artery or vein. Patients may present with arm ischemia (claudication",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute embolic events) or venous thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link\">",
"     \"Overview of thoracic outlet syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disputed TOS (also called nonspecific TOS) is the most controversial form [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Proponents of this entity believe that pathologic processes in the thoracic outlet, such as soft tissue anomalies that can only be appreciated at time of surgery, are the cause of a myriad of symptoms affecting the neck, shoulder, and arm, including involvement of upper trunk nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of true neurogenic TOS is based on a highly characteristic pattern of nerve conduction abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/38,42\">",
"     38,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced or absent ulnar and medial antebrachial cutaneous sensory responses and normal median sensory response",
"     </li>",
"     <li>",
"      Reduced or absent ulnar and median motor responses, with the median response often more affected than the ulnar",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Needle electromyography shows denervation in ulnar and median innervated muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging studies in true neurogenic TOS are of limited diagnostic utility. Cervical ribs can be visualized on plain films, but the fibrous band compressing the brachial plexus is radiolucent and therefore cannot be demonstrated reliably by plain films or CT [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/38,43\">",
"     38,43",
"    </a>",
"    ]. There are sparse and inconsistent data regarding the ability of MRI to identify a fibrous band or distortion of the brachial plexus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86428 \" href=\"UTD.htm?25/12/25798\">",
"     image 1",
"    </a>",
"    ) in patients with true neurogenic TOS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/38,44-47\">",
"     38,44-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of true vascular TOS is supported by abnormal arteriography or venography, while electrodiagnostic tests are normal. The diagnosis of axillosubclavian vein thrombosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link&amp;anchor=H185997417#H185997417\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most advocates of disputed TOS maintain that testing will be normal and the diagnosis is purely clinical with confirmation at surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;With true neurogenic TOS, surgical release of the fibrous band or resection of the rudimentary cervical rib is appropriate. Symptoms of pain typically respond, but strength is unlikely to return do to axonal damage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/38,42\">",
"     38,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decompressive surgery for vascular TOS may also be helpful. The treatment of venous and arterial TOS is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link&amp;anchor=H293628520#H293628520\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Approach to management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link&amp;anchor=H293625095#H293625095\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Thoracic outlet decompression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery for disputed TOS is not to be undertaken lightly because of high postoperative complication rates, which include postoperative iatrogenic brachial plexopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/39,48\">",
"     39,48",
"    </a>",
"    ]. Conservative measures include passage of time, weight reduction, and a strengthening program to improve sloping shoulders and posture [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diabetic-related brachial plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plexopathies related to diabetes mellitus usually involve the lumbosacral plexus, but upper extremity involvement has also been observed as part of the syndrome. In contemporary series, upper extremity involvement occurs in up to one-third of patients and may be in the form of mononeuropathies of the ulnar and median nerves, or at more proximal sites in the brachial plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/50\">",
"     50",
"    </a>",
"    ]. Most upper extremity symptoms are in association with lumbosacral plexus involvement, and thus, clinical features in the arm, such as presence of pain, are not fully reported.",
"   </p>",
"   <p>",
"    Since most cases of brachial plexus involvement occur in the setting of lumbosacral plexus symptoms, the diagnosis of brachial symptoms is linked. Needle EMG studies show denervation in the distribution of a nerve or more diffusely in the plexus.",
"   </p>",
"   <p>",
"    Lumbar polyradiculopathy and diabetic amyotrophy are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link\">",
"     \"Lumbosacral plexus syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     IATROGENIC PLEXOPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic brachial plexopathies related to surgery and other medical procedures account for approximately 7 to 10 percent of all brachial plexopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8,51\">",
"     8,51",
"    </a>",
"    ]. Classic postoperative paralysis, postmedian sternotomy plexopathy, and medial fascial compartment syndrome are briefly reviewed in the following sections. An iatrogenic plexopathy has also been reported following surgery for the disputed form of thoracic outlet syndrome. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Thoracic outlet syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Classic postoperative paresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic postoperative paresis is caused by traction or pressure during surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. The presentation is painless weakness in the distribution of the upper brachial plexus. Some cases are accompanied by paresthesias, and occasional cases are bilateral. The lesions are predominantly demyelinating conduction block, and most patients have rapid and complete recovery unless there is significant axonal loss. Thus, conservative management is employed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Postmedian sternotomy plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the name suggests, postmedian sternotomy plexopathy occurs in the setting of open heart surgery and other operations requiring median sternotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. The typical presentation is that of hand weakness accompanied by paresthesias, and sometimes pain, involving the fourth and fifth fingers. Weakness of muscles supplied by C8 via the median nerve (eg, flexor pollicis longus) and radial nerve (eg, extensor indicis proprius, extensor pollicis brevis) clinically distinguishes this from an ulnar neuropathy. Localization is aided by electrodiagnostic studies.",
"   </p>",
"   <p>",
"    Although the mechanism is not entirely clear, the leading hypothesis is that this type of plexopathy results from traction injuries to the C8 anterior primary ramus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/13\">",
"     13",
"    </a>",
"    ]. The lesions are mainly demyelinating conduction block and the prognosis for full recovery is generally good unless there is significant axon loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Medial brachial fascial compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medial brachial fascial compartment extends from the clavicle to the elbow and is formed by the medial intramuscular septum, which divides into two fascial extensions that enclose the neurovascular bundle, including the five terminal nerves of the brachial plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/52\">",
"     52",
"    </a>",
"    ]. Puncture of the axillary or brachial artery during procedures such as arteriography or axillary regional anesthetic blocks can produce an expanding hematoma that causes a compartment syndrome and compresses one or more of the terminal nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8,13,52-54\">",
"     8,13,52-54",
"    </a>",
"    ]. The median and ulnar nerves are most frequently affected.",
"   </p>",
"   <p>",
"    Initial symptoms of the medial brachial fascial compartment syndrome may be delayed for two weeks or longer after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/13\">",
"     13",
"    </a>",
"    ]. Unilateral pain and paresthesia are followed by progressive weakness. Distal pulses typically remain normal. Urgent surgical decompression may improve recovery, which is otherwise poor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8,55\">",
"     8,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     CONGENITAL BRACHIAL PLEXUS PALSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital brachial plexus palsy (also known as obstetric brachial plexus palsy) is rare, with an estimated incidence of 0.04 to 0.3 percent of live births [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/56-61\">",
"     56-61",
"    </a>",
"    ]. Possible risk factors include large maternal weight gain, maternal diabetes, multiparity, fetal",
"    <span class=\"nowrap\">",
"     macrosomia/high",
"    </span>",
"    birth weight, and breech position [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/57,61-64\">",
"     57,61-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of congenital brachial plexus palsy has been attributed to iatrogenic lateral traction on the fetal head, typically when shoulder dystocia impedes delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8,13,61\">",
"     8,13,61",
"    </a>",
"    ]. However, many cases of brachial plexus injury are not due to shoulder dystocia or excessive force by the provider.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital brachial plexus palsy has been observed after delivery by cesarean section",
"     </li>",
"     <li>",
"      Several case series found that only about one-half of the cases of congenital brachial plexus injuries were associated with antecedent shoulder dystocia, and a prenatal insult was documented in a significant number of affected infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the forces of labor, fetal position, and maternal pushing may be sufficient to cause excessive traction on the brachial plexus in these cases. These issues are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=see_link&amp;anchor=H17#H17\">",
"     \"Intrapartum management and outcome of shoulder dystocia\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of congenital brachial plexus palsy are unilateral, and five different patterns of nerve involvement have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C5 and C6 injury (Erb's palsy) accounts for approximately 50 percent of cases. Weakness involves the deltoid and infraspinatus muscles (mainly C5) and biceps (mainly C6). As a result, the upper arm is adducted and internally rotated, and the forearm is extended, while hand and wrist movement are preserved.",
"     </li>",
"     <li>",
"      C5 to C7 injury (Erb's palsy plus) accounts for approximately 35 percent of cases and manifests as adduction and internal rotation of the arm, extension and pronation of the forearm, and flexion of the wrists and fingers, sometimes referred to as the \"waiter's tip\" posture (",
"      <a class=\"graphic graphic_picture graphicRef67537 \" href=\"UTD.htm?43/2/44064\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      C5 to T1 injury usually presents with arm paralysis and some sparing of finger flexion.",
"     </li>",
"     <li>",
"      Severe damage to all C5 to T1 roots is characterized by a flail arm and Horner's syndrome.",
"     </li>",
"     <li>",
"      C8 to T1 injury (Klumpke's palsy) is the most infrequent pattern and manifests as isolated hand paralysis and Horner's syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Prognosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of congenital brachial plexus palsy is poorly studied. In most cases, there is spontaneous recovery over one to three months, but persistent functional impairment is seen in 18 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/60,65\">",
"     60,65",
"    </a>",
"    ]. Electrodiagnostic studies, usually performed at three months of age, are not reliable for predicting prognosis because motor unit action potentials (MUAPs) are frequently observed at that age in clinically paralyzed muscles, which ordinarily are associated with an absence of MUAPs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/57\">",
"     57",
"    </a>",
"    ]. In contrast, a prospective study of 48 newborns with paralysis of elbow flexion found that absence of MUAPs in the deltoid and biceps muscles on needle electromyography performed at one month of age had high sensitivity for predicting absent elbow flexion at three months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of congenital brachial plexus palsy is controversial, a problem that is compounded by the lack of prognostic indicators [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/8,56,67\">",
"     8,56,67",
"    </a>",
"    ]. A period of physical therapy and observation for evidence of recovery is often employed. Surgical intervention has been advocated in select cases if functional recovery does not ensue in three to nine months, but there is no consensus regarding the utility or timing of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/53/2906/abstract/67-71\">",
"     67-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29078490\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nerve roots from C5 through T1 contribute to the brachial plexus (",
"      <a class=\"graphic graphic_figure graphicRef50576 \" href=\"UTD.htm?34/25/35222\">",
"       figure 1",
"      </a>",
"      ). The plexus can be divided into regions that include (from proximal to distal) trunks, divisions, cords, branches, and nerves. Trunks and divisions are further subdivided with a nomenclature based on overall relationships with other upper extremity anatomic structures and include upper, lower, and middle trunks, and posterior and anterior cords. The pathologic basis and histologic changes seen with brachial plexus lesions vary with the underlying cause, which include compression, transection, ischemia, inflammation, metabolic abnormalities, neoplasia, and radiation therapy. Because the brachial plexus is relatively inaccessible to direct investigation, most pathologic processes are deduced. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of symptoms from brachial plexopathies may vary from acute to insidious. Acute onset is usually characterized by pain in the shoulder or upper arm, while insidious onset can manifest as progressive pain, evolving numbness, weakness of selected muscles, or any combination. Acute onset, in the absence of trauma, favors a metabolic or inflammatory process. Chronic progression of symptoms in patients with a history of cancer and radiation treatment suggests either as a cause. Clinical signs include muscle weakness, atrophy, and sensory loss. Muscle atrophy may not be appreciated for several weeks. The primary pathologic lesion in most plexopathies is axonal loss, with demyelination and conduction block as secondary processes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms and signs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Nerve conduction studies and needle electromyography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traumatic injuries are the most common cause of brachial plexus lesions in children and adults. Motor vehicle accidents, industrial accidents, falls, objects falling on a shoulder, and sports injuries are among the many causes of closed brachial plexus trauma. Open traumatic brachial plexus injuries result from gunshot wounds, lacerations, and animal bites. Open injuries are frequently associated with secondary injury from expanding hematomas, pseudoaneurysms, and arteriovenous fistulas. Root avulsions, the burner syndrome, and backpack palsy are discussed in greater detail. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Traumatic plexopathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nontraumatic brachial plexopathies include neuralgic amyotrophy, hereditary brachial plexopathy, neoplastic and radiation induced plexopathy, thoracic outlet syndrome, and brachial plexopathy related to diabetes. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nontraumatic plexopathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In its classic form, neuralgic amyotrophy is characterized clinically by the onset of severe pain followed by patchy weakness in the distribution of the upper",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      middle brachial plexus, usually involving winging of the scapula. The time to onset of weakness is highly variable. Sensory symptoms occur in a majority of patients, most commonly manifesting as hypesthesia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paresthesia, and usually involving the lateral shoulder and arm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the hand. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neuralgic amyotrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary brachial plexopathy is a rare autosomal dominant disorder characterized by recurrent, painful brachial plexopathies. In some families the cause has been identified as mutations in the SEPT9 gene. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hereditary brachial plexopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast and lung cancers are the most frequent neoplasms leading to brachial plexopathy. Pain in the shoulder and axilla is the most common presenting symptom of neoplastic brachial plexopathy. Invasion of the lower plexus (inferior trunk and medial cord) occurs more frequently than invasion of the upper trunk. Radiation-induced brachial plexopathy is a consideration in patients with cancer who develop plexopathy after radiation therapy in the vicinity of the brachial plexus. Either cancer recurrence or radiation therapy can cause a brachial plexopathy in this setting. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Neoplastic and radiation-induced brachial plexopathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of cancer pain syndromes\", section on 'Plexopathies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link\">",
"       \"Complications of peripheral nerve irradiation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link&amp;anchor=H2#H2\">",
"       \"Complications of peripheral nerve irradiation\", section on 'Brachial plexopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thoracic outlet syndrome (TOS) is a term used to denote a variety of upper extremity syndromes, with only a small number having a neurologic basis. TOS is generally divided into true neurogenic TOS, vascular TOS (with arterial vascular and venous vascular subtypes), and disputed (nonspecific) TOS. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Thoracic outlet syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plexopathies related to diabetes mellitus usually involve the lumbosacral plexus, but upper extremity involvement has also been observed as part of the syndrome. In contemporary series, upper extremity involvement occurs in up to one-third of patients and may be in the form of mononeuropathies of the ulnar and median nerves, or at more proximal sites in the brachial plexus. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Diabetic-related brachial plexopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iatrogenic brachial plexopathies related to surgery and other medical procedures account for approximately 7 to 10 percent of all brachial plexopathies. Examples include classic postoperative paralysis, postmedian sternotomy plexopathy, and medial fascial compartment syndrome. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Iatrogenic plexopathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital brachial plexus palsy (also known as obstetric brachial plexus palsy) is rare. Possible risk factors include large maternal weight gain, maternal diabetes, multiparity, fetal",
"      <span class=\"nowrap\">",
"       macrosomia/high",
"      </span>",
"      birth weight, and breech position. The etiology of congenital brachial plexus palsy has been attributed to iatrogenic lateral traction on the fetal head, typically when shoulder dystocia impedes delivery. However, many cases of brachial plexus injury are not due to shoulder dystocia or excessive force by the provider. The forces of labor, fetal position, and maternal pushing may be sufficient to cause excessive traction on the brachial plexus in these cases. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Congenital brachial plexus palsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/1\">",
"      Ferrante MA, Wilbourn AJ. The utility of various sensory nerve conduction responses in assessing brachial plexopathies. Muscle Nerve 1995; 18:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/2\">",
"      Jaeckle KA. Neurological manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol 2004; 24:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/3\">",
"      Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002; 25:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/4\">",
"      Tsairis P, Dyck PJ, Mulder DW. Natural history of brachial plexus neuropathy. Report on 99 patients. Arch Neurol 1972; 27:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/5\">",
"      Beghi E, Kurland LT, Mulder DW, Nicolosi A. Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970-1981. Ann Neurol 1985; 18:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/6\">",
"      MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123 ( Pt 4):665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/7\">",
"      van Alfen N, van Engelen BG. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain 2006; 129:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/8\">",
"      Ferrante MA. Brachial plexopathies: classification, causes, and consequences. Muscle Nerve 2004; 30:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/9\">",
"      Zhou L, Yousem DM, Chaudhry V. Role of magnetic resonance neurography in brachial plexus lesions. Muscle Nerve 2004; 30:305.",
"     </a>",
"    </li>",
"    <li>",
"     Moore K. MR imaging of peripheral nerve. In: Handbook of Peripheral Neuropathy, 1st ed, Bromberg M, Smith A (Eds), Taylor &amp; Francis Group, Boca Raton 2005. p.91.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/11\">",
"      Tagliafico A, Succio G, Serafini G, Martinoli C. Diagnostic performance of ultrasound in patients with suspected brachial plexus lesions in adults: a multicenter retrospective study with MRI, surgical findings and clinical follow-up as reference standard. Skeletal Radiol 2013; 42:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/12\">",
"      Chen DZ, Cong R, Zheng MJ, et al. Differential diagnosis between pre- and postganglionic adult traumatic brachial plexus lesions by ultrasonography. Ultrasound Med Biol 2011; 37:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/13\">",
"      Wilbourn AJ. Plexopathies. Neurol Clin 2007; 25:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/14\">",
"      Clancy WG Jr, Brand RL, Bergfield JA. Upper trunk brachial plexus injuries in contact sports. Am J Sports Med 1977; 5:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/15\">",
"      Weinberg J, Rokito S, Silber JS. Etiology, treatment, and prevention of athletic \"stingers\". Clin Sports Med 2003; 22:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/16\">",
"      Midha R. Epidemiology of brachial plexus injuries in a multitrauma population. Neurosurgery 1997; 40:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/17\">",
"      Sulaiman OA, Kim DD, Burkett C, Kline DG. Nerve transfer surgery for adult brachial plexus injury: a 10-year experience at Louisiana State University. Neurosurgery 2009; 65:A55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/18\">",
"      Norkus T, Norkus M, Pranckevicius S, et al. Early and late reconstruction in brachial plexus palsy: a preliminary report. Medicina (Kaunas) 2006; 42:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/19\">",
"      Bertelli JA, Ghizoni MF. Results and current approach for Brachial Plexus reconstruction. J Brachial Plex Peripher Nerve Inj 2011; 6:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/20\">",
"      Lin H, Hou C, Chen D. Full-length phrenic nerve transfer as the treatment for brachial plexus avulsion injury to restore wrist and finger extension. Muscle Nerve 2012; 45:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/21\">",
"      Secer HI, Solmaz I, Anik I, et al. Surgical outcomes of the brachial plexus lesions caused by gunshot wounds in adults. J Brachial Plex Peripher Nerve Inj 2009; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/22\">",
"      Jivan S, Kumar N, Wiberg M, Kay S. The influence of pre-surgical delay on functional outcome after reconstruction of brachial plexus injuries. J Plast Reconstr Aesthet Surg 2009; 62:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/23\">",
"      Penkert G, Carvalho GA, Nikkhah G, et al. Diagnosis and surgery of brachial plexus injuries. J Reconstr Microsurg 1999; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/24\">",
"      Kim DH, Cho YJ, Tiel RL, Kline DG. Outcomes of surgery in 1019 brachial plexus lesions treated at Louisiana State University Health Sciences Center. J Neurosurg 2003; 98:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/25\">",
"      Kretschmer T, Ihle S, Antoniadis G, et al. Patient satisfaction and disability after brachial plexus surgery. Neurosurgery 2009; 65:A189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/26\">",
"      van Alfen N, Schuuring J, van Engelen BG, et al. Idiopathic neuralgic amyotrophy in children. A distinct phenotype compared to the adult form. Neuropediatrics 2000; 31:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/27\">",
"      England JD, Sumner AJ. Neuralgic amyotrophy: an increasingly diverse entity. Muscle Nerve 1987; 10:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/28\">",
"      Malamut RI, Marques W, England JD, Sumner AJ. Postsurgical idiopathic brachial neuritis. Muscle Nerve 1994; 17:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/29\">",
"      Cup EH, Ijspeert J, Janssen RJ, et al. Residual complaints after neuralgic amyotrophy. Arch Phys Med Rehabil 2013; 94:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/30\">",
"      Meulemann J, Kuhlenb&auml;umer G, Schirmacher A, et al. Genetic refinement of the hereditary neuralgic amyotrophy (HNA) locus at chromosome 17q25. Eur J Hum Genet 1999; 7:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/31\">",
"      Kuhlenb&auml;umer G, Hannibal MC, Nelis E, et al. Mutations in SEPT9 cause hereditary neuralgic amyotrophy. Nat Genet 2005; 37:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/32\">",
"      Hannibal MC, Ruzzo EK, Miller LR, et al. SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophy. Neurology 2009; 72:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/33\">",
"      Dunn HG, Daube JR, Gomez MR. Heredofamilial branchial plexus neuropathy (hereditary neuralgic amyotrophy with branchial predilection) in childhood. Dev Med Child Neurol 1978; 20:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/34\">",
"      van Alfen N, van Engelen BG, Reinders JW, et al. The natural history of hereditary neuralgic amyotrophy in the Dutch population: two distinct types? Brain 2000; 123 ( Pt 4):718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/35\">",
"      Jeannet PY, Watts GD, Bird TD, Chance PF. Craniofacial and cutaneous findings expand the phenotype of hereditary neuralgic amyotrophy. Neurology 2001; 57:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/36\">",
"      Arts WF, Busch HF, Van den Brand HJ, et al. Hereditary neuralgic amyotrophy. Clinical, genetic, electrophysiological and histopathological studies. J Neurol Sci 1983; 62:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/37\">",
"      van Alfen N, Gabre&euml;ls-Festen AA, Ter Laak HJ, et al. Histology of hereditary neuralgic amyotrophy. J Neurol Neurosurg Psychiatry 2005; 76:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/38\">",
"      Ferrante MA. The thoracic outlet syndromes. Muscle Nerve 2012; 45:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/39\">",
"      Wilbourn AJ. Thoracic outlet syndrome surgery causing severe brachial plexopathy. Muscle Nerve 1988; 11:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/40\">",
"      Roos DB. The thoracic outlet syndrome is underrated. Arch Neurol 1990; 47:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/41\">",
"      Wilbourn AJ. The thoracic outlet syndrome is overdiagnosed. Arch Neurol 1990; 47:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/42\">",
"      Le Forestier N, Moulonguet A, Maisonobe T, et al. True neurogenic thoracic outlet syndrome: electrophysiological diagnosis in six cases. Muscle Nerve 1998; 21:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/43\">",
"      Bilbey JH, M&uuml;ller NL, Connell DG, et al. Thoracic outlet syndrome: evaluation with CT. Radiology 1989; 171:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/44\">",
"      Cherington M, Wilbourn AJ, Schils J, Whitaker J. Thoracic outlet syndromes and MRI. Brain 1995; 118 ( Pt 3):819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/45\">",
"      Poole GV, Thomae KR. Thoracic outlet syndrome reconsidered. Am Surg 1996; 62:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/46\">",
"      Panegyres PK, Moore N, Gibson R, et al. Thoracic outlet syndromes and magnetic resonance imaging. Brain 1993; 116 ( Pt 4):823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/47\">",
"      Luigetti M, Capone F, Di Lazzaro V. Teaching neuroimages: neurogenic thoracic outlet syndrome. Neurology 2012; 79:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/48\">",
"      Dale WA. Thoracic outlet compression syndrome. Critique in 1982. Arch Surg 1982; 117:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/49\">",
"      Cuetter AC, Bartoszek DM. The thoracic outlet syndrome: controversies, overdiagnosis, overtreatment, and recommendations for management. Muscle Nerve 1989; 12:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/50\">",
"      Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999; 53:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/51\">",
"      Wilbourn AJ. Iatrogenic nerve injuries. Neurol Clin 1998; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/52\">",
"      Smith DC, Mitchell DA, Peterson GW, et al. Medial brachial fascial compartment syndrome: anatomic basis of neuropathy after transaxillary arteriography. Radiology 1989; 173:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/53\">",
"      Tsao BE, Wilbourn AJ. The medial brachial fascial compartment syndrome following axillary arteriography. Neurology 2003; 61:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/54\">",
"      Tsao BE, Wilbourn AJ. Infraclavicular brachial plexus injury following axillary regional block. Muscle Nerve 2004; 30:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/55\">",
"      Chitwood RW, Shepard AD, Shetty PC, et al. Surgical complications of transaxillary arteriography: a case-control study. J Vasc Surg 1996; 23:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/56\">",
"      Kay SP. Obstetrical brachial palsy. Br J Plast Surg 1998; 51:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/57\">",
"      van Dijk JG, Pondaag W, Malessy MJ. Obstetric lesions of the brachial plexus. Muscle Nerve 2001; 24:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/58\">",
"      Dawodu A, Sankaran-Kutty M, Rajan TV. Risk factors and prognosis for brachial plexus injury and clavicular fracture in neonates: a prospective analysis from the United Arab Emirates. Ann Trop Paediatr 1997; 17:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/59\">",
"      Evans-Jones G, Kay SP, Weindling AM, et al. Congenital brachial palsy: incidence, causes, and outcome in the United Kingdom and Republic of Ireland. Arch Dis Child Fetal Neonatal Ed 2003; 88:F185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/60\">",
"      Lagerkvist AL, Johansson U, Johansson A, et al. Obstetric brachial plexus palsy: a prospective, population-based study of incidence, recovery, and residual impairment at 18 months of age. Dev Med Child Neurol 2010; 52:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/61\">",
"      Foad SL, Mehlman CT, Ying J. The epidemiology of neonatal brachial plexus palsy in the United States. J Bone Joint Surg Am 2008; 90:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/62\">",
"      Levine MG, Holroyde J, Woods JR Jr, et al. Birth trauma: incidence and predisposing factors. Obstet Gynecol 1984; 63:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/63\">",
"      Eng GD, Binder H, Getson P, O'Donnell R. Obstetrical brachial plexus palsy (OBPP) outcome with conservative management. Muscle Nerve 1996; 19:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/64\">",
"      Wolf H, Hoeksma AF, Oei SL, Bleker OP. Obstetric brachial plexus injury: risk factors related to recovery. Eur J Obstet Gynecol Reprod Biol 2000; 88:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/65\">",
"      Pondaag W, Malessy MJ, van Dijk JG, Thomeer RT. Natural history of obstetric brachial plexus palsy: a systematic review. Dev Med Child Neurol 2004; 46:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/66\">",
"      Van Dijk JG, Pondaag W, Buitenhuis SM, et al. Needle electromyography at 1 month predicts paralysis of elbow flexion at 3 months in obstetric brachial plexus lesions. Dev Med Child Neurol 2012; 54:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/67\">",
"      Spinner RJ, Kline DG. Surgery for peripheral nerve and brachial plexus injuries or other nerve lesions. Muscle Nerve 2000; 23:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/68\">",
"      Bodensteiner JB, Rich KM, Landau WM. Early infantile surgery for birth-related brachial plexus injuries: justification requires a prospective controlled study. J Child Neurol 1994; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/69\">",
"      Shenaq SM, Berzin E, Lee R, et al. Brachial plexus birth injuries and current management. Clin Plast Surg 1998; 25:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/70\">",
"      Grossman JA. Early operative intervention for birth injuries to the brachial plexus. Semin Pediatr Neurol 2000; 7:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/53/2906/abstract/71\">",
"      Lin H, Hou C, Chen D. Modified C7 neurotization for the treatment of obstetrical brachial plexus palsy. Muscle Nerve 2010; 42:764.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5266 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.21-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2906=[""].join("\n");
var outline_f2_53_2906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29078490\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nerve conduction studies and needle electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TRAUMATIC PLEXOPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Root avulsions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Burner syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Backpack palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60765533\">",
"      Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NONTRAUMATIC PLEXOPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuralgic amyotrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Classic form",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Clinical variability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hereditary brachial plexopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neoplastic and radiation-induced brachial plexopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Neoplastic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Radiation-induced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Thoracic outlet syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diabetic-related brachial plexopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      IATROGENIC PLEXOPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Classic postoperative paresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Postmedian sternotomy plexopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Medial brachial fascial compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      CONGENITAL BRACHIAL PLEXUS PALSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29078490\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5266\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5266|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/12/25798\" title=\"diagnostic image 1\">",
"      MRI neurogenic TOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5266|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/25/35222\" title=\"figure 1\">",
"      Trunks and cords of the brachial plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/47/25335\" title=\"figure 2\">",
"      Cutaneous innervation of the arm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5266|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/2/44064\" title=\"picture 1\">",
"      Erb palsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26375?source=related_link\">",
"      Burners (stingers): Acute brachial plexus injury in the athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=related_link\">",
"      Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=related_link\">",
"      Intrapartum management and outcome of shoulder dystocia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=related_link\">",
"      Lumbosacral plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21895?source=related_link\">",
"      Overview of hereditary neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=related_link\">",
"      Overview of thoracic outlet syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=related_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_53_2907="Cervical cancer risk with OCs";
var content_f2_53_2907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of cervical cancer among oral contraceptive users compared to nonusers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Use less than 5 years",
"       </td>",
"       <td>",
"        Relative risk 1.1 (95 percent CI 1.1 to 1.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Use 5 to 9 years",
"       </td>",
"       <td>",
"        Relative risk 1.6 (95 percent CI 1.4 to 1.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Use 10 or more years",
"       </td>",
"       <td>",
"        Relative risk 2.2 (95 percent CI 1.9 to 2.4)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2907=[""].join("\n");
var outline_f2_53_2907=null;
var title_f2_53_2908="ACC AHA gas exchange exercise";
var content_f2_53_2908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Exercise testing with ventilatory gas analysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that exercise testing with ventilatory gas analysis should be performed in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  To evaluate exercise capacity and the response to therapy in patients with heart failure who are being considered for heart transplantation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  To assist in the differentiation between cardiac and pulmonary causes of exercise-induced dyspnea or impaired exercise capacity when the cause is uncertain.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of exercise testing with ventilatory gas analysis in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  To evaluate exercise capacity when indicated for medical reasons when estimated exercise capacity from exercise test time or work rate is unreliable.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established for the usefulness of exercise testing with ventilatory gas analysis in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  To evaluate the response to specific therapeutic interventions when improvement in exercise tolerance is important goal or end point.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  To determine the intensity for exercise training as part of comprehensive cardiac rehabilitation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that exercise testing with ventilatory gas analysis is not useful in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull;  Routine use to assess exercise capacity.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2908=[""].join("\n");
var outline_f2_53_2908=null;
var title_f2_53_2909="ROS overweight child";
var content_f2_53_2909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the review of systems in overweight or obese children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential significance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional studies or referral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed development",
"       </td>",
"       <td>",
"        Genetic syndrome",
"       </td>",
"       <td>",
"        Pediatric geneticist and/or neurologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Short stature or reduced height velocity",
"       </td>",
"       <td>",
"        Genetic syndrome",
"       </td>",
"       <td>",
"        Pediatric geneticist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocrinologic etiology (eg, Cushing syndrome, hypothyroidism, ROHHADNET syndrome [rapid onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumor])",
"       </td>",
"       <td>",
"        24 hour urine collection for free cortisol, thyroid function tests; pediatric endocrinologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headaches",
"       </td>",
"       <td>",
"        Pseudotumor cerebri",
"       </td>",
"       <td>",
"        Pediatric neurologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Snoring",
"       </td>",
"       <td>",
"        Sleep apnea, obesity hypoventilation syndrome",
"       </td>",
"       <td>",
"        Polysomnogram (sleep study) and/or referral to a pediatric sleep medicine or ENT specialist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daytime sleepiness",
"       </td>",
"       <td>",
"        Sleep apnea, obesity hypoventilation syndrome",
"       </td>",
"       <td>",
"        Polysomnogram (sleep study), possibly blood gasses; and/or referral to a pediatric sleep medicine, pulmonologist, or ENT specialist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Abdominal pain",
"       </td>",
"       <td>",
"        Gall bladder disease",
"       </td>",
"       <td>",
"        Liver function tests, abdominal ultrasonography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonalcoholic fatty liver disease",
"       </td>",
"       <td>",
"        Liver function tests; pediatric gastroenterologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hip pain, knee pain, limp",
"       </td>",
"       <td>",
"        Slipped capital femoral epiphysis (SCFE) or Blount disease (tibia vara)",
"       </td>",
"       <td>",
"        Radiographs; pediatric orthopedist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Oligomenorrhea or amenorrhea",
"       </td>",
"       <td>",
"        Polycystic ovary syndrome (PCOS)",
"       </td>",
"       <td>",
"        Pediatric endocrinologist or adolescent specialist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prader-Willi syndrome",
"       </td>",
"       <td>",
"        Pediatric geneticist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary frequency, nocturia, polydipsia, polyuria",
"       </td>",
"       <td>",
"        Type 2 diabetes",
"       </td>",
"       <td>",
"        Urinalysis, fasting blood glucose, hemoglobin A1c, glucose tolerance test; pediatric endocrinologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Binge eating or purging",
"       </td>",
"       <td>",
"        Eating disorder",
"       </td>",
"       <td>",
"        Specialist in eating disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insomnia",
"       </td>",
"       <td>",
"        Depression",
"       </td>",
"       <td>",
"        Pediatric psychologist or psychiatrist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anhedonia",
"       </td>",
"       <td>",
"        Depression",
"       </td>",
"       <td>",
"        Pediatric psychologist or psychiatrist",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ENT: ear/nose/throat.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998; 102:E29 and Dietz WH, Robinson TN. Clinical practice. Overweight children and adolescents. N Engl J Med 2005; 352:2100.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2909=[""].join("\n");
var outline_f2_53_2909=null;
var title_f2_53_2910="Mitochondrial pedigree";
var content_f2_53_2910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Example of a pedigree demonstrating mitochondrial inheritance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that all offspring of an affected female are affected, while none of the offspring of affected males are affected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of V Reid Sutton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2910=[""].join("\n");
var outline_f2_53_2910=null;
var title_f2_53_2911="Oral candidiasis in a patient with CMCC";
var content_f2_53_2911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral candidiasis (thrush) in a patient with chronic mucocutaneous candidiasis (CMCC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_53_2911=[""].join("\n");
var outline_f2_53_2911=null;
